

000007114042-00006210-Q COOPER COMPANIES, INC. 202408292024082916117161741161741 0 000007114042-00006210-Q 81 20240731 20240829 20240829 COOPER COMPANIES, INC. 00000711404 3851 942657368 DE 1031 10 34 301-08597 241263948 6101 BOLLINGER CANYON ROAD SUITE 500 SAN RAMON CA 94583 COOPER COMPANIES INC 19920703 COOPERVISION INC 19870701 10 1 cco-20240731.htm 10-Q cco-20240731false2024Q30000071140410/31http://fasb.org/us-gaap/2024/DebtCurrenthttp://fasb.org/us-gaap/2024/LongTermDebtAndCapitalLeaseObligationsxbrli:sharesiso4217:USDiso4217:USDXbrli:sharesxbrli:purecoo:installmentcoco:interest rate swap contract000007114042023-11-012024-07-31000007114042024-08-23000007114042024-05-012024-07-31000007114042023-05-012023-07-31000007114042022-11-012023-07-31000007114042024-02-162024-02-16000007114042024-07-31000007114042023-10-3100000711404us-gaap:CommonStockExcludingTreasuryStockParNetValueMember2022-10-3100000711404us-gaap:TreasuryStockCommonMember2022-10-3100000711404us-gaap:TreasuryStockParNetValueMember2022-10-3100000711404us-gaap:AdditionalPaidInCapitalMember2022-10-3100000711404us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-10-3100000711404us-gaap:RetainedEarningsMember2022-10-3100000711404us-gaap:NoncontrollingInterestMember2022-10-31000007114042022-10-3100000711404us-gaap:RetainedEarningsMember2022-11-012023-01-31000007114042022-11-012023-01-3100000711404us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-11-012023-01-3100000711404us-gaap:CommonStockExcludingTreasuryStockParNetValueMember2022-11-012023-01-3100000711404us-gaap:AdditionalPaidInCapitalMember2022-11-012023-01-3100000711404us-gaap:CommonStockExcludingTreasuryStockParNetValueMember2023-01-3100000711404us-gaap:TreasuryStockCommonMember2023-01-3100000711404us-gaap:TreasuryStockParNetValueMember2023-01-3100000711404us-gaap:AdditionalPaidInCapitalMember2023-01-3100000711404us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-01-3100000711404us-gaap:RetainedEarningsMember2023-01-3100000711404us-gaap:NoncontrollingInterestMember2023-01-31000007114042023-01-3100000711404us-gaap:RetainedEarningsMember2023-02-012023-04-30000007114042023-02-012023-04-3000000711404us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-02-012023-04-3000000711404us-gaap:CommonStockExcludingTreasuryStockParNetValueMember2023-02-012023-04-3000000711404us-gaap:AdditionalPaidInCapitalMember2023-02-012023-04-3000000711404us-gaap:TreasuryStockCommonMember2023-02-012023-04-3000000711404us-gaap:TreasuryStockParNetValueMember2023-04-3000000711404us-gaap:TreasuryStockCommonMember2023-04-3000000711404us-gaap:TreasuryStockParNetValueMember2023-04-3000000711404us-gaap:AdditionalPaidInCapitalMember2023-04-3000000711404us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-04-3000000711404us-gaap:RetainedEarningsMember2023-04-3000000711404us-gaap:NoncontrollingInterestMember2023-04-30000007114042023-04-3000000711404us-gaap:RetainedEarningsMember2023-05-012023-07-3100000711404us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-05-012023-07-3100000711404us-gaap:CommonStockExcludingTreasuryStockParNetValueMember2023-05-012023-07-3100000711404us-gaap:TreasuryStockCommonMember2023-05-012023-07-3100000711404us-gaap:TreasuryStockParNetValueMember2023-05-012023-07-3100000711404us-gaap:AdditionalPaidInCapitalMember2023-05-012023-07-3100000711404us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-05-012023-07-3100000711404us-gaap:RetainedEarningsMember2023-05-012023-07-3100000711404us-gaap:NoncontrollingInterestMember2023-05-012023-07-3100000711404us-gaap:TreasuryStockCommonMember2023-07-3100000711404us-gaap:TreasuryStockParNetValueMember2023-07-3100000711404us-gaap:AdditionalPaidInCapitalMember2023-07-3100000711404us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-07-3100000711404us-gaap:RetainedEarningsMember2023-07-3100000711404us-gaap:NoncontrollingInterestMember2023-07-31000007114042023-07-3100000711404us-gaap:CommonStockExcludingTreasuryStockParNetValueMember2023-10-3100000711404us-gaap:TreasuryStockCommonMember2023-10-3100000711404us-gaap:TreasuryStockParNetValueMember2023-10-3100000711404us-gaap:AdditionalPaidInCapitalMember2023-10-3100000711404us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-10-3100000711404us-gaap:RetainedEarningsMember2023-10-3100000711404us-gaap:NoncontrollingInterestMember2023-10-3100000711404us-gaap:RetainedEarningsMember2023-11-012024-01-31000007114042023-11-012024-01-3100000711404us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-11-012024-01-3100000711404us-gaap:CommonStockExcludingTreasuryStockParNetValueMember2023-11-012024-01-3100000711404us-gaap:AdditionalPaidInCapitalMember2023-11-012024-01-3100000711404us-gaap:TreasuryStockCommonMember2023-11-012024-01-3100000711404us-gaap:TreasuryStockParNetValueMember2024-01-3100000711404us-gaap:AdditionalPaidInCapitalMember2024-01-3100000711404us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-01-3100000711404us-gaap:RetainedEarningsMember2024-01-3100000711404us-gaap:NoncontrollingInterestMember2024-01-31000007114042024-01-3100000711404us-gaap:RetainedEarningsMember2024-02-012024-04-30000007114042024-02-012024-04-3000000711404us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-02-012024-04-3000000711404us-gaap:CommonStockExcludingTreasuryStockParNetValueMember2024-02-012024-04-3000000711404us-gaap:AdditionalPaidInCapitalMember2024-02-012024-04-3000000711404us-gaap:TreasuryStockCommonMember2024-02-012024-04-3000000711404us-gaap:TreasuryStockParNetValueMember2024-04-3000000711404us-gaap:AdditionalPaidInCapitalMember2024-04-3000000711404us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-04-3000000711404us-gaap:RetainedEarningsMember2024-04-3000000711404us-gaap:NoncontrollingInterestMember2024-04-30000007114042024-04-3000000711404us-gaap:RetainedEarningsMember2024-05-012024-07-3100000711404us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-05-012024-07-3100000711404us-gaap:TreasuryStockCommonMember2024-05-012024-07-3100000711404us-gaap:AdditionalPaidInCapitalMember2024-05-012024-07-3100000711404us-gaap:CommonStockExcludingTreasuryStockParNetValueMember2024-07-3100000711404us-gaap:TreasuryStockCommonMember2024-07-3100000711404us-gaap:TreasuryStockParNetValueMember2024-07-3100000711404us-gaap:AdditionalPaidInCapitalMember2024-07-3100000711404us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-07-3100000711404us-gaap:RetainedEarningsMember2024-07-3100000711404us-gaap:NoncontrollingInterestMember2024-07-31000007114042024-07-3100000711404us-gaap:TreasuryStockParNetValueMember2024-07-3100000711404us-gaap:AdditionalPaidInCapitalMember2024-07-3100000711404us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-07-3100000711404us-gaap:RetainedEarningsMember2024-07-3100000711404us-gaap:NoncontrollingInterestMember2024-07-31000007114042024-07-3100000711404us-gaap:TreasuryStockParNetValueMember2024-07

[illegible]

phrases. Forward-looking statements necessarily depend on assumptions, data or methods that may be incorrect or imprecise and are subject to risks and uncertainties. Among the factors that could cause our actual results and future actions to differ materially from those described in forward-looking statements are: Adverse changes in the global or regional general business, political and economic conditions, including the impact of continuing uncertainty and instability of certain countries, man-made or natural disasters and pandemic conditions, that could adversely affect our global markets, and the potential adverse economic impact and related uncertainty caused by these items. The impact of international conflicts and the global response to international conflicts on the global economy, European economy, financial markets, energy markets, currency rates and our ability to supply product to, or through, affected countries. Our substantial and expanding international operations and the challenges of managing an organization spread throughout multiple countries and complying with a variety of legal, compliance and regulatory requirements. Foreign currency exchange rate and interest rate fluctuations including the risk of fluctuations in the value of foreign currencies or interest rates that would decrease our net sales and earnings. Our existing and future variable rate indebtedness and associated interest expense is impacted by rate increases, which could adversely affect our financial health or limit our ability to borrow additional funds. Changes in tax laws, examinations by tax authorities, and changes in our geographic composition of income. Acquisition-related adverse effects including the failure to successfully achieve the anticipated net sales, margins and earnings benefits of acquisitions, integration delays or costs and the requirement to record significant adjustments to the preliminary fair value of assets acquired and liabilities assumed within the measurement period, required regulatory approvals for an acquisition not being obtained or being delayed or subject to conditions that are not anticipated, adverse impacts of changes to accounting controls and reporting procedures, contingent liabilities or indemnification obligations, increased leverage and lack of access to available financing (including financing for the acquisition or refinancing of debt owed by us on a timely basis and on reasonable terms). Compliance costs and potential liability in connection with U.S. and foreign laws and health care regulations pertaining to privacy and security of personal information, such as HIPAA and the California Consumer Privacy Act (CCPA) in the U.S. and the General Data Protection Regulation (GDPR) requirements in Europe, including but not limited to those resulting from data security breaches. A major disruption in the operations of our manufacturing, accounting and financial reporting, research and development, distribution facilities or raw material supply chain due to challenges associated with integration of acquisitions, man-made or natural disasters, pandemic conditions, cybersecurity incidents or other causes. A major disruption in the operations of our manufacturing, accounting and financial reporting, research and development or distribution facilities due to the failure to perform by third-party vendors, including cloud computing providers or other technological problems, including any related to our information systems maintenance, enhancements or new system deployments, integrations or upgrades. Market consolidation of large customers globally through mergers or acquisitions resulting in a larger proportion or concentration of our business being derived from fewer customers. Disruptions in supplies of raw materials, particularly components used to manufacture our silicone hydrogel lenses. New U.S. and foreign government laws and regulations, and changes in existing laws, regulations and enforcement guidance, which affect areas of our operations including, but not limited to, those affecting the health care industry, including the contact lens industry specifically and the medical device or pharmaceutical industries generally, including THE COOPER COMPANIES, INC. AND SUBSIDIARIES Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations but not limited to the EU Medical Devices Regulation (MDR) and the EU In Vitro Diagnostic Medical Devices Regulation (IVDR). Legal costs, insurance expenses, settlement costs and the risk of an adverse decision, prohibitive injunction or settlement related to product liability, patent infringement, contractual disputes, or other litigation. Limitations on sales following product introductions due to poor market acceptance. New competitors, product innovations or technologies, including but not limited to, technological advances by competitors, new products and patents attained by competitors, and competitors' expansion through acquisitions. Reduced sales, loss of customers, reputational harm and costs and expenses, including from claims and litigation related to product recalls and warning letters. Failure to receive, or delays in receiving, regulatory approvals or certifications for products. Failure of our customers and end users to obtain adequate coverage and reimbursement from third-party payers for our products and services. The requirement to provide for a significant liability or to write off, or accelerate depreciation on, a significant asset, including goodwill, other intangible assets and idle manufacturing facilities and equipment. The success of our research and development activities and other start-up projects. Dilution to earnings per share from acquisitions or issuing stock. Impact and costs incurred from changes in accounting standards and policies. Risks related to environmental laws and requirements applicable to our facilities, products or manufacturing processes, including evolving regulations regarding the use of hazardous substances or chemicals in our products. Risks related to environmental, social and corporate governance (ESG) issues, including those related to regulatory and disclosure requirements, climate change and sustainability. Other events described in our Securities and Exchange Commission filings, including the Business and Risk Factors sections in our Annual Report on Form 10-K for the fiscal year ended October 31, 2023, as such Risk Factors may be updated in quarterly filings including updates made in this filing. We caution investors that forward-looking statements reflect our analysis only on their stated date. We disclaim any intent to update them except as required by law. THE COOPER COMPANIES, INC. AND SUBSIDIARIES Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations Results of Operations In this section, we discuss the results of our operations for the third quarter of fiscal 2024 ended July 31, 2024, compared with the same period of fiscal 2023. We discuss our cash flows and current financial condition under Capital Resources and Liquidity. Within the tables presented, percentages are calculated based on the underlying whole-dollar amounts and, therefore, may not recalculate exactly from the rounded numbers used for disclosure purposes. A Outlook We are optimistic about the long-term prospects for the worldwide contact lens and general health care markets, and the resilience of and growth prospects for our businesses and products. However, we face significant risks and uncertainties in our global operating environment as further described in the Part II, Item 1A "Risk Factors" herein. These risks include uncertain global and regional business, political and economic conditions, including but not limited to those associated with man-made or natural disasters, pandemic conditions, inflation, foreign exchange rate fluctuations, regulatory developments, supply chain disruptions, and escalating global trade barriers. These risks and uncertainties have adversely affected our sales, cash flow and performance in the past and could further adversely affect our future sales, cash flow and performance. CooperVision - We compete in the worldwide contact lens market with our spherical, toric, multifocal, and toric multifocal contact lenses offered in materials like silicone hydrogel Aquaform technology. We believe that there will be lower contact lens wearer dropout rates as technology improves and enhances the wearing experience through a combination of improved designs and materials and the growth of preferred modalities such as single-use and monthly wearing options. CooperVision also competes in the myopia management and specialty eye care contact lens markets with myopia management contact lenses using its ActivControl technology and with products such as orthokeratology (ortho-k) and scleral lenses. CooperVision has U.S. Food and Drug Administration (FDA) approval for its MiSight 1 day lens, which is the first and only FDA-approved product indicated to slow the progression of myopia in children with treatment initiated between the ages of 8-12. Further, CooperVision has Chinese National Medical Products Administration (NMPA) approval for its MiSight 1 day lens for use in China. CooperVision is focused on greater worldwide market penetration using recently introduced products, and we continue to expand our presence in existing and emerging markets, including through acquisitions. Our ability to compete successfully with a full range of silicone hydrogel products is an important factor to achieving our desired future levels of sales growth and profitability. CooperVision manufactures and markets a wide variety of silicone hydrogel contact lenses. Our single-use silicone hydrogel product franchises, clariti, MyDay and MyDay Energys remain a focus as we expect increasing demand for these products, as well as future single-use products, as the global contact lens market continues to shift to this modality. Outside of single-use, the Biofinity and Avaira Vitality product families comprise our focus in the FRP, or frequent replacement product, market which encompasses the monthly and two-week modalities. Included in this segment are unique products such as Biofinity Energys, which helps individuals with digital eye fatigue. CooperSurgical - Our CooperSurgical business competes in the fertility and women's health care market through its diversified portfolio of products and services, including fertility products and services, medical devices, cryostorage (such as cord blood and cord tissue storage) and contraception. CooperSurgical has established its market presence and distribution system by developing products and acquiring companies, products and services that complement its business model. Competitive factors in the segments in which CooperSurgical competes include technological and scientific advances, product quality and availability, price and customer service (including response time and effective communication of product information to physicians, consumers, fertility clinics and hospitals). We protect our products through patents and trademark registrations, both in the United States and in international markets. We monitor competitive products trademark use worldwide and, when determined appropriate, we have enforced and plan to continue to enforce and defend our patent and trademark rights. We also rely upon trade secrets, licenses, technical know-how and continuing technological innovation to develop and maintain our competitive position. CooperVision, CooperSurgical, and other trade names, trademarks or service marks of the Company and its subsidiaries appearing in this report are the property of the Company and its subsidiaries. Trade names, trademarks and service marks of the other companies appearing in this report are the property of their respective holders. THE COOPER COMPANIES, INC. AND SUBSIDIARIES Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations Net Sales CooperVision Net Sales The contact lens market has two major product categories: Toric and multifocal lenses including lenses that, in addition to correcting near- and farsightedness, address more complex visual defects such as astigmatism and presbyopia by adding optical properties of cylinder and axis, which correct for irregularities in the shape of the cornea; and Spherical lenses, including lenses that correct near- and farsightedness uncomplicated by more complex visual defects, myopia management lenses, which slow the progression of and correct myopia in age-appropriate children, and other specialty lenses. CooperVision Net Sales by Category Three Months Ended July 31, 2024 vs 2023% Change (\$ in millions) 2024 2023 Toric and Multifocal \$326.4A \$296.5A 10A %Sphere, other \$349.2A 333.7A 5A %\$675.6A \$630.2A 7A %20THE COOPER COMPANIES, INC. AND SUBSIDIARIES Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations Nine Months Ended July 31, 2024 vs 2023% Change (\$ in millions) 2024 2023 Toric and Multifocal \$934.0A \$838.5A 11A %Sphere, other \$999.0A 962.3A 4A %\$1,933.0A \$1,800.8A 7A %In the three and nine months ended July 31, 2024, the growth experienced across all categories was partially offset by unfavorable foreign exchange rate fluctuations of approximately \$13.1A million and \$19.8A million, respectively. Toric and multifocal grew primarily through the success of Biofinity and MyDay. Sphere, other grew primarily through Biofinity, MiSight, and MyDay. Other products represented approximately 1% of net sales in the three and nine months ended July 31, 2024, and 2023, respectively. CooperVision Net Sales by Geography CooperVision competes in the worldwide soft contact lens market and services in three primary regions: the Americas, EMEA (Europe, Middle East and Africa) and Asia Pacific. Periods Ended July 31, Three Months Nine Months (\$ in millions) 2024 2023 2024 vs 2023% Change 2024 2023 2024 vs 2023% Change Americas \$279.8A \$248.6A 13A %\$796.8A \$733.3A 9A %EMEA \$256.5A 242.2A 6A %\$731.7A 666.6A 10A %Asia Pacific \$139.3A 139.4A 0A %\$404.5A 400.9A 1A %\$675.6A \$630.2A 7A %\$1,933.0A \$1,800.8A 7A %CooperVision's growth in net sales across all regions was primarily attributable to market gains of silicone hydrogel contact lenses. Refer to CooperVision Net Sales by Category above for further discussion. THE COOPER COMPANIES, INC. AND SUBSIDIARIES Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations CooperSurgical Net Sales CooperSurgical supplies the fertility and women's health care market with a diversified portfolio of products and services in two categories: Office and surgical offerings include products that facilitate surgical and non-surgical procedures that are commonly performed primarily by obstetricians and gynecologists in hospitals, surgical centers, and medical offices. This includes medical devices, cryostorage (such as cord blood and cord tissue storage), and contraception. Fertility offerings include highly specialized products and services that target the IVF process, including diagnostics testing with a goal to make fertility treatment safer, more efficient and convenient. This includes fertility consumables and equipment, donor gamete services, and genomic services (including genetic testing). CooperSurgical Net Sales by Category Three Months Ended July 31, 2024 vs 2023% Change (\$ in millions) 2024 2023 Office and surgical \$197.9A \$178.4A 11A %Fertility \$129.3A 121.6A 6A %\$327.2A \$300.0A 9A %22THE COOPER COMPANIES, INC. AND SUBSIDIARIES Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations Nine Months Ended July 31, 2024 vs 2023% Change (\$ in millions) 2024 2023 Office and surgical \$571.9A \$506.6A 13A %Fertility \$372.1A 358.7A 4A %\$944.0A \$865.3A 9A %In the three months ended July 31, 2024, office and surgical net sales increased primarily due to the addition of Cook Medical on November 1, 2023. Fertility net sales increased due to an increase in revenue from consumable products and genetic testing. In the nine months ended July 31, 2024, office and surgical net sales increased primarily due to the addition of Cook Medical on November 1, 2023, and an increase in revenue from Paragard. Fertility net sales increased due to an increase in revenue from consumable products and genomic services, partially offset by a decrease in revenue from gamete services. The above growth experienced across all categories was partially offset by unfavorable foreign exchange rate fluctuations of approximately \$3.0A million and \$9.7A million for the three and nine months ended July 31, 2024, respectively. Gross Margin Consolidated gross margin was relatively flat at 66% and 67% in the three and nine months ended July 31, 2024, respectively, compared to 66% in the three and nine months ended July 31, 2023. 23THE COOPER COMPANIES, INC. AND SUBSIDIARIES Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations Selling, General and Administrative (SGA) Expenses Three Months Ended July 31, 2024 vs 2023% Change (\$ in millions) 2024A Net Sales 2023% Net Sales CooperVision \$232.5A 34A %\$28.2A 36A %2A CooperSurgical \$127.1A 39A %128.1A 43A %1(1)%Corporate \$21.5A 6A %18.9A 14A %38A %\$375.2A 40A %2A %Nine Months Ended July 31, 2024 vs 2023% Change (\$ in millions) 2024A Net Sales 2023% Net Sales CooperVision \$679.9A 35A %\$637.3A 35A %7A CooperSurgical \$395.1A 42A %423.7A 49A %7(7)%Corporate \$67.3A 6A %52.6A 28A %\$1,142.3A 40A %\$1,113.6A 42A %3A CooperVision's SGA expenses increased in the three months ended July 31, 2024, compared to the three months ended July 31, 2023, due to increase in advertising and marketing activities. The increase in the nine months ended July 31, 2024, was primarily due to \$31.8 million release of contingent consideration liability associated with SightGlass Vision's regulatory approval milestone in the nine months ended July 31, 2023. CooperSurgical's SGA expenses was relatively flat in the three months ended July 31, 2024, compared to the three months ended July 31, 2023. The decrease in the nine months ended July 31, 2024 was due to an accrual of \$45.0 million associated with the payment of a termination fee under an asset purchase agreement related to Cook Medical's reproductive health business in the nine months ended July 31, 2023, partially offset by an increase in selling activities and distribution costs. Corporate SGA expenses increased in the three and nine months ended July 31, 2024, compared to the three and nine months ended July 31, 2023, primarily due to share-based compensation related expenses. Research and Development (R&D) Expenses Three Months Ended July 31, 2024 vs 2023% Change (\$ in millions) 2024A Net Sales 2023% Net Sales CooperVision \$21.6A 3A %\$19.4A 3A %11A CooperSurgical \$17.4A 5A %17.1A 6A %2A %\$39.0A 4A %\$36.5A 4A %7A %Nine Months Ended July 31, 2024 vs 2023% Change (\$ in millions) 2024A Net Sales 2023% Net Sales CooperVision \$63.2A 3A %\$53.0A 3A %19A CooperSurgical \$54.2A 6A %47.7A 6A %14A %\$117.4A 4A %\$100.7A 4A %17A CooperVision's R&D expenses increased in the three and nine months ended July 31, 2024, compared to the three and nine months ended July 31, 2023, primarily due to myopia management programs and R&D projects. CooperVision's R&D activities are primarily focused on the development of contact lenses, manufacturing technology and process enhancements. CooperSurgical's R&D expenses increased in the three and nine months ended July 31, 2024, compared to the three and nine months ended July 31, 2023, mainly due to an increase in R&D project spend. CooperSurgical's R&D activities are focused on developing and refining diagnostic and therapeutic products including medical interventions, surgical devices and fertility solutions. 24THE COOPER COMPANIES, INC. AND SUBSIDIARIES Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations Amortization Expense Three Months Ended July 31, 2024 vs 2023% Change (\$ in millions) 2024A Net Sales 2023% Net Sales CooperVision \$7.9A 1A %\$8.3A 1A %5(5)%CooperSurgical \$42.5A 13A %\$38.4A 13A %11A %\$50.4A 5A %\$46.7A 5A %8A %Nine Months Ended July 31, 2024 vs 2023% Change (\$ in millions) 2024A Net Sales 2023% Net Sales CooperVision \$23.3A 1A %\$25.0A 1A %7(7)%CooperSurgical \$127.7A 14A %114.7A 13A %11A %\$151.0A 5A %\$139.7A 5A %8A CooperVision's amortization expense for the three and nine months ended July 31, 2024, remained relatively flat year over year. CooperSurgical's amortization expense increased in the three and nine months ended July 31, 2024, compared to the three and nine months ended July 31, 2023, primarily due to the amortization of intangible assets recently acquired through acquisitions. Operating Income Three Months Ended July 31, 2024 vs 2023% Change (\$ in millions) 2024A Net Sales 2023% Net Sales CooperVision \$172.7A 26A %\$151.7A 24A %14A CooperSurgical \$41.3A 13A %16.8A 6A %120A Corporate (21.5)A (18.9)A 14A %\$192.5A 19A %\$151.6A 16A %27A %Nine Months Ended July 31, 2024 vs 2023% Change (\$ in millions) 2024A Net Sales 2023% Net

SalesCooperVision\$487.7A 25A %\$449.7A 25A %8A %CooperSurgical86.9A 9A %0.3A æ"Å %28,003A %Corporate(67.3)æ"Å (52.6)æ"Å 28A %\$507.3A 18A %\$397.4A 15A %28A %CooperVision' operating income increased in the three and nine months ended JulyA 31, 2024, compared to the three and nine months ended JulyA 31, 2023, primarily due to a net increase in net sales, partially offset by a net increase in operating expenses.CooperSurgical's operating income increased in the three months ended JulyA 31, 2024, compared to the three months ended JulyA 31, 2023, primarily due to a net increase in net sales, partially offset by a net increase in operating expenses. The increase in the nine months ended JulyA 31, 2023, was due to an accrual of \$45.0 million associated with the payment of a termination fee under an asset purchase agreement related to Cook Medicalæ"™'s reproductive health business. Corporate operating loss increased in the three and nine months ended JulyA 31, 2024, compared to the three and nine months ended JulyA 31, 2023, primarily due to higher share-based compensation expenses.25THE COOPER COMPANIES, INC. AND SUBSIDIARIESItem 2. Managementæ"™'s Discussion and Analysis of Financial Conditionand Results of OperationsInterest ExpenseThree Months Ended July 31,2024 vs 2023% Change(\$ in millions)2024% Net Sales2023%Net SalesInterest expenses\$28.5A 3A %\$26.8A 3A %7A %Nine Months Ended July 31,2024 vs 2023% Change(\$ in millions)2024% Net Sales2023% Net SalesInterest expense\$87.3A 3A %\$79.0A 3A %11A %Interest expense increased during the three and nine months ended JulyA 31, 2024, compared to the three and nine months ended JulyA 31, 2023, primarily due to higher debt balances and higher interest rates.Other Expense, NetPeriods Ended July 31,Three MonthsNine Months(\$ in millions)2024202320242023Foreign exchange (gain) loss\$(0.5)\$4.3A 3.2A \$6.1A Other expense, net0.8A 1.7A 3.1A 5.8A \$0.3A \$6.0A \$6.3A \$11.9A Foreign exchange (gain) loss was primarily associated with the relative weakening of the U.S. dollar against foreign currencies and the effect on intercompany receivables during the three and nine months ended JulyA 31, 2024.Other expense, net decreased in the three and nine months ended JulyA 31, 2024, compared to the three and nine months ended JulyA 31, 2023, primarily due to a decrease in loss on minority investments.Provision for Income TaxesThe effective tax rates for the three months ended July 31, 2024, and 2023, were 36.1% and 28.2%, respectively. The effective tax rates for the nine months ended July 31, 2024, and 2023, were 33.6% and 31.6%, respectively. The increases were primarily due to changes in the geographic composition of pre-tax earnings and an increase in the UK statutory tax rate from 19% to 25%.26THE COOPER COMPANIES, INC. AND SUBSIDIARIESItem 2. Managementæ"™'s Discussion and Analysis of Financial Conditionand Results of OperationsCapital Resources and LiquidityWorking capital as of JulyA 31, 2024, and OctoberA 31, 2023, was \$957.2A million and \$735.9A million, respectively. The increase in working capital was primarily due to an increase in trade accounts receivable mainly due to higher sales and timing of collections, an increase in prepaid expenses and other current assets, and an increase in inventories.Cash FlowNine Months Ended July 31,(\$ in millions)20242023Operating activities\$441.2A \$433.3A Investing activities(\$23.0)(288.2)(21.0)Financing activities67.6A (167.4)Effect of exchange rate changes on cash, cash equivalents, restricted cash3.1A 1.2A Net decrease in cash, cash equivalents, and restricted cash\$(11.1)\$(21.1)Operating Cash FlowCash provided by operating activities in the first nine months of fiscal 2024 increased compared to the first nine months of fiscal 2023, primarily due to net changes in other non-cash items and the \$31.8 million release of contingent consideration liability associated with SightGlass Vision's regulatory approval milestone in the first nine months of fiscal 2023, partially offset by net changes in operating capital.Investing Cash FlowCash used in investing activities in the first nine months of fiscal 2024 increased compared to the first nine months of fiscal 2023, primarily attributable to \$233.5A million cash paid for acquisitions in the first nine months of fiscal 2024, and an increase in purchases of property, plant and equipment.Financing Cash FlowCash provided by financing activities in the first nine months of fiscal 2024 was primarily attributable to funds received from the 2024 Revolving Credit Facility, partially offset by repayments to fully repay all borrowings outstanding under the 2020 Term Loan Facility and the 2020 Revolving Credit Facility.Cash used in financing activities in the first nine months of fiscal 2023 was primarily due to repayments of \$338.0A million on the 2021 364-day term loan, partially offset by \$163.5A million of funds drawn on the 2020 Revolving Credit Facility.The following is a summary of the maximum commitments and the net amounts available to us under different credit facilities as of JulyA 31, 2024:(In millions)Facility LimitOutstanding BorrowingsOutstanding Letters of CreditTotal Amount AvailableMaturity DateRevolving Credit:2024 Revolving Credit\$2,300.0A \$1,090.2A \$2.4A \$1,207.4A May 1, 2029Term loan:2021 Term Loan1,500.0A 1,500.0A n/aæ"Å A December 17, 2026Totals\$3,800.0A \$2,590.2A \$2.4A \$1,207.4A As of JulyA 31, 2024, the Company was in compliance with all debt covenants. On May 1, 2024, the Company entered into a Revolving Credit Agreement (the 2024 Credit Agreement). The Company drew on the 2024 Credit Agreement to fully repay borrowings outstanding under the 2020 Term Loan and 2020 Revolving Credit Facility and terminated the 2020 Credit Agreement. See Note 5. Financing Arrangements of the Consolidated Condensed Financial Statements for further information.27THE COOPER COMPANIES, INC. AND SUBSIDIARIESItem 2. Managementæ"™'s Discussion and Analysis of Financial Conditionand Results of OperationsConsidering recent market conditions, we have re-evaluated our operating cash flows and cash requirements and continue to believe that current cash, cash equivalents, future cash flow from operating activities and cash available under our 2024 Credit Agreement will be sufficient to meet our anticipated cash needs, including working capital needs, capital expenditures and contractual obligations for at least 12 months from the issuance date of the Consolidated Condensed Financial Statements included in this quarterly report. To the extent additional funds are necessary to meet our liquidity needs such as for acquisitions, share repurchases or other activities as we execute our business strategy, we anticipate that additional funds could be obtained through the incurrence of additional indebtedness, additional equity financings or a combination of these potential sources of funds; however, such financing may not be available on favorable terms, or at all.Share RepurchaseIn March 2017, the authorization under the 2012 Share Repurchase Program was increased to \$1.0 billion by the Company's Board of Directors. As of JulyA 31, 2024, \$256.4 million remains authorized for repurchase.During the nine months ended JulyA 31, 2024, and 2023, there were no share repurchases.DividendsIn December 2023, the Company's Board of Directors decided to end the declaration of the semiannual dividend.Stock SplitOn FebruaryA 16, 2024, the Company effected a four-for-one stock split of its outstanding shares of common stock. All share and per share information has been retroactively adjusted to reflect the stock split for all periods presented. The par value of the common stock remains \$0.10 per share. Estimates and Critical Accounting PoliciesInformation regarding estimates and critical accounting policies is included in Management's Discussion and Analysis in our Form 10-K for the fiscal year ended OctoberA 31, 2023. There have been no material changes in our policies2 from those previously discussed in our Form 10-K for the fiscal year ended OctoberA 31, 2023.Accounting Pronouncements Information regarding new accounting pronouncements is included in Note 1. General of the Consolidated Condensed Financial Statements of this Quarterly Report on Form 10-Q.2 To further clarify the policy detailed in our Annual Report on Form 10-K for the fiscal year ended OctoberA 31, 2023, the current portion of the deferred revenue balances at the beginning of each period presented were generally fully recognized in a ratable manner in the subsequent 12-month period. We recognized revenue of approximately \$30.0A million and \$92.0A million for the three and nine months ended JulyA 31, 2024, respectively, that was included in the deferred revenue balance at AprilA 30, 2024, and OctoberA 31, 2023.We recognized revenue of approximately \$30.0 million and \$80.0A million for the three and nine months ended JulyA 31, 2023, respectively, that was included in the deferred revenue balance at AprilA 30, 2023, and OctoberA 31, 2022.28THE COOPER COMPANIES, INC. AND SUBSIDIARIESItemA 3. Quantitative and Qualitative Disclosure About Market RiskWe are exposed to market risks that relate principally to changes in interest rates and foreign currency fluctuations. We do not enter into derivative financial instrument transactions for speculative purposes.Foreign Currency Exchange RiskWe operate multiple foreign subsidiaries that manufacture and market our products worldwide. As a result, our earnings, cash flow and financial position are exposed to foreign currency risk from foreign currency denominated receivables and payables, sales transactions, capital expenditures and net investment in certain foreign operations. Most of our operations outside the United States have their local currency as their functional currency. We have exposure to multiple foreign currencies, including, among others, the British pound, Euro and Japanese yen. We have taken steps to minimize our balance sheet exposure by entering into foreign currency forward contracts to minimize the short-term impact of foreign currency exchange rate fluctuations on certain trade and intercompany receivables and payables. At JulyA 31, 2024, a uniform hypothetical 10% increase or decrease in the foreign currency exchange rates in comparison to the value of the U.S. dollar would have resulted in a corresponding increase or decrease of approximately \$22.0 million in operating income for the fiscal quarter ended JulyA 31, 2024. See Note 12. Financial Derivatives and Hedging of the Consolidated Condensed Financial Statements for further information.Interest Rate RiskWe are exposed to risks associated with changes in interest rates, as the interest rates on our revolving lines of credit and term loans may vary with the federal funds rate and SOFR. As of JulyA 31, 2024, we had outstanding debt for an aggregate carrying amount of \$2.6 billion. We have entered, and in the future may enter, into interest rate swaps to manage interest rate risk.Our ultimate realized gain or loss with respect to interest rate fluctuations will depend on interest rates, the exposures that arise during the period and our hedging strategies at that time. As an example, if interest rates were to increase or decrease by 1% or 100 basis points, the quarterly interest expense would not have a material impact, based on average debt outstanding, after consideration of our interest rate swap contracts, during the third quarter of fiscal 2024. See Note 5. Financing Arrangements of the Consolidated Condensed Financial Statements for further information.ItemA 4. Controls and ProceduresEvaluation of Disclosure Controls and ProceduresBased on managementæ"™'s evaluation (with the participation of our Chief Executive Officeræ"™ (our Principal Executive Officer) and Chief Financial Officer (our Principal Financial Officer)), as of the end of the period covered by this report, our Chief Executive Officer and Chief Financial Officer have concluded that our disclosure controls and procedures (as defined in RulesA 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended, (the Exchange Act)) are effective as of JulyA 31, 2024 to provide reasonable assurance that information required to be disclosed by us in reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in Securities and Exchange Commission rules and forms and is accumulated and communicated to management, including our Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosure. Changes in Internal Control over Financial ReportingThere have been no changes in our internal control over financial reporting identified in connection with the evaluation required by Rules 13a-15(d)A and 15d-15(d)A of the Exchange Act during our third quarter of fiscal 2024, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting. 29THE COOPER COMPANIES, INC. AND SUBSIDIARIESPART IIæ"™"OTHER INFORMATIONItemA 1. Legal ProceedingsInformation regarding legal proceedings is included in Note 10. Contingencies of the Consolidated Condensed Financial Statements of this Quarterly Report on Form 10-Q.ItemA 1A. Risk FactorsOur business faces significant risks. These risks include those described below and may include additional risks and uncertainties not presently known to us or that we currently deem immaterial. Our business, financial condition and results of operations could be materially adversely affected by any of these risks, and the trading prices of our common stock could decline by virtue of these risks. These risks should be read in conjunction with the other information in this report.Risk factors describing the major risks to our business can be found under Item 1A. Risk Factors in our Annual Report on Form 10-K for the fiscal year ended OctoberA 31, 2023. There have been no material changes to the risk factors previously disclosed in our Annual Report on Form 10-K for the fiscal year ended OctoberA 31, 2023.ItemA 2. Unregistered Sales of Equity Securities and Use of ProceedsIn March 2017, the authorization under the 2012 Share Repurchase Program was increased to \$1.0 billion by the Company's Board of Directors. As of JulyA 31, 2024, \$256.4 million remains authorized for repurchase.During the nine months ended JulyA 31, 2024, and 2023, there were no share repurchases. Item 3. Defaults Upon Senior SecuritiesNone.Item 4. Mine Safety DisclosuresNot applicable.Item 5. Other InformationDuring the three months ended JulyA 31, 2024, no director or officer of the Company adopted or terminated a Rule 10b5-1 trading arrangement or non-Rule 10b5-1 trading arrangement, as each term is defined in Item 408(a) of Regulation S-K.30THE COOPER COMPANIES, INC. AND SUBSIDIARIESItemA 6. ExhibitsIncorporated by ReferenceFiled HerewithExhibitNumberDescription of DocumentFormExhibitFiling Date/Period EndDate31.1Certification of the Chief Executive Officer, pursuant to Rule 13a-14(a) under the Securities Exchange Act of 1934X31.2Certification of the Chief Financial Officer, pursuant to Rule 13a-14(a) under the Securities Exchange Act of 1934X32.1*Certification of the Chief Executive Officer, pursuant to 18 U.S.C. Section 1350X32.2*Certification of the Chief Financial Officer, pursuant to 18 U.S.C. Section 1350X101.1The following materials from the Company's Quarterly Report on Form 10-Q for the three and nine months period ended JulyA 31, 2024 formatted in Inline XBRL (Extensible Business Reporting Language): (i) Consolidated Condensed Statements of Income and Comprehensive Income, (ii) Consolidated Condensed Balance Sheets, (iii) Consolidated Condensed Statements of Stockholders' Equity, (iv) Consolidated Condensed Statements of Cash Flows and (v) related Notes to Consolidated Condensed Financial Statements.104.1Cover Page Interactive Data File (embedded within the Inline XBRL document)* Furnished herewith31THE COOPER COMPANIES, INC. AND SUBSIDIARIESSIGNATURESPursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.The Cooper Companies, Inc.(Registrant)Date: AugustA 29, 2024/s/ Brian G. AndrewsBrian G. AndrewsExecutive Vice President, Chief Financial Officer and Treasurer(Principal Financial Officer)Date: AugustA 29, 2024/s/ Agostino RicupatiAgostino RicupatiSenior Vice President and Chief Accounting Officer (Principal Accounting Officer)32 EX-31.1 2 coo-ex311 2024x07x31x10q.htm EX-31.1 DocumentExhibit 31.1CERTIFICATION PURSUANT TO EXCHANGE ACT RULE 13a-14(a)/15d-14(a) AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002I, Albert G. White III, certify that:I.I have reviewed this Quarterly Report on Form 10-Q of The Cooper Companies, Inc. (the æ"œregistrantæ"™);2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;4.The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:a.Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;b.Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;c.Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; andd.Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and5.The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):a.All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; andb.Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.Date: AugustA 29, 2024/s/ Albert G. White IIIAAlbert G. White IIIPresident and Chief Executive Officer EX-31.2 3 coo-ex312 2024x07x31x10q.htm EX-31.2 DocumentExhibit 31.2 CERTIFICATION PURSUANT TO EXCHANGE ACT RULE 13a-14(a)/15d-14(a) AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002I, Brian G. Andrews, certify that: I.I have reviewed this Quarterly Report on Form 10-Q of The Cooper Companies, Inc. (the æ"œregistrantæ"™);2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;4.The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:a.Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;b.Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;c.Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based

such evaluation; and disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and 5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions): a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting. Date: August 29, 2024/s/ Brian G. Andrews Brian G. Andrews Executive Vice President, Chief Financial Officer and Treasurer EX-32.1 2024x07x31x10q.htm EX-32.1 Document Exhibit 32.1 CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350 AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 I, Albert G. White III, do hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge: a. The Quarterly Report on Form 10-Q of The Cooper Companies, Inc. (the "Company") for the quarterly period ended July 31, 2024, as filed with the Securities and Exchange Commission (the "Report"), fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and b. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. Date: August 29, 2024/s/ Albert G. White III Albert G. White III President and Chief Executive Officer EX-32.2 2024x07x31x10q.htm EX-32.2 Document Exhibit 32.2 CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350 AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 I, Brian G. Andrews, do hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge: a. The Quarterly Report on Form 10-Q of The Cooper Companies, Inc. (the "Company") for the quarterly period ended July 31, 2024, as filed with the Securities and Exchange Commission (the "Report"), fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and b. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. Date: August 29, 2024/s/ Brian G. Andrews Brian G. Andrews Executive Vice President, Chief Financial Officer and Treasurer EX-101.SCH 6 coo-20240731.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0000001 - Document - Cover link: presentationLink link: calculationLink link: definitionLink link: definitionLink 9952151 - Statement - Consolidated Condensed Statements of Income and Comprehensive Income link: presentationLink link: calculationLink link: definitionLink link: definitionLink 9952152 - Statement - Consolidated Condensed Statements of Income and Comprehensive Income (Parenthetical) link: presentationLink link: calculationLink link: definitionLink link: definitionLink 9952153 - Statement - Consolidated Condensed Balance Sheets link: presentationLink link: calculationLink link: definitionLink link: definitionLink 9952154 - Statement - Consolidated Condensed Balance Sheets (Parenthetical) link: presentationLink link: calculationLink link: definitionLink link: definitionLink 9952155 - Statement - Consolidated Condensed Statements of Stockholders' Equity link: presentationLink link: calculationLink link: definitionLink link: definitionLink 9952156 - Statement - Consolidated Condensed Statements of Stockholders' Equity (Parenthetical) link: presentationLink link: calculationLink link: definitionLink link: definitionLink 9952157 - Statement - Consolidated Condensed Statements of Cash Flows link: presentationLink link: calculationLink link: definitionLink link: definitionLink 9952158 - Disclosure - General link: presentationLink link: calculationLink link: definitionLink link: definitionLink 9952159 - Disclosure - Acquisitions and Joint Venture link: presentationLink link: calculationLink link: definitionLink link: definitionLink 9952160 - Disclosure - Inventories link: presentationLink link: calculationLink link: definitionLink link: definitionLink 9952161 - Disclosure - Intangible Assets link: presentationLink link: calculationLink link: definitionLink link: definitionLink 9952162 - Disclosure - Financing Arrangements link: presentationLink link: calculationLink link: definitionLink link: definitionLink 9952163 - Disclosure - Income Taxes link: presentationLink link: calculationLink link: definitionLink link: definitionLink 9952164 - Disclosure - Earnings Per Share link: presentationLink link: calculationLink link: definitionLink link: definitionLink 9952165 - Disclosure - Share-Based Compensation link: presentationLink link: calculationLink link: definitionLink link: definitionLink 9952166 - Disclosure - Stockholders' Equity link: presentationLink link: calculationLink link: definitionLink link: definitionLink 9952167 - Disclosure - Contingencies and Commitments link: presentationLink link: calculationLink link: definitionLink link: definitionLink 9952168 - Disclosure - Business Segment Information link: presentationLink link: calculationLink link: definitionLink link: definitionLink 9952169 - Disclosure - Financial Derivatives and Hedging link: presentationLink link: calculationLink link: definitionLink link: definitionLink 9954471 - Disclosure - General (Policies) link: presentationLink link: calculationLink link: definitionLink link: definitionLink 9954472 - Disclosure - Inventories (Tables) link: presentationLink link: calculationLink link: definitionLink link: definitionLink 9954473 - Disclosure - Intangible Assets (Tables) link: presentationLink link: calculationLink link: definitionLink link: definitionLink 9954474 - Disclosure - Financing Arrangements (Tables) link: presentationLink link: calculationLink link: definitionLink link: definitionLink 9954475 - Disclosure - Earnings Per Share (Tables) link: presentationLink link: calculationLink link: definitionLink link: definitionLink 9954476 - Disclosure - Share-Based Compensation (Tables) link: presentationLink link: calculationLink link: definitionLink link: definitionLink 9954477 - Disclosure - Stockholders' Equity (Tables) link: presentationLink link: calculationLink link: definitionLink link: definitionLink 9954478 - Disclosure - Business Segment Information (Tables) link: presentationLink link: calculationLink link: definitionLink link: definitionLink 9954479 - Disclosure - Financial Derivatives and Hedging (Tables) link: presentationLink link: calculationLink link: definitionLink link: definitionLink 9954480 - Disclosure - General (Details) link: presentationLink link: calculationLink link: definitionLink link: definitionLink 9954481 - Disclosure - Acquisitions and Joint Venture (Details) link: presentationLink link: calculationLink link: definitionLink link: definitionLink 9954482 - Disclosure - Inventories (Details) link: presentationLink link: calculationLink link: definitionLink link: definitionLink 9954483 - Disclosure - Intangible Assets - Summary Of Intangible Assets (Details) link: presentationLink link: calculationLink link: definitionLink link: definitionLink 9954484 - Disclosure - Intangible Assets - Remaining Amortization Expenses for Intangible Assets with Definite Lives (Details) link: presentationLink link: calculationLink link: definitionLink link: definitionLink 9954485 - Disclosure - Intangible Assets - Narrative (Details) link: presentationLink link: calculationLink link: definitionLink link: definitionLink 9954486 - Disclosure - Financing Arrangements - Total Debt (Details) link: presentationLink link: calculationLink link: definitionLink link: definitionLink 9954487 - Disclosure - Financing Arrangements - Narrative (Details) link: presentationLink link: calculationLink link: definitionLink link: definitionLink 9954488 - Disclosure - Income Taxes (Details) link: presentationLink link: calculationLink link: definitionLink link: definitionLink 9954489 - Disclosure - Earnings Per Share - Schedule of Earnings Per Share (Details) link: presentationLink link: calculationLink link: definitionLink link: definitionLink 9954490 - Disclosure - Earnings Per Share - Schedule of Stock Options and Restricted Stock Units that were not Included in the Diluted Earnings Per Share Calculation (Details) link: presentationLink link: calculationLink link: definitionLink link: definitionLink 9954491 - Disclosure - Share-Based Compensation (Details) link: presentationLink link: calculationLink link: definitionLink link: definitionLink 9954492 - Disclosure - Stockholders' Equity - Schedule of Changes in Accumulated Other Comprehensive Income (Loss) Income (Details) link: presentationLink link: calculationLink link: definitionLink link: definitionLink 9954493 - Disclosure - Stockholders' Equity - Narrative (Details) link: presentationLink link: calculationLink link: definitionLink link: definitionLink 9954494 - Disclosure - Contingencies and Commitments (Details) link: presentationLink link: calculationLink link: definitionLink link: definitionLink 9954495 - Disclosure - Business Segment Information - Schedule of Segment Information (Details) link: presentationLink link: calculationLink link: definitionLink link: definitionLink 9954496 - Disclosure - Business Segment Information - Schedule of Identifiable Assets by Segment (Details) link: presentationLink link: calculationLink link: definitionLink link: definitionLink 9954497 - Disclosure - Business Segment Information - Schedule of Net Sales to Unaffiliated Customers by Country of Domicile (Details) link: presentationLink link: calculationLink link: definitionLink link: definitionLink 9954498 - Disclosure - Business Segment Information - Schedule of Net Property, Plant and Equipment by Country of Domicile (Details) link: presentationLink link: calculationLink link: definitionLink link: definitionLink 9954499 - Disclosure - Financial Derivatives and Hedging - Narrative (Details) link: presentationLink link: calculationLink link: definitionLink link: definitionLink 9954500 - Disclosure - Financial Derivatives and Hedging - Schedule of Derivative Instruments Recognized in Condensed Consolidated Statements of Income (Details) link: presentationLink link: calculationLink link: definitionLink link: definitionLink 9954501 - Disclosure - Financial Derivatives and Hedging - Schedule of Changes in Accumulated Other Comprehensive Income (Details) link: presentationLink link: calculationLink link: definitionLink link: definitionLink EX-101.CAL 7 coo-20240731_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 8 coo-20240731_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 9 coo-20240731_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Statistical Measurement [Domain] Statistical Measurement [Domain] Repayments of long-term debt Repayments of Long-Term Debt Share repurchase program, remaining authorized amount for repurchase Share Repurchase Program, Remaining Authorized, Amount Cover [Abstract] Cover [Abstract] Net decrease in cash, cash equivalents, and restricted cash Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Other current liabilities Other Liabilities, Current Trading Symbol Trading Symbol Segment Reporting Information [Line Items] Segment Reporting Information [Line Items] Equity method investment, ownership percentage Equity Method Investment, Ownership Percentage Comprehensive income Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest All Trading Arrangements All Trading Arrangements [Member] Long-term debt (Note 5) Long-term debt Long-Term Debt and Lease Obligation Compensation Actually Paid vs. Net Income Compensation Actually Paid vs. Net Income [Text Block] Non-NEOs Non-NEOs [Member] Schedule of earnings per share Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Related income tax benefit Share-Based Payment Arrangement, Expense, Tax Benefit Rule 10b5-1 Arrangement Adopted Rule 10b5-1 Arrangement Adopted [Flag] Awards Close in Time to MNPI Disclosures Awards Close in Time to MNPI Disclosures [Table] Rest of world Rest of World Rest Of World, Excluding United States And Europe [Member] Rest Of World, Excluding United States And Europe [Member] Trade accounts receivable, allowance for doubtful accounts Accounts Receivable, Allowance for Credit Loss, Current Pay vs Performance Disclosure [Line Items] Sphere, other Sphere, other [Member] Sphere, Other Peer Group Total Shareholder Return Amount Peer Group Total Shareholder Return Amount Long-term Debt Long-Term Debt, Unclassified [Abstract] Non-Rule 10b5-1 Arrangement Adopted Non-Rule 10b5-1 Arrangement Adopted [Flag] Interest rate Line of Credit Facility, Interest Rate at Period End Gross change in value Other Comprehensive Income (Loss), before Tax Award Timing Disclosures [Line Items] Investment, Name [Domain] Investment, Name [Domain] Other Performance Measure, Amount Other Performance Measure, Amount 2027 Finite-Lived Intangible Asset, Expected Amortization, Year Three Common stock, outstanding (in shares) Common stock, beginning balance (in shares) Common stock, ending balance (in shares) Common Stock, Shares, Outstanding Deferred revenue Contract with Customer, Liability, Current United States United States UNITED STATES Other assets Other Assets, Noncurrent Entity Tax Identification Number Entity Tax Identification Number Gross Carrying Amount Finite-Lived Intangible Assets, Gross Schedule of Finite-Lived Intangible Assets [Table] Intangible Asset, Finite-Lived [Table] Number of shares (in shares) Treasury Stock, Shares, Acquired Antidilutive Securities, Name [Domain] Antidilutive Securities, Name [Domain] Unrecorded Unconditional Purchase Obligation by Category of Item Purchased [Axis] Unrecorded Unconditional Purchase Obligation by Category of Item Purchased [Axis] Operating Segments Operating Segments [Member] Selling, general and administrative expense Selling, General and Administrative Expenses [Member] Net cash provided by operating activities Net Cash Provided by (Used in) Operating Activities Cash flows from operating activities: Net Cash Provided by (Used in) Operating Activities [Abstract] Treasury Stock Treasury Stock, Common [Member] 2024 Credit Agreement Credit Agreement 2024 [Member] Credit Agreement 2024 Schedule of changes in accumulated other comprehensive income Schedule of changes in accumulated other comprehensive income Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block] Equity Components [Axis] Equity Components [Axis] Award Timing Method Award Timing Method [Text Block] Trading Arrangements, by Individual Trading Arrangements, by Individual [Table] Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Office and surgical Office And Surgical [Member] Office And Surgical Insider Trading Policies and Procedures [Line Items] Estimates Use of Estimates, Policy [Policy Text Block] Business Acquisition, Acquiree [Domain] Business Acquisition, Acquiree [Domain] Adjustment to Compensation, Amount Adjustment to Compensation Amount Potential additional borrowing capacity, percentage of EBITDA Line Of Credit Facility, Accordion Feature, Increase Limit, Percentage of EBITDA Line Of Credit Facility, Accordion Feature, Increase Limit, Percentage of EBITDA U.S.-based medical device company U.S.-Based Medical Device Company [Member] U.S.-Based Medical Device Company Compensation Amount Outstanding Recovery Compensation Amount Diluted: Earnings Per Share, Diluted [Abstract] Payables First Installment Payables First Installment [Member] Payables First Installment Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member] Entity Small Business Entity Small Business Company Selected Measure Amount Company Selected Measure Amount Geographical [Axis] Geographical [Axis] Tabular List, Table Tabular List [Table Text Block] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Intangible assets acquired Finite-Lived Intangible Assets Acquired Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member] Lessee, Lease, Description [Line Items] Lessee, Lease, Description [Line Items] Long-term tax payable Accrued Income Taxes, Noncurrent Number of awards excluded (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Asset Acquisition [Axis] Asset Acquisition [Axis] Credit Facility [Domain] Credit Facility [Domain] Cash, cash equivalents, and restricted cash at beginning of period Cash, cash equivalents, and restricted cash at end of period Total cash, cash equivalents, and restricted cash Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Current assets: Assets, Current [Abstract] Goodwill Goodwill Consolidation Items [Axis] Consolidation Items [Axis] Other comprehensive income, net of tax: Other Comprehensive Income

allowance for credit losses of \$42.8 at JulyÁ 31, 2024, and \$31.3 at OctoberÁ 31, 2023 Accounts Receivable, after Allowance for Credit Loss, Current Cost of sales Cost of Sales [Member] Revenues from External Customers and Long-Lived Assets [Line Items] Revenues from External Customers and Long-Lived Assets [Line Items] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Pension Adjustments Prior Service Cost Pension Adjustments Prior Service Cost [Member] Document Fiscal Period Focus Document Fiscal Period Focus All Executive Categories All Executive Categories [Member] Effect of dilutive stock plans (in shares) Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements Other Other Debt [Member] Other Debt [Member] 2026 Finite-Lived Intangible Asset, Expected Amortization, Year Two Changed Peer Group, Footnote Changed Peer Group, Footnote [Text Block] ASSETS Assets [Abstract] Composite intangible assets Composite intangible assets Composite [Member] Composite [Member] Other comprehensive income (loss), net of tax Other Comprehensive Income (Loss), Net of Tax Document Type Document Type Derivative Contract [Domain] Derivative Contract [Domain] AOCI Attributable To Parent, Before Reclassification And Tax [Roll Forward] AOCI Attributable To Parent, Before Reclassification And Tax [Roll Forward] AOCI Attributable To Parent, Before Reclassification And Tax [Roll Forward] AOCI Attributable To Parent, Before Reclassification And Tax [Roll Forward] Pension Benefits Adjustments, Footnote Pension Benefits Adjustments, Footnote [Text Block] Schedule of segment information Schedule of Segment Reporting Information, by Segment [Table Text Block] Total Shareholder Return Vs Peer Group Total Shareholder Return Vs Peer Group [Text Block] Exercise prices, lower limit (in dollars per share) Share-Based Payment Arrangement, Option, Exercise Price Range, Lower Range Limit Intangible assets with indefinite lives, net Indefinite-Lived Intangible Assets (Excluding Goodwill) Maximum Maximum [Member] Amortization of intangibles Amortization of Intangible Assets Equity Valuation Assumption Difference, Footnote Equity Valuation Assumption Difference, Footnote [Text Block] Intangible assets with definite lives, net Finite-Lived Intangible Assets, Net Antidilutive Securities [Axis] Antidilutive Securities [Axis] Accounts payable Accounts Payable, Current Contingencies and Commitments Commitments and Contingencies, Policy [Policy Text Block] Current Fiscal Year End Date Current Fiscal Year End Date Statistical Measurement [Axis] Statistical Measurement [Axis] PEO Name PEO Name Non-Rule 10b5-1 Arrangement Terminated Non-Rule 10b5-1 Arrangement Terminated [Flag] Income before income taxes Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest All Award Types Award Type [Domain] Non-PEO NEO Average Total Compensation Amount Non-PEO NEO Average Total Compensation Amount Name Outstanding Recovery, Individual Name Schedule of stock options and restricted stock units that were not included in the diluted earnings per share calculation Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Compensation Actually Paid vs. Company Selected Measure Compensation Actually Paid vs. Company Selected Measure [Text Block] Deferred tax assets Deferred Income Tax Assets, Net Non-PEO NEO Non-PEO NEO [Member] Weighted-Average Amortization Period (in years) Finite-Lived Intangible Asset, Useful Life Additional Paid-In Capital Additional Paid-in Capital [Member] Financing lease liabilities Finance Lease, Liability, Noncurrent Award Timing Predetermined Award Timing Predetermined [Flag] Subsequent Event Type [Domain] Subsequent Event Type [Domain] Dividends on common stock Dividends on common stock Payments of Ordinary Dividends, Common Stock Investment, Name [Axis] Investment, Name [Axis] Contingencies and Commitments Contingencies Disclosure [Text Block] Customer relationships Customer Relationships [Member] Accounting Pronouncements Issued But Not Yet Adopted New Accounting Pronouncements, Policy [Policy Text Block] Diluted (in dollars per share) Diluted earnings per share (in dollars per share) Earnings Per Share, Diluted Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets by Major Class [Axis] Accumulated Amortization Finite-Lived Intangible Assets, Accumulated Amortization Schedule of remaining amortization expenses for intangible assets with definite lives Finite-Lived Intangible Assets Amortization Expense [Table Text Block] Name Measure Name Entity Interactive Data Current Entity Interactive Data Current Restatement does not require Recovery Restatement Does Not Require Recovery [Text Block] Preferred stock, issued (in shares) Preferred Stock, Shares Issued Statement of Financial Position [Abstract] Statement of Financial Position [Abstract] Minimum Pension Liability Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member] Repayment of borrowings Repayments of Secured Debt Provision for income taxes (Note 6) Income Tax Expense (Benefit) Derivative notional amount Derivative, Notional Amount Corporate Segment Reporting, Reconciling Item, Corporate Nonsement [Member] 2020 Credit Agreement Credit Agreement 2020 [Member] Credit Agreement 2020 [Member] Thereafter Finite-Lived Intangible Asset, Expected Amortization, After Year Four Finite-Lived Intangible Asset, Expected Amortization, After Year Four Net sales Total net sales Revenue from Contract with Customer, Excluding Assessed Tax Finance lease liabilities, long-term, location Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration] Effective income tax rate Effective Income Tax Rate Reconciliation, Percent Net cash used in investing activities Net Cash Provided by (Used in) Investing Activities Operating income Total operating income Operating Income (Loss) Variable Rate [Domain] Variable Rate [Domain] Business Acquisition [Line Items] Business Acquisition [Line Items] Total liabilities and stockholdersâ€™ equity Liabilities and Equity Rule 10b5-1 Arrangement Terminated Rule 10b5-1 Arrangement Terminated [Flag] All Adjustments to Compensation All Adjustments to Compensation [Member] Employee compensation and benefits Employee-related Liabilities, Current Additional paid-in capital Additional Paid in Capital Financial Derivatives and Hedging Derivative Instruments and Hedging Activities Disclosure [Text Block] Accumulated Other Comprehensive Income (Loss) [Line Items] Accumulated Other Comprehensive Income (Loss) [Line Items] Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] Legal Entity [Axis] Legal Entity [Axis] Finite-Lived Intangible Assets, Major Class Name [Domain] Finite-Lived Intangible Assets, Major Class Name [Domain] General Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block] Underlying Security Market Price Change Underlying Security Market Price Change, Percent Individual: Individual [Axis] Accumulated Other Comprehensive Loss AOCI Attributable to Parent [Member] Payables incurred in acquisition Business Combination, Consideration Transferred, Liabilities Incurred Derivative Instruments Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent [Member] Inventories (Note 3) Total inventories Inventory, Net Product and Service [Axis] Product and Service [Axis] Long-term Debt, Type [Domain] Long-Term Debt, Type [Domain] Entity Address, State or Province Entity Address, State or Province Statement [Line Items] Statement [Line Items] Derivative Instruments and Hedging Activities Disclosure [Abstract] Derivative Instruments and Hedging Activities Disclosure [Abstract] Erroneous Compensation Analysis Erroneous Compensation Analysis [Text Block] Potential additional borrowing capacity Line Of Credit Facility, Accordion Feature, Increase Limit Line Of Credit Facility, Accordion Feature, Increase Limit Treasury Stock Treasury Stock Par Net Value [Member] Treasury Stock Par Net Value [Member] Present value of acquisition purchase price Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net Compensation Actually Paid vs. Total Shareholder Return Compensation Actually Paid vs. Total Shareholder Return [Text Block] Aggregate consideration Business Combination, Consideration Transferred LIABILITIES AND STOCKHOLDERSâ€™ EQUITY Liabilities and Equity [Abstract] Derivative, remaining maturity (less than) Derivative, Term of Contract Acquisitions and Joint Venture Business Combination And Asset Acquisition [Text Block] Business Combination And Asset Acquisition Accumulated Gain (Loss), Net, Cash Flow Hedge, Before Tax, Parent Accumulated Gain (Loss), Net, Cash Flow Hedge, Before Tax, Parent [Member] Accumulated Gain (Loss), Net, Cash Flow Hedge, Before Tax, Parent [Member] Minimum Minimum [Member] Restatement Determination Date Restatement Determination Date Adoption Date Trading Arrangement Adoption Date Pay vs Performance Disclosure Pay vs Performance Disclosure [Table] Deferred revenue Contract with Customer, Liability, Noncurrent Erroneously Awarded Compensation Recovery Erroneously Awarded Compensation Recovery [Table] Cook Medical Cook Medical [Member] Cook Medical Segments [Axis] Segments [Axis] Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member] Payments to form joint venture Payments to Acquire Equity Method Investments Derivative Instrument [Axis] Derivative Instrument [Axis] Long-term debt, gross Long-Term Debt, Gross Exercise Price Award Exercise Price Earnings Per Share Earnings Per Share [Text Block] Arrangement Duration Trading Arrangement Duration Subsequent Event Subsequent Event [Member] Intangible Assets Goodwill and Intangible Assets Disclosure [Text Block] Restricted cash included in other current assets Restricted Cash and Cash Equivalents, Current Amount recognized in other comprehensive income on interest rate swaps contracts, net of tax Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, after Tax Peer Group Issuers, Footnote Peer Group Issuers, Footnote [Text Block] Segments [Domain] Segments [Domain] Tax effect Other Comprehensive Income (Loss), Tax Material Terms of Trading Arrangement Material Terms of Trading Arrangement [Text Block] 2028 Finite-Lived Intangible Asset, Expected Amortization, Year Four All Individuals All Individuals [Member] PEO PEO [Member] Variable Rate [Axis] Variable Rate [Axis] Income Tax Disclosure [Abstract] Income Tax Disclosure [Abstract] Name Trading Arrangement, Individual Name Other expense, net Other expense, net Other Nonoperating Income (Expense) Statement of Stockholders' Equity [Abstract] Statement of Stockholders' Equity [Abstract] Other intangibles, net (Note 4) Total other intangibles, net Intangible Assets, Net (Excluding Goodwill) Adjusted foreign currency rate Foreign Currency Rate [Member] Foreign Currency Rate Treasury stock at cost: 17.6 shares at JulyÁ 31, 2024, and 17.7 shares at OctoberÁ 31, 2023 Treasury Stock, Common, Value Commitment fee percentage Line of Credit Facility, Unused Capacity, Commitment Fee Percentage Business Combination And Asset Acquisition [Abstract] Business Combination, Asset Acquisition, and Joint Venture Formation [Abstract] Awards Close in Time to MNPI Disclosures, Table Awards Close in Time to MNPI Disclosures [Table Text Block] Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table] Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table] Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Failed to Meet Applicable Vesting Conditions During Covered Year Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Failed to Meet Applicable Vesting Conditions During Covered Year [Member] Aggregate Erroneous Compensation Amount Aggregate Erroneous Compensation Amount Local Phone Number Local Phone Number Total debt Debt, Long-Term and Short-Term, Combined Amount Aggregate Erroneous Compensation Not Yet Determined Aggregate Erroneous Compensation Not Yet Determined [Text Block] Deferred tax liabilities Deferred Income Tax Liabilities, Net Interest expense (income) Interest Expense [Member] SightGlass Vision, Inc. SightGlass Vision, Inc. [Member] SightGlass Vision, Inc. Adjusted SOFR Secured Overnight Financing Rate (SOFR) [Member] Acquisitions of businesses and assets, net of cash acquired, and other Payments To Acquire Businesses And Assets, Net Of Cash Acquired, And Other Payments To Acquire Businesses And Assets, Net Of Cash Acquired, And Other PEO Total Compensation Amount PEO Total Compensation Amount Finite-lived intangibles Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles Income Statement Location [Axis] Statement of Income Location, Balance [Axis] Schedule of net property, plant and equipment by country of domicile Long-Lived Assets by Geographic Areas [Table Text Block] Debt Disclosure [Abstract] Debt Disclosure [Abstract] Fertility Fertility [Member] Fertility [Member] Operating leases not yet commenced Operating Lease, Lease Not yet Commenced [Member] Measure: Measure [Axis] Preferred stock, authorized (in shares) Preferred Stock, Shares Authorized Stock split, conversion ratio Stockholders' Equity Note, Stock Split, Conversion Ratio Forgone Recovery due to Expense of Enforcement, Amount Forgone Recovery due to Expense of Enforcement, Amount Schedule of Business Acquisitions, by Acquisition [Table] Schedule of Business Acquisitions, by Acquisition [Table] Issuance of common stock for stock plans, net and employee stock purchase plan (in shares) Stock Issued During Period, Shares, New Issues Revolving Credit Facility And Term Loan Facility 2020 Revolving Credit Facility And Term Loan Facility 2020 [Member] Revolving Credit Facility And Term Loan Facility 2020 [Member] Line of Credit Line of Credit [Member] Entity Emerging Growth Company Entity Emerging Growth Company Segment Reporting [Abstract] Segment Reporting [Abstract] Entity Central Index Key Entity Central Index Key Schedule of inventories Schedule of Inventory, Current [Table Text Block] Lessee, Lease, Description [Table] Lessee, Lease, Description [Table] Non-GAAP Measure Description Non-GAAP Measure Description [Text Block] Foreign Currency Translation Adjustment Accumulated Foreign Currency Adjustment Attributable to Parent [Member] Non-PEO NEO Average Compensation Actually Paid Amount Non-PEO NEO Average Compensation Actually Paid Amount CooperSurgical CooperSurgical CooperSurgical Segment [Member] CooperSurgical Segment [Member] CooperVision CooperVision CooperVision Segment [Member] CooperVision Segment [Member] Stockholders' Equity Equity [Text Block] Award Timing, How MNPI Considered Award Timing, How MNPI Considered [Text Block] Equity Component [Domain] Equity Component [Domain] Preferred stock, par value (in dollars per share) Preferred Stock, Par or Stated Value Per Share Business Segment Information Segment Reporting Disclosure [Text Block] Lease term (in years) Lessee, Operating Lease, Lease Not yet Commenced, Term of Contract Reconciliation of cash flow information: Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents [Abstract] Additional 402(v) Disclosure Additional 402(v) Disclosure [Text Block] Change in fair value of contingent consideration Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability Share-based compensation expense APIC, Share-Based Payment Arrangement, Increase for Cost Recognition Entity Shell Company Entity Shell Company Unconditional Purchase Obligation, Category of Goods or Services Acquired [Domain] Unconditional Purchase Obligation, Category of Goods or Services Acquired [Domain] Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Title Trading Arrangement, Individual Title Statement [Table] Statement [Table] Consolidation Items [Domain] Consolidation Items [Domain] City Area Code City Area Code Current liabilities: Liabilities, Current [Abstract] Schedule of derivative instruments recognized in condensed consolidated statements of income Schedule of Cash Flow Hedging Instruments, Statements of Financial Performance and Financial Position, Location [Table Text Block] Insider Trading Policies and Procedures Not Adopted Insider Trading Policies and Procedures Not Adopted [Text Block] Stockholders' Equity Note [Abstract] Stockholders' Equity Note [Abstract] Foreign currency translation adjustment Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax Total current assets Assets, Current Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] Schedule of Long Term and Short Term Debt Instruments [Table] Schedule of Long-Term Debt Instruments [Table] Net changes in operating capital Increase (Decrease) in Operating Capital Long-term debt, excluding financing leases Long-Term Debt, Excluding Current Maturities Schedule of Segment Reporting Information, by Segment [Table] Schedule of Segment Reporting Information, by Segment [Table] Accumulated Other Comprehensive Income (Loss) [Table] Accumulated Other Comprehensive Income (Loss) [Table] Undiscounted lease payments Unrecorded Unconditional Purchase Obligation Subsequent Event Type [Axis] Subsequent Event Type [Axis] Income Taxes Income Tax Disclosure [Text Block] Earnings per share (Note 7): Earnings Per Share [Abstract] Raw materials Inventory, Raw Materials, Net of Reserves Retained earnings Retained Earnings (Accumulated Deficit) Derivative loss expected to be realized in earnings over the next twelve months Cash Flow Hedge Gain (Loss) to be Reclassified within 12 Months Schedule of debt Schedule of Debt [Table Text Block] Common Shares Common Stock, Excluding Treasury Stock Par Net Value [Member] Common Stock, Excluding Treasury Stock Par Net Value [Member] Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization, Consolidation and Presentation of Financial Statements [Abstract] Aggregate Available Trading Arrangement, Securities Aggregate Available Amount Equity Awards Adjustments Equity Awards Adjustments [Member] Net repayments of short-term debt Proceeds from (Repayments of) Short-Term Debt Net cash provided by (used in) financing activities Net Cash Provided by (Used in) Financing Activities Underlying Securities Award Underlying Securities Amount 2021 Term Loan Facility Term Loan Facility 2021 [Member] Term Loan Facility 2021 Credit Facility [Axis] Credit Facility [Axis] Dividends on common stock (\$0.01 per share) Dividends, Common Stock, Cash Amendment Flag Amendment Flag Entity Registrant Name Entity Registrant Name Payments to acquire business Payments to Acquire Businesses, Gross Stock Appreciation Rights (SARs) Stock Appreciation Rights (SARs) [Member] Adjustment to Non-PEO NEO Compensation Footnote Adjustment to Non-PEO NEO Compensation Footnote [Text Block] Depreciation and amortization Depreciation, Depletion and Amortization Gross profit Gross Profit Toric and multifocal Toric And Multifocal [Member] Toric And Multifocal Schedule of Long Term and Short Term Debt Instruments [Table] Schedule of Long Term and Short Term Debt Instruments [Table] Schedule of Long Term and Short Term Debt Instruments [Table] Fair Value as of Grant Date Award Grant Date Fair Value Schedule of identifiable assets by segment Reconciliation of Assets from Segment to Consolidated [Table Text Block] Financing Arrangements Debt Disclosure [Text Block] Stockholdersâ€™ equity: Equity, Including Portion Attributable to Noncontrolling Interest [Abstract] Geographical [Domain] Geographical [Domain] Schedule of indefinite-lived intangible assets Schedule of Indefinite-Lived Intangible Assets [Table Text Block] Recovery of Erroneously Awarded Compensation Disclosure [Line Items] Issuance of common stock for stock plans, net and employee stock purchase plan Stock Issued During Period, Value, New Issues Technology Technology-Based Intangible Assets [Member] Entity Address, Postal Zip Code Entity Address, Postal Zip Code Schedule of compensation expense and related income tax benefit for share-based awards Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] Interest Rate Swap Interest Rate Swap [Member] Restatement Determination Date: Restatement Determination Date [Axis] Title of 12(b) Security Title of 12(b) Security Common stock, \$0.10 par value, 480.0 shares authorized, 216.7 issued and 199.1 outstanding at JulyÁ 31, 2024, and 215.8 issued and 198.1 outstanding at OctoberÁ 31, 2023 Common Stock, Value, Issued Share-based Payment Arrangement [Abstract] Share-Based Payment Arrangement [Abstract] Finance lease liabilities, short-term, location Finance Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration] Cash and cash equivalents Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Short-term Debt Short-Term Debt [Abstract] Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member] Finite-Lived Intangible Assets [Line Items] Finite-Lived Intangible Assets [Line Items] Derivative Instruments and Hedging Activities Disclosures [Line Items] Derivative Instruments and Hedging Activities Disclosures [Line Items]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

2025-01-10 10:00:00

[illegible]

Cost of sales	339.8	320.2	959.0	914.7
Gross profit	663.0	610.0	1,918.0	1,751.4
Selling, general and administrative expense	381.1	375.2	1,142.3	1,113.6
Research and development expense	39.0	36.5	117.4	100.7
Amortization of intangibles	50.4	46.7	151.0	139.7
Operating income	192.5	151.6	507.3	397.4
Interest expense	28.5	26.8	87.3	79.0
Other expense, net	0.3	6.0	6.3	11.9
Income before income taxes	163.7	118.8	413.7	306.5
Provision for income taxes (Note 6)	59.0	33.5	138.9	96.8
Net income	\$ 104.7	\$ 85.3	\$ 274.8	\$ 209.7
Earnings per share (Note 7):				
Basic (in dollars per share)	[1] \$ 0.53	\$ 0.43	\$ 1.38	\$ 1.06
Diluted (in dollars per share)	[1] \$ 0.52	\$ 0.43	\$ 1.37	\$ 1.05
Number of shares used to compute earnings per share:				
Basic (in shares)	[1] 199.1	198.1	198.8	197.8
Diluted (in shares)	[1] 200.6	199.6	200.3	199.2
Other comprehensive income, net of tax:				
Cash flow hedges	\$ (27.2)	\$ 14.6	\$ (33.8)	\$ (11.9)
Foreign currency translation adjustment	24.7	34.4	62.5	103.9
Comprehensive income	\$ 102.2	\$ 134.3	\$ 303.5	\$ 301.7

[1] All periods presented have been adjusted to reflect the four-for-one stock split effected on February 16, 2024. Refer to Note 1. General for further information.

~~XML-24-R3.htm~~ ~~IDEA: XBRL DOCUMENT~~

Consolidated
Condensed
Statements of Income and Comprehensive Income
(Parenthetical)
Feb. 16, 2024
Income Statement [Abstract]

[Stock split, conversion ratio](#) 4

~~XML-25-R4.htm~~ ~~IDEA: XBRL DOCUMENT~~

Consolidated Condensed Balance Sheets - USD (\$) \$ in Millions	Jul. 31, 2024	Oct. 31, 2023
Current assets:		
Cash and cash equivalents	\$ 109.7	\$ 120.8
Trade accounts receivable, net of allowance for credit losses of \$42.8 at July 31, 2024, and \$31.3 at October 31, 2023	739.0	609.7
Inventories (Note 3)	779.3	735.6
Prepaid expense and other current assets	298.7	238.8
Total current assets	1,926.7	1,704.9
Property, plant and equipment, net	1,747.6	1,632.6
Goodwill	3,777.2	3,624.5
Other intangibles, net (Note 4)	1,786.8	1,710.3
Deferred tax assets	2,248.3	2,349.5
Other assets	621.4	637.1
Total assets	12,108.0	11,658.9
Current liabilities:		
Short-term debt (Note 5)	40.8	45.4
Accounts payable	222.0	261.9
Employee compensation and benefits	156.5	174.8
Deferred revenue	126.4	123.6
Other current liabilities	423.8	363.3
Total current liabilities	969.5	969.0
Long-term debt (Note 5)	2,591.6	2,523.8
Deferred tax liabilities	94.9	101.5
Long-term tax payable	59.0	90.2
Deferred revenue	190.8	184.2
Other liabilities	277.0	239.2
Total liabilities	4,182.8	4,107.9
Stockholders' equity:		
Preferred stock, \$0.10 par value, 1.0 shares authorized, zero shares issued or outstanding	[1] 0.0	0.0
Common stock, \$0.10 par value, 480.0 shares authorized, 216.7 issued and 199.1 outstanding at July 31, 2024, and 215.8 issued and 198.1 outstanding at October 31, 2023	[1] 21.7	21.6
Additional paid-in capital	[1] 1,884.7	1,817.2
Accumulated other comprehensive loss	[1] (425.1)	(453.8)
Retained earnings	[1] 7,150.9	6,876.1
Treasury stock at cost: 17.6 shares at July 31, 2024, and 17.7 shares at October 31, 2023	[1] (707.2)	(710.3)
Total Cooper stockholders' equity	[1] 7,925.0	7,550.8
Noncontrolling interests	[1] 0.2	0.2
Stockholders' equity (Note 9)	7,925.2	[2] 7,551.0
Total liabilities and stockholders' equity	\$ 12,108.0	[1] \$ 11,658.9

[1] All periods presented have been adjusted to reflect the four-for-one stock split effected on February 16, 2024. Refer to Note 1. General for further information.

[2] All periods presented have been adjusted to reflect the four-for-one stock split effected on February 16, 2024. Refer to Note 1. General for further information.

~~XML-26-R5.htm~~ ~~IDEA: XBRL DOCUMENT~~

Consolidated Condensed Balance Sheets (Parenthetical) \$ in Millions	Jul. 31, 2024 USD (\$) \$ / shares shares	Oct. 31, 2023 USD (\$) \$ / shares shares
Statement of Financial Position [Abstract]		
Trade accounts receivable, allowance for doubtful accounts \$	\$ 42.8	\$ 31.3
Preferred stock, par value (in dollars per share) \$ / shares	[1] \$ 0.10	\$ 0.10
Preferred stock, authorized (in shares)	[1] 1,000,000.0	1,000,000.0
Preferred stock, issued (in shares)	[1] 0	0
Preferred stock, outstanding (in shares)	[1] 0	0
Common stock, par value (in dollars per share) \$ / shares	[1] \$ 0.10	\$ 0.10
Common stock, authorized (in shares)	[1] 480,000,000.0	480,000,000.0
Common stock, issued (in shares)	[1] 216,700,000	215,800,000
Common stock, outstanding (in shares)	[1] 199,100,000	198,100,000
Treasury stock (in shares)	[1] 17,600,000	17,700,000

[1] All periods presented have been adjusted to reflect the four-for-one stock split effected on February 16, 2024. Refer to Note 1. General for further information.

~~XML-27-R6.htm~~ ~~IDEA: XBRL DOCUMENT~~

Consolidated Condensed Statements of Stockholders' Equity -	Total	Common	Treasury	Treasury	Additional Paid-	Accumulated Other	Retained	Noncontrolling
--	-------	--------	----------	----------	------------------	-------------------	----------	----------------

USD (\$) shares in Millions, \$ in Millions		Shares	Stock	Stock	In Capital	Comprehensive Loss	Earnings	Interests	
Common stock, beginning balance (in shares) at Oct. 31, 2022	(1)	197.4							
Stockholders' equity, beginning balance at Oct. 31, 2022	(1) \$	7,174.7	\$ 19.7	\$ (714.5)	\$ 1.8	\$ 1,749.4	\$ (466.8)	\$ 6,584.9	\$ 0.2
Treasury stock, beginning balance (in shares) at Oct. 31, 2022	(1)		17.8						
Increase (Decrease) in Stockholders' Equity [Roll Forward]									
Net income		84.6					84.6		
Other comprehensive income (loss), net of tax		63.0				63.0			
Issuance of common stock for stock plans, net and employee stock purchase plan (in shares)		0.4	1.2						
Issuance of common stock for stock plans, net and employee stock purchase plan	(1.3)				(2.5)				
Dividends on common stock (\$0.01 per share)	(1.5)						(1.5)		
Share-based compensation expense	16.2				16.2				
Common stock, ending balance (in shares) at Jan. 31, 2023	(1)	197.8							
Stockholders' equity, ending balance at Jan. 31, 2023	(1) 7,335.7	\$ 19.7	\$ (713.3)	1.8	1,763.1	(403.8)	6,668.0	0.2	
Treasury stock, ending balance (in shares) at Jan. 31, 2023	(1)		17.8						
Common stock, beginning balance (in shares) at Oct. 31, 2022	(1)	197.4							
Stockholders' equity, beginning balance at Oct. 31, 2022	(1) 7,174.7	\$ 19.7	\$ (714.5)	1.8	1,749.4	(466.8)	6,584.9	0.2	
Treasury stock, beginning balance (in shares) at Oct. 31, 2022	(1)		17.8						
Increase (Decrease) in Stockholders' Equity [Roll Forward]									
Net income		209.7							
Common stock, ending balance (in shares) at Jul. 31, 2023	(1)	198.1							
Stockholders' equity, ending balance at Jul. 31, 2023	(1) 7,528.5	\$ 19.8	\$ (711.3)	1.8	1,801.2	(374.8)	6,791.6	0.2	
Treasury stock, ending balance (in shares) at Jul. 31, 2023	(1)		17.7						
Common stock, beginning balance (in shares) at Jan. 31, 2023	(1)	197.8							
Stockholders' equity, beginning balance at Jan. 31, 2023	(1) 7,335.7	\$ 19.7	\$ (713.3)	1.8	1,763.1	(403.8)	6,668.0	0.2	
Treasury stock, beginning balance (in shares) at Jan. 31, 2023	(1)		17.8						
Increase (Decrease) in Stockholders' Equity [Roll Forward]									
Net income		39.8					39.8		
Other comprehensive income (loss), net of tax		(20.0)				(20.0)			
Issuance of common stock for stock plans, net and employee stock purchase plan (in shares)		0.2							
Issuance of common stock for stock plans, net and employee stock purchase plan	7.8	\$ 0.1	\$ 1.0		6.7				
Share-based compensation expense	14.7				14.7				
Common stock, ending balance (in shares) at Apr. 30, 2023	(1)	198.0							
Stockholders' equity, ending balance at Apr. 30, 2023	(1) 7,378.0	\$ 19.8	\$ (712.3)	1.8	1,784.5	(423.8)	6,707.8	0.2	
Treasury stock, ending balance (in shares) at Apr. 30, 2023	(1)		17.8						
Increase (Decrease) in Stockholders' Equity [Roll Forward]									
Net income		85.3					85.3		
Other comprehensive income (loss), net of tax		49.0				49.0			
Issuance of common stock for stock plans, net and employee stock purchase plan (in shares)		0.1	(0.1)						
Issuance of common stock for stock plans, net and employee stock purchase plan	2.5		\$ 1.0		1.5				
Dividends on common stock (\$0.01 per share)	(1.5)						(1.5)		
Share-based compensation expense	15.2				15.2				
Common stock, ending balance (in shares) at Jul. 31, 2023	(1)	198.1							
Stockholders' equity, ending balance at Jul. 31, 2023	(1) \$ 7,528.5	\$ 19.8	\$ (711.3)	1.8	1,801.2	(374.8)	6,791.6	0.2	
Treasury stock, ending balance (in shares) at Jul. 31, 2023	(1)		17.7						
Common stock, beginning balance (in shares) at Oct. 31, 2023	198.1	(2) 198.1	(1)						
Stockholders' equity, beginning balance at Oct. 31, 2023	\$ 7,551.0	(2) \$ 19.8	(1) \$ (710.3)	(1) 1.8	(1) 1,817.2	(1) (453.8)	(1) 6,876.1	(1) 0.2	
Treasury stock, beginning balance (in shares) at Oct. 31, 2023	17.7	(2)	17.7	(1)					
Increase (Decrease) in Stockholders' Equity [Roll Forward]									
Net income		\$ 81.2					81.2		
Other comprehensive income (loss), net of tax		31.8				31.8			
Issuance of common stock for stock plans, net and employee stock purchase plan (in shares)		0.6							
Issuance of common stock for stock plans, net and employee stock purchase plan	7.7		\$ 1.1		6.6				
Share-based compensation expense	23.6				23.6				
Common stock, ending balance (in shares) at Jan. 31, 2024	(1)	198.7							
Stockholders' equity, ending balance at Jan. 31, 2024	(1) \$ 7,695.3	\$ 19.8	\$ (709.2)	1.8	1,847.4	(422.0)	6,957.3	0.2	
Treasury stock, ending balance (in shares) at Jan. 31, 2024	(1)		17.7						
Common stock, beginning balance (in shares) at Oct. 31, 2023	198.1	(2) 198.1	(1)						
Stockholders' equity, beginning balance at Oct. 31, 2023	\$ 7,551.0	(2) \$ 19.8	(1) \$ (710.3)	(1) 1.8	(1) 1,817.2	(1) (453.8)	(1) 6,876.1	(1) 0.2	
Treasury stock, beginning balance (in shares) at Oct. 31, 2023	17.7	(2)	17.7	(1)					
Increase (Decrease) in Stockholders' Equity [Roll Forward]									
Net income		\$ 274.8							
Common stock, ending balance (in shares) at Jul. 31, 2024	199.1	(2) 199.1	(1)						
Stockholders' equity, ending balance at Jul. 31, 2024	(1) \$ 7,925.2	\$ 19.9	\$ (707.2)	1.8	1,884.7	(425.1)	7,150.9	0.2	
Treasury stock, ending balance (in shares) at Jul. 31, 2024	17.6	(2)	17.6	(1)					
Common stock, beginning balance (in shares) at Jan. 31, 2024	(1)	198.7							
Stockholders' equity, beginning balance at Jan. 31, 2024	(1) \$	\$ 19.8	\$	1.8	1,847.4	(422.0)	6,957.3	0.2	

Treasury stock, beginning balance (in shares) at Jan. 31, 2024	(1)	7,695.3	(709.2)					
			17.7					
Increase (Decrease) in Stockholders' Equity [Roll Forward]								
Net income		88.9					88.9	
Other comprehensive income (loss), net of tax		(0.6)			(0.6)			
Issuance of common stock for stock plans, net and employee stock purchase plan (in shares)			0.4					
Issuance of common stock for stock plans, net and employee stock purchase plan		3.5	\$ 0.1	\$ 0.9		2.5		
Share-based compensation expense		16.8				16.8		
Common stock, ending balance (in shares) at Apr. 30, 2024	(1)		199.1					
Stockholders' equity, ending balance at Apr. 30, 2024	(1)	7,803.9	\$ 19.9	\$ (708.3)	1.8	1,866.7	(422.6)	7,046.2 0.2
Treasury stock, ending balance (in shares) at Apr. 30, 2024	(1)			17.7				
Increase (Decrease) in Stockholders' Equity [Roll Forward]								
Net income		104.7					104.7	
Other comprehensive income (loss), net of tax		(2.5)			(2.5)			
Issuance of common stock for stock plans, net and employee stock purchase plan (in shares)				(0.1)				
Issuance of common stock for stock plans, net and employee stock purchase plan		2.0		\$ 1.1		0.9		
Share-based compensation expense		\$ 17.1				17.1		
Common stock, ending balance (in shares) at Jul. 31, 2024		199.1	(2) 199.1	(1)				
Stockholders' equity, ending balance at Jul. 31, 2024	(1)	\$ 7,925.2	\$ 19.9	\$ (707.2)	\$ 1.8	\$ 1,884.7	\$ (425.1)	\$ 7,150.9 \$ 0.2
Treasury stock, ending balance (in shares) at Jul. 31, 2024		17.6	(2)	17.6	(1)			

[1] All periods presented have been adjusted to reflect the four-for-one stock split effected on February 16, 2024. Refer to Note 1. General for further information.

[2] All periods presented have been adjusted to reflect the four-for-one stock split effected on February 16, 2024. Refer to Note 1. General for further information.

~~XML-28-R7.htm-IDEA: XBRL DOCUMENT~~

Consolidated Condensed Statements of Stockholders' Equity (Parenthetical)	3 Months Ended	
	Jul. 31, 2023	Jan. 31, 2023
	\$ / shares	\$ / shares

Statement of Stockholders' Equity [Abstract]

Dividends on common stock (in dollars per share) \$ 0.01 \$ 0.01

~~XML-29-R8.htm-IDEA: XBRL DOCUMENT~~

Consolidated Condensed Statements of Cash Flows - USD (\$) \$ in Millions	9 Months Ended	
	Jul. 31, 2024	Jul. 31, 2023

Cash flows from operating activities:

Net income	\$ 274.8	\$ 209.7
Depreciation and amortization	284.1	275.0
Change in fair value of contingent consideration	0.0	(31.8)
Accrual for acquisition termination fee	0.0	45.0
Net changes in operating capital	(302.5)	(188.8)
Other non-cash items	184.8	124.2
Net cash provided by operating activities	441.2	433.3

Cash flows from investing activities:

Purchases of property, plant and equipment	(281.2)	(247.5)
Acquisitions of businesses and assets, net of cash acquired, and other	(241.8)	(40.7)
Net cash used in investing activities	(523.0)	(288.2)

Cash flows from financing activities:

Proceeds from long-term debt, net of issuance costs	2,807.8	1,652.0
Repayments of long-term debt	(2,749.2)	(1,490.4)
Net repayments of short-term debt	(3.4)	(335.5)
Net proceeds related to share-based compensation awards	6.5	2.2
Dividends on common stock	0.0	(1.5)
Issuance of common stock for employee stock purchase plan	5.9	5.8
Net cash provided by (used in) financing activities	67.6	(167.4)
Effect of exchange rate changes on cash, cash equivalents and restricted cash	3.1	1.2
Net decrease in cash, cash equivalents, and restricted cash	(11.1)	(21.1)
Cash, cash equivalents, and restricted cash at beginning of period	120.9	138.6
Cash, cash equivalents, and restricted cash at end of period	109.8	117.5

Reconciliation of cash flow information:

Cash and cash equivalents	109.7	117.3
Restricted cash included in other current assets	0.1	0.2
Total cash, cash equivalents, and restricted cash	\$ 109.8	\$ 117.5

~~XML-30-R9.htm-IDEA: XBRL DOCUMENT~~

General	9 Months Ended Jul. 31, 2024
---------	---------------------------------

Organization, Consolidation and Presentation of Financial Statements [Abstract]

General

Note 1. General

The accompanying Consolidated Condensed Financial Statements of The Cooper Companies, Inc. and its subsidiaries have been prepared in accordance with generally accepted accounting principles in the United States (GAAP) for interim financial information and with the requirements of Regulation S-X, Rule 10-01 for financial statements required to be filed as a part of this Quarterly Report on Form 10-Q. Unless the context requires otherwise, terms "the Company", "we", "us", and "our" are used to refer collectively to The Cooper Companies, Inc. and its subsidiaries.

The accompanying Consolidated Condensed Financial Statements and related notes are unaudited and should be read in conjunction with the audited Consolidated Financial Statements of the Company and related notes as contained in the Company's Annual Report on Form 10-K for the fiscal year ended October 31, 2023. The Consolidated Condensed Financial Statements include all adjustments (consisting only of normal recurring adjustments) and accruals necessary in the judgment of management for a fair presentation of the results for the interim periods presented.

Accounting Policies

There have been no material changes to our significant accounting policies¹ described in our Annual Report on Form 10-K for the fiscal year ended October 31, 2023.

Estimates

The preparation of Consolidated Condensed Financial Statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported amounts of net sales and expenses during the reporting period. Actual results could differ from those estimates. The Company continually monitors and evaluates the estimates used as additional information becomes available. Adjustments will be made to these provisions periodically to reflect new facts and circumstances that may indicate that historical experience may not be indicative of current and/or future results.

Stock Split

On February 16, 2024, the Company effected a four-for-one stock split of its outstanding shares of common stock. The par value of the common stock remains at \$0.10 per share. Accordingly, an amount equal to the par value of the increased shares resulting from the stock split was reclassified from "Additional paid-in capital" to "Common stock". All share and per share information has been retroactively adjusted to reflect the stock split for all periods presented.

Accounting Pronouncements Issued But Not Yet Adopted

In December 2023, the Financial Accounting Standards Board (FASB) issued ASU 2023-09, *Income Taxes (Topic 740): Improvements to Income Tax Disclosures*. This ASU requires public entities to disclose specific categories in the effective tax rate reconciliation and additional information for reconciling items that exceed a quantitative threshold. The guidance also requires all disaggregated

information pertaining to taxes paid, net of refunds received, for federal, state and foreign income taxes. The new guidance is effective for fiscal years beginning after December 15, 2024, with the option to apply prospectively or retrospectively. Early adoption is permitted. We are currently evaluating the impact that the adoption of this guidance will have on our consolidated financial statements and disclosures.

In November 2023, the FASB issued ASU 2023-07, *Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures*, which enhances the disclosures required for operating segments in our annual and interim consolidated financial statements. The ASU is effective for us beginning on November 1, 2024, and will be applied retrospectively. Early adoption is permitted. We are currently evaluating the impact of adopting this ASU on our consolidated financial statements and disclosures.

~~XML 31 R10.htm IDEA~~ ~~XBRL DOCUMENT~~

Acquisitions and Joint Venture

Business Combination, Asset Acquisition, and Joint Venture

Formation [Abstract]

Acquisitions and Joint Venture

9 Months Ended
Jul. 31, 2024

Note 2. Acquisitions and Joint Venture

All acquisitions were funded by cash generated from operations or facility borrowings.

On June 7, 2024, CooperSurgical acquired a fertility company that specializes in sperm separation devices. The purchase price of the acquisition was \$33.5 million. The Company accounted for this acquisition as an asset acquisition, whereby the Company allocated the total cost of the acquisition to the net assets acquired on the basis of their estimated relative fair values on the acquisition date. The primary asset acquired in this asset acquisition is a composite intangible asset of \$39.6 million. The value of the composite intangible asset reflects, in addition to the purchase price, a deferred tax liability of \$8.3 million arising from book/tax basis differences generated upon the acquisition. The composite intangible asset encompasses the portfolio of intellectual property associated with the sperm separation devices including the patents, trademarks, customer relationships, regulatory approvals, and commercialization rights, which have been valued as a single composite intangible asset as they are inextricably linked.

On November 1, 2023, CooperSurgical completed the acquisition of select Cook Medical assets focused primarily on the obstetrics, doppler monitoring, and gynecology surgery markets. The purchase price of the acquisition was \$300.0 million, with \$200.0 million paid at closing and two cash payments of \$50.0 million each to be paid on November 1, 2024, and November 1, 2025. The present value of the acquisition purchase price was \$291.6 million, which is included in the Company's balance sheet. Assets acquired primarily comprised of \$157.9 million of technologies, \$26.6 million of customer relationship related intangibles, and \$107.2 million of goodwill. The goodwill is deductible for tax purposes.

Joint Venture

CooperVision and Essilor International SAS (Essilor) executed a Contribution Agreement and a Stock Purchase Agreement (the Agreements) in March 2022 to form a joint venture in SightGlass Vision, Inc. (SGV), which is a medical device company developing spectacle lenses for myopia management. Essilor paid CooperVision \$52.1 million in exchange for a 50% interest in SGV and their proportionate share of the revenue payments. As part of the Agreements, each party contributed their interest in SGV and \$10 million in cash. Prior to March 2022, CooperVision owned 100% of SGV.

Further information regarding the joint venture is included in the notes to our consolidated financial statements in our Annual Report on Form 10-K for the fiscal year ended October 31, 2023.

Subsequent Event

On August 1, 2024, subsequent to fiscal quarter ended July 31, 2024, CooperSurgical completed the acquisition of obp Surgical, a U.S.-based medical device company with a suite of single-use cordless surgical retractors with integrated light source and evacuation channels. The purchase price of the acquisition was approximately \$100.0 million, paid on August 1, 2024. The Company is in the process of finalizing purchase accounting information.

~~XML 32 R11.htm IDEA~~ ~~XBRL DOCUMENT~~

Inventories

9 Months Ended
Jul. 31, 2024

Inventory Disclosure [Abstract]

Inventories

Note 3. Inventories

(In millions)	July 31, 2024	October 31, 2023
Raw materials	\$ 214.6	\$ 207.3
Work-in-process	19.5	19.0
Finished goods	545.2	509.3
Total inventories	<u>\$ 779.3</u>	<u>\$ 735.6</u>

~~XML 33 R12.htm IDEA~~ ~~XBRL DOCUMENT~~

Intangible Assets

9 Months Ended
Jul. 31, 2024

Goodwill and Intangible Assets Disclosure [Abstract]

Intangible Assets

Note 4. Intangible Assets

Intangible assets consisted of the following:

(In millions)	July 31, 2024		October 31, 2023		Weighted-Average Amortization Period (in years)
	Gross Carrying Amount	Accumulated Amortization	Gross Carrying Amount	Accumulated Amortization	
Intangible assets with definite lives:					
Customer relationships	\$ 1,123.0	\$ 387.6	\$ 1,099.2	\$ 345.8	19
Composite intangible assets ⁽¹⁾	1,101.5	477.9	1,061.9	424.8	15
Technology	660.0	372.7	494.5	335.4	12
Trademarks	204.2	87.1	208.9	81.1	15
License and distribution rights and other	48.0	26.5	51.6	28.0	11
	<u>3,136.7</u>	<u>\$ 1,351.8</u>	<u>2,916.1</u>	<u>\$ 1,215.1</u>	16
Less: accumulated amortization and translation	<u>1,351.8</u>		<u>1,215.1</u>		
Intangible assets with definite lives, net	1,784.9		1,701.0		
Intangible assets with indefinite lives, net ⁽²⁾	1.9		9.3		
Total other intangibles, net	<u>\$ 1,786.8</u>		<u>\$ 1,710.3</u>		

⁽¹⁾ Composite intangible assets primarily consist of technology, trade name, New Drug Application approval and physician relationships. The components are not reflected separately or within the corresponding categories because they are inextricably linked.

⁽²⁾ Intangible assets with indefinite lives include technology and trademarks.

Balances include foreign currency translation adjustments.

As of July 31, 2024, the estimate of future amortization expenses for intangible assets with definite lives is as follows:

Fiscal Years:	(In millions)
Remainder of 2024	\$ 48.6
2025	191.6
2026	184.0
2027	169.7
2028	165.2
Thereafter	1,025.8
Total remaining amortization for intangible assets with definite lives	<u>\$ 1,784.9</u>

The Company performed its annual impairment assessment in the third quarter of fiscal 2024 and concluded there was no material impairment of goodwill or intangible assets recorded in the nine months ended July 31, 2024. Further information regarding our annual impairment assessment is included in our notes to our consolidated financial statements in our Annual Report on Form 10-K for the fiscal year ended October 31, 2023.

~~XML 34 R13.htm IDEA~~ ~~XBRL DOCUMENT~~

Financing Arrangements

Debt Disclosure [Abstract]

Financing Arrangements

9 Months Ended
Jul. 31, 2024

Note 5. Financing Arrangements

The Company had outstanding debt as follows:

(In millions)	July 31, 2024	October 31, 2023
Short-term debt, excluding financing leases	\$ 39.8	\$ 44.4
Financing lease liabilities	1.0	1.0
Short-term debt	<u>\$ 40.8</u>	<u>\$ 45.4</u>
Revolving credit	\$ 1,090.2	\$ 172.6
Term loans	1,500.0	2,350.0
Other	0.2	0.2
Less: unamortized debt issuance cost	<u>(1.6)</u>	<u>(2.4)</u>
Long-term debt, excluding financing leases	2,588.8	2,520.4
Financing lease liabilities	2.8	3.4
Long-term debt	<u>\$ 2,591.6</u>	<u>\$ 2,523.8</u>
Total debt	<u>\$ 2,632.4</u>	<u>\$ 2,569.2</u>

Additional information regarding our indebtedness is included in our notes to our consolidated financial statements in our Annual Report on Form 10-K for the fiscal year ended October 31, 2023. The carrying value of the Company's revolving credit facility and term loans approximates fair value based on current market rates (Level 2). As of July 31, 2024, the Company was in compliance with all debt covenants.

Revolving Credit Agreement on May 1, 2024

On May 1, 2024, the Company entered into a Revolving Credit Agreement (the 2024 Credit Agreement), among the Company, CooperVision International Limited, the lenders from time to time party thereto, and PNC Bank, National Association, as administrative agent. The 2024 Credit Agreement provides for a multicurrency revolving credit facility (the 2024 Revolving Credit Facility) in an aggregate principal amount of \$2.3 billion which, unless terminated earlier, matures on May 1, 2029. On May 1, 2024, the Company used \$1.170 million under the 2024 Revolving Credit Facility to fully repay all borrowings outstanding under the 2020 Term Loan Facility and the 2020 Revolving Credit Facility, and terminated the 2020 Credit Agreement. The Company has an uncommitted option to increase the revolving credit facility or establish a new term loan in an aggregate amount up to the greater of \$1,150 million or 100% of consolidated Earnings Before Interest, Taxes, Depreciation and Amortization (EBITDA), as defined in the 2024 Credit Agreement.

The 2024 Credit Agreement will bear interest, at the Company's option, at either the base rate, or the adjusted SOFR, or adjusted foreign currency rate, plus, in each case, an applicable rate of between 0.00% and 0.50% in respect of base rate loans, and between 0.87% and 1.50% in respect of adjusted SOFR or adjusted foreign currency rate loans, in each case in accordance with a pricing grid tied to the Total Leverage Ratio, as defined in the 2024 Credit Agreement.

The Company pays an annual commitment fee that ranges from 0.10% to 0.20% of the unused portion of the 2024 Revolving Credit Facility based upon the Company's Total Leverage Ratio, as defined in the 2024 Credit Agreement.

The 2024 Credit Agreement contains customary restrictive covenants, as well as financial covenants that require the Company to maintain a certain Total Leverage Ratio and Interest Coverage Ratio, each as defined in the 2024 Credit Agreement, consistent with the 2020 Credit Agreement discussed above.

On July 31, 2024, the Company had \$1.1 billion outstanding under the 2024 Revolving Credit Facility and the weighted-average interest rate on the 2024 Revolving Credit Facility was 6.57%.

Term Loan Agreement on December 17, 2021

On December 17, 2021, the Company entered into a Term Loan Agreement (the 2021 Credit Agreement) by and among the Company, the lenders from time to time party thereto, and PNC Bank, National Association, as administrative agent. The 2021 Credit Agreement provides for a term loan facility (the 2021 Term Loan Facility) in an aggregate principal amount of \$1.5 billion, which, unless terminated earlier, matures on December 17, 2026.

On May 1, 2024, in connection with the Company's entry into the 2024 Credit Agreement, the Company entered into Amendment No. 2 to the 2021 Credit Agreement, modifying the 2021 Credit Agreement by, among other things, conforming certain provisions therein to those contained in the 2024 Credit Agreement.

On July 31, 2024, the Company had \$1.5 billion outstanding under the 2021 Term Loan Facility and the interest rate was 6.44%.

Revolving Credit and Term Loan Agreement on April 1, 2020

On April 1, 2020, the Company entered into a Revolving Credit and Term Loan Agreement (the 2020 Credit Agreement), among the Company, CooperVision International Holding Company, LP, CooperSurgical Netherlands B.V., CooperVision Holding Kft, the lenders from time to time party thereto, and KeyBank National Association, as administrative agent. The 2020 Credit Agreement provides for (a) a multicurrency revolving credit facility (the 2020 Revolving Credit Facility) in an aggregate principal amount of \$1,290 million and (b) a term loan facility (the 2020 Term Loan Facility) in an aggregate principal amount of \$850.0 million, each of which, unless terminated earlier, mature on April 1, 2025. The Company has an uncommitted option to increase the revolving credit facility or establish a new term loan in an aggregate amount up to \$1,605 million.

On May 1, 2024, in connection with the Company's entry into the 2024 Credit Agreement, the Company terminated the 2020 Credit Agreement. In connection with the termination, all borrowings outstanding under the 2020 Credit Agreement were repaid.

~~XML 35 R14.htm IDEA XBRL DOCUMENT~~

Income Taxes

[Income Tax Disclosure \[Abstract\]](#)
[Income Taxes](#)

Note 6. Income Taxes

The effective tax rates for the three months ended July 31, 2024, and 2023, were 36.1% and 28.2%, respectively. The effective tax rates for the nine months ended July 31, 2024, and 2023, were 33.6% and 31.6%, respectively. The increases were primarily due to changes in the geographic composition of pre-tax earnings and an increase in the UK statutory tax rate from 19% to 25%.

~~XML 36 R15.htm IDEA XBRL DOCUMENT~~

Earnings Per Share

[Earnings Per Share \[Abstract\]](#)
[Earnings Per Share](#)

Note 7. Earnings Per Share

Periods Ended July 31, (In millions, except per share amounts)	Three Months		Nine Months	
	2024	2023	2024	2023
Net income	\$ 104.7	\$ 85.3	\$ 274.8	\$ 209.7
Basic:				
Weighted-average common shares	199.1	198.1	198.8	197.8
Basic earnings per share	\$ 0.53	\$ 0.43	\$ 1.38	\$ 1.06
Diluted:				
Weighted-average common shares	199.1	198.1	198.8	197.8
Effect of dilutive stock plans	1.5	1.5	1.5	1.4
Diluted weighted-average common shares	200.6	199.6	200.3	199.2
Diluted earnings per share	\$ 0.52	\$ 0.43	\$ 1.37	\$ 1.05

The following table sets forth stock options to purchase our common stock and restricted stock units that were not included in the diluted earnings per share calculation because their effect would have been antidilutive for the periods presented:

Periods Ended July 31, (In thousands, except exercise prices)	Three Months		Nine Months	
	2024	2023	2024	2023
Stock option shares excluded	828	820	828	1,244
Exercise prices	\$82.46 - \$101.54	\$82.46 - \$101.54	\$82.46 - \$101.54	\$75.03 - \$101.54
Restricted stock units excluded	5	8	2	64

~~XML 37 R16.htm IDEA XBRL DOCUMENT~~

Share-Based Compensation

[Share-Based Payment Arrangement \[Abstract\]](#)
[Share-Based Compensation](#)

Note 8. Share-Based Compensation

The Company has several stock plans that are described in the Company's Annual Report on Form 10-K for the fiscal year ended October 31, 2023. The compensation expense and related income tax benefit recognized in our Consolidated Condensed Statements of Income and Comprehensive Income for share-based awards, including the Employee Stock Purchase Plan, were as follows:

Periods Ended July 31, (In millions)	Three Months		Nine Months	
	2024	2023	2024	2023
Selling, general and administrative expense	\$ 15.8	\$ 13.7	\$ 53.0	\$ 41.5
Cost of sales	1.3	1.1	3.6	3.1
Research and development expense	0.5	0.7	2.1	2.3
Total share-based compensation expense	\$ 17.6	\$ 15.5	\$ 58.7	\$ 46.9
Related income tax benefit	\$ 1.0	\$ 1.3	\$ 5.8	\$ 4.6

~~XML 38 R17.htm IDEA XBRL DOCUMENT~~

Stockholders' Equity

[Stockholders' Equity Note \[Abstract\]](#)
[Stockholders' Equity](#)

Note 9. Stockholders' Equity

Analysis of Changes in Accumulated Other Comprehensive Loss:

(In millions)	Foreign Currency Translation Adjustment	Minimum Pension Liability	Derivative Instruments	Total
Balance at October 31, 2022	\$ (555.0)	\$ (6.2)	\$ 94.4	\$ (466.8)
Gross change in value	103.9	—	(15.7)	88.2
Tax effect	—	—	3.8	3.8
Balance at July 31, 2023	\$ (451.1)	\$ (6.2)	\$ 82.5	\$ (374.8)
Balance at October 31, 2023	\$ (538.0)	\$ (3.2)	\$ 87.4	\$ (453.8)
Gross change in value	62.5	—	(44.4)	18.1
Tax effect	—	—	10.6	10.6
Balance at July 31, 2024	\$ (475.5)	\$ (3.2)	\$ 53.6	\$ (425.1)

Share Repurchases

In March 2017, the authorization under the 2012 Share Repurchase Program was increased to \$1.0 billion by the Company's Board of Directors. As of July 31, 2024, \$256.4 million remains authorized for repurchase.

During the three and nine months ended July 31, 2024, and 2023, there were no share repurchases.

Dividends

In December 2023, the Company's Board of Directors decided to end the declaration of the semiannual dividend.

The Company paid dividends of approximately \$1.5 million during the nine months ended July 31, 2023.

~~XML 39 R18.htm IDEA XBRL DOCUMENT~~

Contingencies and Commitments

**9 Months Ended
Jul. 31, 2024**

**9 Months Ended
Jul. 31, 2024**

**9 Months Ended
Jul. 31, 2024**

**9 Months Ended
Jul. 31, 2024**

**9 Months Ended
Jul. 31, 2024**

Note 10. Contingencies and Commitments

The Company is involved in various lawsuits, claims and other legal matters from time to time that arise in the ordinary course of conducting business, including matters involving our products, intellectual property, supplier relationships, distributors, competitor relationships, employees and other matters. The Company does not believe that the ultimate resolution of these proceedings or claims pending against it could have a material adverse effect on its financial condition or results of operations. At each reporting period, the Company evaluates whether or not a potential loss amount or a potential range of loss is probable and reasonably estimable under ASC 450, *Contingencies*. Legal fees are expensed as incurred.

As of July 31, 2024, the Company entered into additional leases that have not yet commenced in order to expand capacity. The undiscounted lease payments are estimated at \$214.0 million for leases that will commence between the fourth quarter of fiscal 2024 through fiscal 2026, with initial terms ranging from 15 to 25 years.

~~XML 40 R19.htm IDEA: XBRL DOCUMENT~~

Business Segment Information **9 Months Ended Jul. 31, 2024**

[Segment Reporting \[Abstract\]](#)
[Business Segment Information](#)

Note 11. Business Segment Information

The following tables present revenue and other financial information by reportable segment:

Segment information:

Periods Ended July 31, (In millions)	Three Months		Nine Months	
	2024	2023	2024	2023
CooperVision net sales by category:				
Toric and multifocal	\$ 326.4	\$ 296.5	\$ 934.0	\$ 838.5
Sphere, other	349.2	333.7	999.0	962.3
Total CooperVision net sales	\$ 675.6	\$ 630.2	\$ 1,933.0	\$ 1,800.8
CooperSurgical net sales by category:				
Office and surgical	\$ 197.9	\$ 178.4	\$ 571.9	\$ 506.6
Fertility	129.3	121.6	372.1	358.7
Total CooperSurgical net sales	327.2	300.0	944.0	865.3
Total net sales	\$ 1,002.8	\$ 930.2	\$ 2,877.0	\$ 2,666.1
Operating income (loss):				
CooperVision	\$ 172.7	\$ 151.7	\$ 487.7	\$ 449.7
CooperSurgical	41.3	18.8	86.9	0.3
Corporate	(21.5)	(18.9)	(67.3)	(52.6)
Total operating income	192.5	151.6	507.3	397.4
Interest expense	28.5	26.8	87.3	79.0
Other expense, net	0.3	6.0	6.3	11.9
Income before income taxes	\$ 163.7	\$ 118.8	\$ 413.7	\$ 306.5

(In millions)	July 31, 2024	October 31, 2023
Total identifiable assets:		
CooperVision	\$ 7,172.0	\$ 7,044.0
CooperSurgical	4,716.8	4,351.8
Corporate	219.2	263.1
Total	\$ 12,108.0	\$ 11,658.9

Geographic information:

Periods Ended July 31, (In millions)	Three Months		Nine Months	
	2024	2023	2024	2023
Net sales to unaffiliated customers by country of domicile:				
United States	\$ 511.2	\$ 462.5	\$ 1,460.6	\$ 1,340.4
Europe	297.0	279.7	850.3	777.4
Rest of world	194.6	188.0	566.1	548.3
Total	\$ 1,002.8	\$ 930.2	\$ 2,877.0	\$ 2,666.1

(In millions)	July 31, 2024	October 31, 2023
Net property, plant and equipment by country of domicile:		
United States	\$ 1,094.1	\$ 1,027.6
Europe	377.9	325.9
Rest of world	275.6	279.1
Total	\$ 1,747.6	\$ 1,632.6

~~XML 41 R20.htm IDEA: XBRL DOCUMENT~~

Financial Derivatives and Hedging **9 Months Ended Jul. 31, 2024**

[Derivative Instruments and Hedging Activities Disclosure \[Abstract\]](#)
[Financial Derivatives and Hedging](#)

Note 12. Financial Derivatives and Hedging

As of July 31, 2024, the notional amount of outstanding foreign currency forward contracts was \$58.6 million. The resulting impact on our Consolidated Financial Statements from currency hedging activities was not significant for the three and nine months ended July 31, 2024, and July 31, 2023.

As of July 31, 2024, the Company has 9 interest rate swap contracts that have a total notional amount of \$1.8 billion and remaining maturities of less than four years.

The following table summarizes the amounts recognized with respect to our derivative instruments within the accompanying Consolidated Condensed Statements of Income and Comprehensive Income:

Periods Ended July 31, (In millions)		Three Months		Nine Months	
		2024	2023	2024	2023
Derivatives designated as cash flow hedges	Location of (Gain)/Loss Recognized on Derivatives				
Interest rate swap contracts	Interest expense (income)	\$ (14.1)	\$ (12.1)	\$ (41.3)	\$ (30.3)

The cumulative pre-tax impact of the gain on derivatives designated for hedge accounting is recognized in "Accumulated other comprehensive loss". The following table details the changes in the cumulative pre-tax impact of the gain on derivatives designated for hedge accounting:

Periods Ended July 31, (In millions)	Three Months		Nine Months	
	2024	2023	2024	2023
Beginning balance gain	\$ 106.4	\$ 89.5	\$ 115.1	\$ 124.5
Amount recognized in accumulated other comprehensive income on interest rate swap contracts, gross	(21.6)	31.4	(3.1)	14.6
Amount reclassified from accumulated other comprehensive income into earnings, gross	(14.1)	(12.1)	(41.3)	(30.3)
Ending balance gain	\$ 70.7	\$ 108.8	\$ 70.7	\$ 108.8

The amount recognized in other comprehensive income on interest rate swap contracts was \$(16.5) million and \$(2.7) million, net of tax, for the three and nine months ended July 31, 2024, respectively, and \$23.8 million and \$11.1 million, net of tax, for the three and nine months ended July 31, 2023, respectively.

The amount reclassified from other comprehensive income into earnings was \$(10.7) million and \$(31.1) million, net of tax, for the three and nine months ended July 31, 2024, respectively, and \$(9.2) million and \$(23.0) million, net of tax, for the three and nine months ended July 31, 2023, respectively.

Refer to Note 9. Stockholders' Equity for amounts presented net of the related tax impact in "Accumulated other comprehensive loss."

The Company expects that \$(41.8) million recorded as a component of "Accumulated other comprehensive loss" will be realized in the Consolidated Condensed Statements of Income over the next twelve months and the amount will vary depending on prevailing interest rates.

~~XML 42 R21.htm IDEA: XBRL DOCUMENT~~

Pay vs Performance Disclosure - USD (\$) **3 Months Ended** **9 Months Ended**
\$ in Millions **Jul. 31, 2024** **Apr. 30, 2024** **Jan. 31, 2024** **Jul. 31, 2023** **Apr. 30, 2023** **Jan. 31, 2023** **Jul. 31, 2024** **Jul. 31, 2023**

[Pay vs Performance Disclosure](#)

Net income	\$ 104.7	\$ 88.9	\$ 81.2	\$ 85.3	\$ 39.8	\$ 84.6	\$ 274.8	\$ 209.7
------------	----------	---------	---------	---------	---------	---------	----------	----------

~~XML 43 R22.htm IDEA: XBRL DOCUMENT~~

Insider Trading Arrangements **3 Months Ended**
Jul. 31, 2024

[Trading Arrangements, by Individual](#)

[Rule 10b5-1 Arrangement Adopted](#) false

[Non-Rule 10b5-1 Arrangement Adopted](#) false

[Rule 10b5-1 Arrangement Terminated](#) false

[Non-Rule 10b5-1 Arrangement Terminated](#) false

~~XML 44 R23.htm IDEA: XBRL DOCUMENT~~

General (Policies) **9 Months Ended**
Jul. 31, 2024

Estimates

The preparation of Consolidated Condensed Financial Statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported amounts of net sales and expenses during the reporting period. Actual results could differ from those estimates. The Company continually monitors and evaluates the estimates used as additional information becomes available. Adjustments will be made to these provisions periodically to reflect new facts and circumstances that may indicate that historical experience may not be indicative of current and/or future results.

Accounting Pronouncements Issued But Not Yet Adopted

In December 2023, the Financial Accounting Standards Board (FASB) issued ASU 2023-09, *Income Taxes (Topic 740): Improvements to Income Tax Disclosures*. This ASU requires public entities to disclose specific categories in the effective tax rate reconciliation and additional information for reconciling items that exceed a quantitative threshold. The guidance also requires all disaggregated information pertaining to taxes paid, net of refunds received, for federal, state and foreign income taxes. The new guidance is effective for fiscal years beginning after December 15, 2024, with the option to apply prospectively or retrospectively. Early adoption is permitted. We are currently evaluating the impact that the adoption of this guidance will have on our consolidated financial statements and disclosures.

In November 2023, the FASB issued ASU 2023-07, *Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures*, which enhances the disclosures required for operating segments in our annual and interim consolidated financial statements. The ASU is effective for us beginning on November 1, 2024, and will be applied retrospectively. Early adoption is permitted. We are currently evaluating the impact of adopting this ASU on our consolidated financial statements and disclosures.

The Company is involved in various lawsuits, claims and other legal matters from time to time that arise in the ordinary course of conducting business, including matters involving our products, intellectual property, supplier relationships, distributors, competitor relationships, employees and other matters. The Company does not believe that the ultimate resolution of these proceedings or claims pending against it could have a material adverse effect on its financial condition or results of operations. At each reporting period, the Company evaluates whether or not a potential loss amount or a potential range of loss is probable and reasonably estimable under ASC 450, *Contingencies*. Legal fees are expensed as incurred.

~~X~~**ML 45 R24.htm IDEA- XBRL DOCUMENT**

Inventories (Tables)

9 Months Ended
Jul. 31, 2024

(In millions)	July 31, 2024	October 31, 2023
Raw materials	\$ 214.6	\$ 207.3
Work-in-process	19.5	19.0
Finished goods	545.2	509.3
Total inventories	\$ 779.3	\$ 735.6

~~X~~**ML 46 R25.htm IDEA- XBRL DOCUMENT**

Intangible Assets
(Tables)

9 Months Ended
Jul. 31, 2024

Intangible assets consisted of the following:

	July 31, 2024		October 31, 2023		Weighted-Average Amortization Period (in years)
(In millions)	Gross Carrying Amount	Accumulated Amortization	Gross Carrying Amount	Accumulated Amortization	
Intangible assets with definite lives:					
Customer relationships	\$ 1,123.0	\$ 387.6	\$ 1,099.2	\$ 345.8	19
Composite intangible assets ⁽¹⁾	1,101.5	477.9	1,061.9	424.8	15
Technology	660.0	372.7	494.5	335.4	12
Trademarks	204.2	87.1	208.9	81.1	15
License and distribution rights and other	48.0	26.5	51.6	28.0	11
	3,136.7	\$ 1,351.8	2,916.1	\$ 1,215.1	16
Less: accumulated amortization and translation	1,351.8		1,215.1		
Intangible assets with definite lives, net	1,784.9		1,701.0		
Intangible assets with indefinite lives, net ⁽²⁾	1.9		9.3		
Total other intangibles, net	\$ 1,786.8		\$ 1,710.3		

⁽¹⁾ Composite intangible assets primarily consist of technology, trade name, New Drug Application approval and physician relationships. The components are not reflected separately or within the corresponding categories because they are inextricably linked.

⁽²⁾ Intangible assets with indefinite lives include technology and trademarks.

Intangible assets consisted of the following:

	July 31, 2024		October 31, 2023		Weighted-Average Amortization Period (in years)
(In millions)	Gross Carrying Amount	Accumulated Amortization	Gross Carrying Amount	Accumulated Amortization	
Intangible assets with definite lives:					
Customer relationships	\$ 1,123.0	\$ 387.6	\$ 1,099.2	\$ 345.8	19
Composite intangible assets ⁽¹⁾	1,101.5	477.9	1,061.9	424.8	15
Technology	660.0	372.7	494.5	335.4	12
Trademarks	204.2	87.1	208.9	81.1	15
License and distribution rights and other	48.0	26.5	51.6	28.0	11
	3,136.7	\$ 1,351.8	2,916.1	\$ 1,215.1	16
Less: accumulated amortization and translation	1,351.8		1,215.1		
Intangible assets with definite lives, net	1,784.9		1,701.0		
Intangible assets with indefinite lives, net ⁽²⁾	1.9		9.3		
Total other intangibles, net	\$ 1,786.8		\$ 1,710.3		

⁽¹⁾ Composite intangible assets primarily consist of technology, trade name, New Drug Application approval and physician relationships. The components are not reflected separately or within the corresponding categories because they are inextricably linked.

⁽²⁾ Intangible assets with indefinite lives include technology and trademarks.

As of July 31, 2024, the estimate of future amortization expenses for intangible assets with definite lives is as follows:

Fiscal Years:	(In millions)
Remainder of 2024	\$ 48.6
2025	191.6
2026	184.0
2027	169.7
2028	165.2
Thereafter	1,025.8
Total remaining amortization for intangible assets with definite lives	\$ 1,784.9

~~X~~**ML 47 R26.htm IDEA- XBRL DOCUMENT**

Financing
Arrangements
(Tables)

9 Months Ended
Jul. 31, 2024

The Company had outstanding debt as follows:

(In millions)	July 31, 2024	October 31, 2023
Short-term debt, excluding financing leases	\$ 39.8	\$ 44.4
Financing lease liabilities	1.0	1.0
Short-term debt	\$ 40.8	\$ 45.4
Revolving credit	\$ 1,090.2	\$ 172.6
Term loans	1,500.0	2,350.0
Other	0.2	0.2
Less: unamortized debt issuance cost	(1.6)	(2.4)
Long-term debt, excluding financing leases	2,588.8	2,520.4
Financing lease liabilities	2.8	3.4
Long-term debt	\$ 2,591.6	\$ 2,523.8
Total debt	\$ 2,632.4	\$ 2,569.2

~~X~~**ML 48 R27.htm IDEA- XBRL DOCUMENT**

Earnings Per Share
(Tables)

9 Months Ended
Jul. 31, 2024

Periods Ended July 31, (In millions, except per share amounts)	Three Months		Nine Months	
	2024	2023	2024	2023
Net income	\$ 104.7	\$ 85.3	\$ 274.8	\$ 209.7
<i>Basic:</i>				
Weighted-average common shares	199.1	198.1	198.8	197.8
Basic earnings per share	\$ 0.53	\$ 0.43	\$ 1.38	\$ 1.06
<i>Diluted:</i>				
Weighted-average common shares	199.1	198.1	198.8	197.8
Effect of dilutive stock plans	1.5	1.5	1.5	1.4
Diluted weighted-average common shares	200.6	199.6	200.3	199.2
Diluted earnings per share	\$ 0.52	\$ 0.43	\$ 1.37	\$ 1.05

[Schedule of stock options and restricted stock units that were not included in the diluted earnings per share calculation](#)

The following table sets forth stock options to purchase our common stock and restricted stock units that were not included in the diluted earnings per share calculation because their effect would have been antidilutive for the periods presented:

Periods Ended July 31, (In thousands, except exercise prices)	Three Months		Nine Months	
	2024	2023	2024	2023
Stock option shares excluded	828	820	828	1,244
Exercise prices	\$82.46 - \$101.54	\$82.46 - \$101.54	\$82.46 - \$101.54	\$75.03 - \$101.54
Restricted stock units excluded	5	8	2	64

~~XML 49 R28.htm IDEA: XBRL DOCUMENT~~

Share-Based Compensation (Tables)

9 Months Ended

Jul. 31, 2024

[Share-Based Payment Arrangement \[Abstract\]](#)

[Schedule of compensation expense and related income tax benefit for share-based awards](#)

The compensation expense and related income tax benefit recognized in our Consolidated Condensed Statements of Income and Comprehensive Income for share-based awards, including the Employee Stock Purchase Plan, were as follows:

Periods Ended July 31, (In millions)	Three Months		Nine Months	
	2024	2023	2024	2023
Selling, general and administrative expense	\$ 15.8	\$ 13.7	\$ 53.0	\$ 41.5
Cost of sales	1.3	1.1	3.6	3.1
Research and development expense	0.5	0.7	2.1	2.3
Total share-based compensation expense	\$ 17.6	\$ 15.5	\$ 58.7	\$ 46.9
Related income tax benefit	\$ 1.0	\$ 1.3	\$ 5.8	\$ 4.6

~~XML 50 R29.htm IDEA: XBRL DOCUMENT~~

Stockholders' Equity (Tables)

9 Months Ended

Jul. 31, 2024

[Stockholders' Equity Note \[Abstract\]](#)

[Schedule of changes in accumulated other comprehensive income](#)

Analysis of Changes in Accumulated Other Comprehensive Loss:

(In millions)	Foreign Currency Translation Adjustment	Minimum Pension Liability	Derivative Instruments	Total
Balance at October 31, 2022	\$ (555.0)	\$ (6.2)	\$ 94.4	\$ (466.8)
Gross change in value	103.9	—	(15.7)	88.2
Tax effect	—	—	3.8	3.8
Balance at July 31, 2023	\$ (451.1)	\$ (6.2)	\$ 82.5	\$ (374.8)
Balance at October 31, 2023	\$ (538.0)	\$ (3.2)	\$ 87.4	\$ (453.8)
Gross change in value	62.5	—	(44.4)	18.1
Tax effect	—	—	10.6	10.6
Balance at July 31, 2024	\$ (475.5)	\$ (3.2)	\$ 53.6	\$ (425.1)

The following table details the changes in the cumulative pre-tax impact of the gain on derivatives designated for hedge accounting:

Periods Ended July 31, (In millions)	Three Months		Nine Months	
	2024	2023	2024	2023
Beginning balance gain	\$ 106.4	\$ 89.5	\$ 115.1	\$ 124.5
Amount recognized in accumulated other comprehensive income on interest rate swap contracts, gross	(21.6)	31.4	(3.1)	14.6
Amount reclassified from accumulated other comprehensive income into earnings, gross	(14.1)	(12.1)	(41.3)	(30.3)
Ending balance gain	\$ 70.7	\$ 108.8	\$ 70.7	\$ 108.8

~~XML 51 R30.htm IDEA: XBRL DOCUMENT~~

Business Segment Information (Tables)

9 Months Ended

Jul. 31, 2024

[Segment Reporting \[Abstract\]](#)

[Schedule of segment information](#)

Segment information:

Periods Ended July 31, (In millions)	Three Months		Nine Months	
	2024	2023	2024	2023
CooperVision net sales by category:				
Toric and multifocal	\$ 326.4	\$ 296.5	\$ 934.0	\$ 838.5
Sphere, other	349.2	333.7	999.0	962.3
Total CooperVision net sales	\$ 675.6	\$ 630.2	\$ 1,933.0	\$ 1,800.8
CooperSurgical net sales by category:				
Office and surgical	\$ 197.9	\$ 178.4	\$ 571.9	\$ 506.6
Fertility	129.3	121.6	372.1	358.7
Total CooperSurgical net sales	327.2	300.0	944.0	865.3
Total net sales	\$ 1,002.8	\$ 930.2	\$ 2,877.0	\$ 2,666.1
Operating income (loss):				
CooperVision	\$ 172.7	\$ 151.7	\$ 487.7	\$ 449.7
CooperSurgical	41.3	18.8	86.9	0.3
Corporate	(21.5)	(18.9)	(67.3)	(52.6)
Total operating income	192.5	151.6	507.3	397.4
Interest expense	28.5	26.8	87.3	79.0
Other expense, net	0.3	6.0	6.3	11.9
Income before income taxes	\$ 163.7	\$ 118.8	\$ 413.7	\$ 306.5

[Schedule of identifiable assets by segment](#)

(In millions)	July 31, 2024	October 31, 2023
Total identifiable assets:		
CooperVision	\$ 7,172.0	\$ 7,044.0
CooperSurgical	4,716.8	4,351.8
Corporate	219.2	263.1
Total	\$ 12,108.0	\$ 11,658.9

[Schedule of net sales to unaffiliated customers by country of domicile](#)

Geographic information:

Periods Ended July 31, (In millions)	Three Months		Nine Months	
	2024	2023	2024	2023
Net sales to unaffiliated customers by country of domicile:				
United States	\$ 511.2	\$ 462.5	\$ 1,460.6	\$ 1,340.4
Europe	297.0	279.7	850.3	777.4
Rest of world	194.6	188.0	566.1	548.3
Total	\$ 1,002.8	\$ 930.2	\$ 2,877.0	\$ 2,666.1

[Schedule of net property, plant and equipment by country of domicile](#)

(In millions)	July 31, 2024	October 31, 2023
Net property, plant and equipment by country of domicile:		
United States	\$ 1,094.1	\$ 1,027.6
Europe	377.9	325.9
Rest of world	275.6	279.1
Total	\$ 1,747.6	\$ 1,632.6

~~XML 52 R31.htm IDEA: XBRL DOCUMENT~~

Financial Derivatives and Hedging (Tables)

9 Months Ended

Jul. 31, 2024

[Derivative Instruments and Hedging Activities Disclosure](#)

[Abstract]

Schedule of derivative instruments recognized in condensed consolidated statements of income

Schedule of changes in accumulated other comprehensive income

The following table summarizes the amounts recognized with respect to our derivative instruments within the accompanying Consolidated Condensed Statements of Income and Comprehensive Income:

Periods Ended July 31, (In millions)	Three Months		Nine Months	
	2024	2023	2024	2023
Derivatives designated as cash flow hedges		Location of (Gain)/Loss Recognized on Derivatives		
Interest rate swap contracts		Interest expense (income)		
	\$	(14.1)	\$	(12.1)
			\$	(41.3)
			\$	(30.3)

Analysis of Changes in Accumulated Other Comprehensive Loss:

(In millions)	Foreign Currency Translation Adjustment	Minimum Pension Liability	Derivative Instruments	Total
Balance at October 31, 2022	\$ (555.0)	\$ (6.2)	\$ 94.4	\$ (466.8)
Gross change in value	103.9	—	(15.7)	88.2
Tax effect	—	—	3.8	3.8
Balance at July 31, 2023	\$ (451.1)	\$ (6.2)	\$ 82.5	\$ (374.8)
Balance at October 31, 2023	\$ (538.0)	\$ (3.2)	\$ 87.4	\$ (453.8)
Gross change in value	62.5	—	(44.4)	18.1
Tax effect	—	—	10.6	10.6
Balance at July 31, 2024	\$ (475.5)	\$ (3.2)	\$ 53.6	\$ (425.1)

The following table details the changes in the cumulative pre-tax impact of the gain on derivatives designated for hedge accounting:

Periods Ended July 31, (In millions)	Three Months		Nine Months	
	2024	2023	2024	2023
Beginning balance gain	\$ 106.4	\$ 89.5	\$ 115.1	\$ 124.5
Amount recognized in accumulated other comprehensive income on interest rate swap contracts, gross	(21.6)	31.4	(3.1)	14.6
Amount reclassified from accumulated other comprehensive income into earnings, gross	(14.1)	(12.1)	(41.3)	(30.3)
Ending balance gain	\$ 70.7	\$ 108.8	\$ 70.7	\$ 108.8

~~XML 53 R32.htm IDEA XBRL DOCUMENT~~

General (Details) \$ / shares in Units, \$ in Millions	3 Months Ended			9 Months Ended		
	Feb. 16, 2024 \$ / shares	Jul. 31, 2024 USD (\$) \$ / shares	Jul. 31, 2023 USD (\$)	Jul. 31, 2024 USD (\$) \$ / shares	Jul. 31, 2023 USD (\$)	Oct. 31, 2023 \$ / shares [1]
Organization, Consolidation and Presentation of Financial Statements [Abstract]						
Stock split, conversion ratio	4					
Common stock, par value (in dollars per share) \$ / shares	\$ 0.10	\$ 0.10 [1]		\$ 0.10 [1]		\$ 0.10
Revenue recognized \$		\$ 30.0	\$ 30.0	\$ 92.0	\$ 80.0	

[1] All periods presented have been adjusted to reflect the four-for-one stock split effected on February 16, 2024. Refer to Note 1. General for further information.

~~XML 54 R33.htm IDEA XBRL DOCUMENT~~

Acquisitions and Joint Venture (Details) \$ in Millions	1 Months Ended					
	Aug. 01, 2024 USD (\$)	Jun. 07, 2024 USD (\$)	Nov. 01, 2023 USD (\$) installment	Mar. 31, 2022 USD (\$)	Jul. 31, 2024 USD (\$)	Oct. 31, 2023 USD (\$)
Business Acquisition [Line Items]						
Goodwill					\$ 3,777.2	\$ 3,624.5
Proceeds from sale of interest in a subsidiary				\$ 52.1		
Payments to form joint venture				10.0		
Essilor International SAS						
Business Acquisition [Line Items]						
Payments to form joint venture				\$ 10.0		
SightGlass Vision, Inc.						
Business Acquisition [Line Items]						
Equity method investment, ownership percentage				50.00%		100.00%
Cook Medical						
Business Acquisition [Line Items]						
Aggregate consideration		\$ 300.0				
Payments to acquire business		\$ 200.0				
Number of installments installment		2				
Present value of acquisition purchase price		\$ 291.6				
Goodwill		107.2				
Cook Medical Technology						
Business Acquisition [Line Items]						
Finite-lived intangibles		157.9				
Cook Medical Customer relationships						
Business Acquisition [Line Items]						
Finite-lived intangibles		26.6				
Cook Medical Payables First Installment						
Business Acquisition [Line Items]						
Payables incurred in acquisition		50.0				
Cook Medical Payables Second Installment						
Business Acquisition [Line Items]						
Payables incurred in acquisition		\$ 50.0				
U.S.-based medical device company Subsequent Event						
Business Acquisition [Line Items]						
Aggregate consideration	\$ 100.0					
Fertility company						
Business Acquisition [Line Items]						
Purchase price of acquisition		\$ 33.5				
Deferred tax liability		8.3				
Fertility company Composite intangible assets						
Business Acquisition [Line Items]						
Intangible assets acquired		\$ 39.6				

~~XML 55 R34.htm IDEA XBRL DOCUMENT~~

Inventories (Details) - USD (\$) \$ in Millions		Jul. 31, 2024	Oct. 31, 2023
Inventory Disclosure [Abstract]			
Raw materials	\$ 214.6	\$ 207.3	
Work-in-process	19.5	19.0	
Finished goods	545.2	509.3	
Total inventories	\$ 779.3	\$ 735.6	

~~XML 56 R35.htm IDEA XBRL DOCUMENT~~

Intangible Assets - Summary Of Intangible Assets (Details) - USD (\$) \$ in Millions		Jul. 31, 2024	Oct. 31, 2023
Finite-Lived Intangible Assets [Line Items]			
Gross Carrying Amount	\$ 3,136.7	\$ 2,916.1	
Accumulated Amortization	1,351.8	1,215.1	
Intangible assets with definite lives, net	\$ 1,784.9	1,701.0	

Weighted-Average Amortization Period (in years)	16 years	
Intangible assets with indefinite lives, net	\$ 1.9	9.3
Total other intangibles, net	1,786.8	1,710.3
Customer relationships		
Finite-Lived Intangible Assets [Line Items]		
Gross Carrying Amount	1,123.0	1,099.2
Accumulated Amortization	\$ 387.6	345.8
Weighted-Average Amortization Period (in years)	19 years	
Composite intangible assets		
Finite-Lived Intangible Assets [Line Items]		
Gross Carrying Amount	\$ 1,101.5	1,061.9
Accumulated Amortization	\$ 477.9	424.8
Weighted-Average Amortization Period (in years)	15 years	
Technology		
Finite-Lived Intangible Assets [Line Items]		
Gross Carrying Amount	\$ 660.0	494.5
Accumulated Amortization	\$ 372.7	335.4
Weighted-Average Amortization Period (in years)	12 years	
Trademarks		
Finite-Lived Intangible Assets [Line Items]		
Gross Carrying Amount	\$ 204.2	208.9
Accumulated Amortization	\$ 87.1	81.1
Weighted-Average Amortization Period (in years)	15 years	
License and distribution rights and other		
Finite-Lived Intangible Assets [Line Items]		
Gross Carrying Amount	\$ 48.0	51.6
Accumulated Amortization	\$ 26.5	\$ 28.0
Weighted-Average Amortization Period (in years)	11 years	

XML-57-R36.htm IDEA- XBRL DOCUMENT		
Intangible Assets - Remaining Amortization Expenses for Intangible Assets with Definite Lives (Details) - USD (\$)		Jul. 31, 2024 Oct. 31, 2023
\$ in Millions		

Goodwill and Intangible Assets Disclosure [Abstract]		
Remainder of 2024	\$ 48.6	
2025	191.6	
2026	184.0	
2027	169.7	
2028	165.2	
Thereafter	1,025.8	
Intangible assets with definite lives, net	\$ 1,784.9	\$ 1,701.0

XML-58-R37.htm IDEA- XBRL DOCUMENT		
Intangible Assets - Narrative (Details)		9 Months Ended Jul. 31, 2024 USD (\$)

Goodwill and Intangible Assets Disclosure [Abstract]	
Impairment of goodwill and intangible assets	\$ 0

XML-59-R38.htm IDEA- XBRL DOCUMENT		
Financing Arrangements - Total Debt (Details) - USD (\$)	Jul. 31, 2024	Oct. 31, 2023
\$ in Millions		

Short-term Debt		
Short-term debt	\$ 39.8	\$ 44.4
Financing lease liabilities	\$ 1.0	1.0
Finance lease liabilities, short-term, location	Short-term debt	
Short-term debt	\$ 40.8	45.4
Long-term Debt		
Less: unamortized debt issuance cost	(1.6)	(2.4)
Long-term debt, excluding financing leases	2,588.8	2,520.4
Financing lease liabilities	\$ 2.8	3.4
Finance lease liabilities, long-term, location	Long-term debt	
Long-term debt	\$ 2,591.6	2,523.8
Total debt	2,632.4	2,569.2
Term loans		
Long-term Debt		
Long-term debt, gross	1,500.0	2,350.0
Other		
Long-term Debt		
Long-term debt, gross	0.2	0.2
Revolving Credit Facility Line of Credit		
Long-term Debt		
Long-term debt, gross	\$ 1,090.2	\$ 172.6

XML-60-R39.htm IDEA- XBRL DOCUMENT		
Financing Arrangements - Narrative (Details) - Line of Credit - USD (\$)		May 01, 2024 Jul. 31, 2024 Dec. 17, 2021 Apr. 01, 2020
\$ in Millions		

2024 Credit Agreement		
Schedule of Long Term And Short Term Debt Instruments [Line Items]		
Potential additional borrowing capacity		\$ 1,150.0
Potential additional borrowing capacity, percentage of EBITDA		100.00%
2024 Credit Agreement Base rate Minimum		
Schedule of Long Term And Short Term Debt Instruments [Line Items]		
Basis spread on variable rate		0.00%
2024 Credit Agreement Base rate Maximum		
Schedule of Long Term And Short Term Debt Instruments [Line Items]		
Basis spread on variable rate		0.50%
2024 Credit Agreement Adjusted SOFR Minimum		
Schedule of Long Term And Short Term Debt Instruments [Line Items]		
Basis spread on variable rate		0.87%
2024 Credit Agreement Adjusted SOFR Maximum		
Schedule of Long Term And Short Term Debt Instruments [Line Items]		

Basis spread on variable rate	1.50%								
2024 Credit Agreement Adjusted foreign currency rate Minimum									
Schedule of Long Term And Short Term Debt Instruments [Line Items]									
Basis spread on variable rate	0.87%								
2024 Credit Agreement Adjusted foreign currency rate Maximum									
Schedule of Long Term And Short Term Debt Instruments [Line Items]									
Basis spread on variable rate	1.50%								
2021 Term Loan Facility									
Schedule of Long Term And Short Term Debt Instruments [Line Items]									
Aggregate principal amount								\$ 1,500.0	
Amount outstanding								\$ 1,500.0	
Interest rate								6.44%	
Revolving Credit Facility 2024 Credit Agreement									
Schedule of Long Term And Short Term Debt Instruments [Line Items]									
Aggregate principal amount		\$ 2,300.0							
Amount outstanding								\$ 1,100.0	
Interest rate								6.57%	
Revolving Credit Facility 2024 Credit Agreement Minimum									
Schedule of Long Term And Short Term Debt Instruments [Line Items]									
Commitment fee percentage	0.10%								
Revolving Credit Facility 2024 Credit Agreement Maximum									
Schedule of Long Term And Short Term Debt Instruments [Line Items]									
Commitment fee percentage	0.20%								
Revolving Credit Facility 2020 Credit Agreement									
Schedule of Long Term And Short Term Debt Instruments [Line Items]									
Aggregate principal amount								\$ 1,290.0	
Revolving Credit Facility And Term Loan Facility 2020 2020 Credit Agreement									
Schedule of Long Term And Short Term Debt Instruments [Line Items]									
Potential additional borrowing capacity								1,605.0	
Term Loan Facility 2020 2020 Credit Agreement									
Schedule of Long Term And Short Term Debt Instruments [Line Items]									
Aggregate principal amount								\$ 850.0	
Repayment of borrowings		\$ 1,170.0							
XML-61-R40.htm IDEA- XBRL DOCUMENT									
Income Taxes (Details)		3 Months Ended		9 Months Ended					
		Jul. 31, 2024	Jul. 31, 2023	Jul. 31, 2024	Jul. 31, 2023				
Income Tax Disclosure [Abstract]									
Effective income tax rate	36.10%	28.20%	33.60%	31.60%					
XML-62-R41.htm IDEA- XBRL DOCUMENT									
Earnings Per Share - Schedule of Earnings Per Share (Details) - USD (\$)		3 Months Ended				9 Months Ended			
\$ / shares in Units, shares in Millions, \$ in Millions		Jul. 31, 2024	Apr. 30, 2024	Jan. 31, 2024	Jul. 31, 2023	Apr. 30, 2023	Jan. 31, 2023	Jul. 31, 2024	Jul. 31, 2023
Earnings Per Share [Abstract]									
Net income		\$ 104.7	\$ 88.9	\$ 81.2	\$ 85.3	\$ 39.8	\$ 84.6	\$ 274.8	\$ 209.7
Basic:									
Weighted-average common shares (in shares)	[1]	199.1			198.1			198.8	197.8
Basic earnings per share (in dollars per share)	[1]	\$ 0.53			\$ 0.43			\$ 1.38	\$ 1.06
Diluted:									
Weighted-average common shares (in shares)	[1]	199.1			198.1			198.8	197.8
Effect of dilutive stock plans (in shares)		1.5			1.5			1.5	1.4
Diluted weighted average common shares (in shares)	[1]	200.6			199.6			200.3	199.2
Diluted earnings per share (in dollars per share)	[1]	\$ 0.52			\$ 0.43			\$ 1.37	\$ 1.05
[1] All periods presented have been adjusted to reflect the four-for-one stock split effected on February 16, 2024. Refer to Note 1. General for further information.									
XML-63-R42.htm IDEA- XBRL DOCUMENT									
Earnings Per Share - Schedule of Stock Options and Restricted Stock Units that were not Included in the Diluted Earnings Per Share Calculation (Details) - \$ / shares shares in Thousands		3 Months Ended				9 Months Ended			
		Jul. 31, 2024	Jul. 31, 2023	Jul. 31, 2024	Jul. 31, 2023				
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]									
Exercise prices, lower limit (in dollars per share)		\$ 82.46	\$ 82.46	\$ 82.46	\$ 75.03				
Exercise prices, upper limit (in dollars per share)		\$ 101.54	\$ 101.54	\$ 101.54	\$ 101.54				
Stock options									
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]									
Number of awards excluded (in shares)		828	820	828	1,244				
Restricted stock units									
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]									
Number of awards excluded (in shares)		5	8	2,000	64				
XML-64-R43.htm IDEA- XBRL DOCUMENT									
Share-Based Compensation (Details) - USD (\$)		3 Months Ended				9 Months Ended			
\$ in Millions		Jul. 31, 2024	Jul. 31, 2023	Jul. 31, 2024	Jul. 31, 2023				
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]									
Total share-based compensation expense		\$ 17.6	\$ 15.5	\$ 58.7	\$ 46.9				
Related income tax benefit		1.0	1.3	5.8	4.6				
Selling, general and administrative expense									
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]									
Total share-based compensation expense		15.8	13.7	53.0	41.5				
Cost of sales									
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]									
Total share-based compensation expense		1.3	1.1	3.6	3.1				
Research and development expense									
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]									
Total share-based compensation expense		\$ 0.5	\$ 0.7	\$ 2.1	\$ 2.3				
XML-65-R44.htm IDEA- XBRL DOCUMENT									
Stockholders' Equity - Schedule of Changes in Accumulated Other Comprehensive Income (Loss) Income (Details) - USD (\$)		9 Months Ended							
		Jul. 31, 2024	Jul. 31, 2023						

\$ in Millions			
AOCI Attributable to Parent, Net of Tax [Roll Forward]			
Stockholders' equity, beginning balance	\$ 7,551.0	[1]	\$ 7,174.7 [2]
Gross change in value	18.1		88.2
Tax effect	10.6		3.8
Stockholders' equity, ending balance	[2] 7,925.2		7,528.5
Accumulated Other Comprehensive Loss			
AOCI Attributable to Parent, Net of Tax [Roll Forward]			
Stockholders' equity, beginning balance	[2] (453.8)		(466.8)
Stockholders' equity, ending balance	[2] (425.1)		(374.8)
Foreign Currency Translation Adjustment			
AOCI Attributable to Parent, Net of Tax [Roll Forward]			
Stockholders' equity, beginning balance	(538.0)		(555.0)
Gross change in value	62.5		103.9
Tax effect	0.0		0.0
Stockholders' equity, ending balance	(475.5)		(451.1)
Minimum Pension Liability			
AOCI Attributable to Parent, Net of Tax [Roll Forward]			
Stockholders' equity, beginning balance	(3.2)		(6.2)
Gross change in value	0.0		0.0
Tax effect	0.0		0.0
Stockholders' equity, ending balance	(3.2)		(6.2)
Derivative Instruments			
AOCI Attributable to Parent, Net of Tax [Roll Forward]			
Stockholders' equity, beginning balance	87.4		94.4
Gross change in value	(44.4)		(15.7)
Tax effect	10.6		3.8
Stockholders' equity, ending balance	\$ 53.6		\$ 82.5

[1] All periods presented have been adjusted to reflect the four-for-one stock split effected on February 16, 2024. Refer to Note 1. General for further information.

[2] All periods presented have been adjusted to reflect the four-for-one stock split effected on February 16, 2024. Refer to Note 1. General for further information.

~~XML-66-R45.htm IDEA: XBRL DOCUMENT~~

Stockholders' Equity - Narrative (Details) - USD (\$) \$ in Millions	3 Months Ended		9 Months Ended	
	Jul. 31, 2024	Jul. 31, 2023	Jul. 31, 2024	Jul. 31, 2023
	Mar. 31, 2017			

Stockholders' Equity Note [Abstract]				
Share repurchase program, authorized amount for repurchase				\$ 1,000.0
Share repurchase program, remaining authorized amount for repurchase	\$ 256.4		\$ 256.4	
Number of shares (in shares)	0	0	0	0
Dividends on common stock			\$ 0.0	\$ 1.5

~~XML-67-R46.htm IDEA: XBRL DOCUMENT~~

Contingencies and Commitments (Details) \$ in Millions	Jul. 31, 2024
	USD (\$)

Operating leases not yet commenced	
Lessee, Lease, Description [Line Items]	
Undiscounted lease payments	\$ 214.0
Minimum	
Lessee, Lease, Description [Line Items]	
Lease term (in years)	15 years
Maximum	
Lessee, Lease, Description [Line Items]	
Lease term (in years)	25 years

~~XML-68-R47.htm IDEA: XBRL DOCUMENT~~

Business Segment Information - Schedule of Segment Information (Details) - USD (\$) \$ in Millions	3 Months Ended		9 Months Ended	
	Jul. 31, 2024	Jul. 31, 2023	Jul. 31, 2024	Jul. 31, 2023

Segment Reporting Information [Line Items]				
Total net sales	\$ 1,002.8	\$ 930.2	\$ 2,877.0	\$ 2,666.1
Total operating income	192.5	151.6	507.3	397.4
Interest expense	28.5	26.8	87.3	79.0
Other expense, net	0.3	6.0	6.3	11.9
Income before income taxes	163.7	118.8	413.7	306.5
Operating Segments CooperVision				
Segment Reporting Information [Line Items]				
Total net sales	675.6	630.2	1,933.0	1,800.8
Total operating income	172.7	151.7	487.7	449.7
Operating Segments CooperSurgical				
Segment Reporting Information [Line Items]				
Total net sales	327.2	300.0	944.0	865.3
Total operating income	41.3	18.8	86.9	0.3
Operating Segments Toric and multifocal CooperVision				
Segment Reporting Information [Line Items]				
Total net sales	326.4	296.5	934.0	838.5
Operating Segments Sphere, other CooperVision				
Segment Reporting Information [Line Items]				
Total net sales	349.2	333.7	999.0	962.3
Operating Segments Office and surgical CooperSurgical				
Segment Reporting Information [Line Items]				
Total net sales	197.9	178.4	571.9	506.6
Operating Segments Fertility CooperSurgical				
Segment Reporting Information [Line Items]				
Total net sales	129.3	121.6	372.1	358.7
Corporate				
Segment Reporting Information [Line Items]				
Total operating income	\$ (21.5)	\$ (18.9)	\$ (67.3)	\$ (52.6)

~~XML-69-R48.htm IDEA: XBRL DOCUMENT~~

Business Segment Information - Schedule of Identifiable Assets by Segment (Details) - USD (\$) \$ in Millions	Jul. 31, 2024		Oct. 31, 2023
Segment Reporting Information [Line Items]			
Total identifiable assets	\$ 12,108.0		\$ 11,658.9

[Operating Segments | CooperVision](#)

[Segment Reporting Information \[Line Items\]](#)

Total identifiable assets 7,172.0 7,044.0

[Operating Segments | CooperSurgical](#)

[Segment Reporting Information \[Line Items\]](#)

Total identifiable assets 4,716.8 4,351.8

[Corporate](#)

[Segment Reporting Information \[Line Items\]](#)

Total identifiable assets \$ 219.2 \$ 263.1

~~XML-70-R49.htm IDEA XBRL DOCUMENT~~

Business Segment Information - Schedule of Net Sales to Unaffiliated Customers by Country of Domicile (Details) - USD (\$) \$ in Millions	3 Months Ended		9 Months Ended	
	Jul. 31, 2024	Jul. 31, 2023	Jul. 31, 2024	Jul. 31, 2023

[Revenues from External Customers and Long-Lived Assets \[Line Items\]](#)

Total net sales \$ 1,002.8 \$ 930.2 \$ 2,877.0 \$ 2,666.1

[United States](#)

[Revenues from External Customers and Long-Lived Assets \[Line Items\]](#)

Total net sales 511.2 462.5 1,460.6 1,340.4

[Europe](#)

[Revenues from External Customers and Long-Lived Assets \[Line Items\]](#)

Total net sales 297.0 279.7 850.3 777.4

[Rest of world](#)

[Revenues from External Customers and Long-Lived Assets \[Line Items\]](#)

Total net sales \$ 194.6 \$ 188.0 \$ 566.1 \$ 548.3

~~XML-71-R50.htm IDEA XBRL DOCUMENT~~

Business Segment Information - Schedule of Net Property, Plant and Equipment By Country of Domicile (Details) - USD (\$) \$ in Millions	3 Months Ended	
	Jul. 31, 2024	Oct. 31, 2023

[Revenues from External Customers and Long-Lived Assets \[Line Items\]](#)

Net property, plant and equipment \$ 1,747.6 \$ 1,632.6

[United States](#)

[Revenues from External Customers and Long-Lived Assets \[Line Items\]](#)

Net property, plant and equipment 1,094.1 1,027.6

[Europe](#)

[Revenues from External Customers and Long-Lived Assets \[Line Items\]](#)

Net property, plant and equipment 377.9 325.9

[Rest of world](#)

[Revenues from External Customers and Long-Lived Assets \[Line Items\]](#)

Net property, plant and equipment \$ 275.6 \$ 279.1

~~XML-72-R51.htm IDEA XBRL DOCUMENT~~

Financial Derivatives and Hedging - Narrative (Details) \$ in Millions	3 Months Ended		9 Months Ended	
	Jul. 31, 2024 USD (\$) interest_rate_swap_contract	Jul. 31, 2023 USD (\$)	Jul. 31, 2024 USD (\$) interest_rate_swap_contract	Jul. 31, 2023 USD (\$)
Derivative Instruments and Hedging Activities Disclosures [Line Items]				
Amount recognized in other comprehensive income on interest rate swaps contracts, net of tax	\$ (16.5)	\$ 23.8	\$ (2.7)	\$ 11.1
Amount reclassified from other comprehensive income into earnings, net of tax	(10.7)	\$ (9.2)	(31.1)	\$ (23.0)
Derivative loss expected to be realized in earnings over the next twelve months			(41.8)	
Foreign Exchange Forward				
Derivative Instruments and Hedging Activities Disclosures [Line Items]				
Derivative notional amount	58.6		58.6	
Interest Rate Swap				
Derivative Instruments and Hedging Activities Disclosures [Line Items]				
Derivative notional amount	\$ 1,800.0		\$ 1,800.0	
Number of interest rate swap contracts held interest_rate_swap_contract	9		9	
Derivative, remaining maturity (less than)			4 years	

~~XML-73-R52.htm IDEA XBRL DOCUMENT~~

Financial Derivatives and Hedging - Schedule of Derivative Instruments Recognized in Condensed Consolidated Statements of Income (Details) - USD (\$) \$ in Millions	3 Months Ended		9 Months Ended	
	Jul. 31, 2024	Jul. 31, 2023	Jul. 31, 2024	Jul. 31, 2023

[Interest expense \(income\) | Interest Rate Swap](#)

[Derivative Instruments and Hedging Activities Disclosures \[Line Items\]](#)

(Gain) loss recognized on derivatives within interest expense \$ (14.1) \$ (12.1) \$ (41.3) \$ (30.3)

~~XML-74-R53.htm IDEA XBRL DOCUMENT~~

Financial Derivatives and Hedging - Schedule of Changes in Accumulated Other Comprehensive Income (Details) - USD (\$) \$ in Millions	3 Months Ended		9 Months Ended	
	Jul. 31, 2024	Jul. 31, 2023	Jul. 31, 2024	Jul. 31, 2023
AOCI Attributable To Parent, Before Reclassification And Tax [Roll Forward]				
Stockholders' equity, beginning balance	\$ 7,803.9	[1] \$ 7,378.0	[1] \$ 7,551.0	[2] \$ 7,174.7
Stockholders' equity, ending balance	[1] 7,925.2	7,528.5	7,925.2	7,528.5
Accumulated Gain (Loss), Net, Cash Flow Hedge, Before Tax, Parent				
AOCI Attributable To Parent, Before Reclassification And Tax [Roll Forward]				
Stockholders' equity, beginning balance	106.4	89.5	115.1	124.5
Stockholders' equity, ending balance	70.7	108.8	70.7	108.8
Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent				
AOCI Attributable To Parent, Before Reclassification And Tax [Roll Forward]				
Stockholders' equity, beginning balance			87.4	94.4
Amount recognized in accumulated other comprehensive income on interest rate swap contracts, gross	(21.6)	31.4	(3.1)	14.6
Amount reclassified from accumulated other comprehensive income into earnings, gross	(14.1)	(12.1)	(41.3)	(30.3)

[illegible]

of Income (Details) Sheet

http://www.cooperco.com/role/FinancialDerivativesandHedgingScheduleofDerivativeInstrumentsRecognizedinCondensedConsolidatedStatementsofIncomeDetails
Financial Derivatives and Hedging - Schedule of Derivative Instruments Recognized in Condensed Consolidated Statements of Income (Details) Details 52 false false
R53.htm 9954501 - Disclosure - Financial Derivatives and Hedging - Schedule of Changes in Accumulated Other Comprehensive Income (Details) Sheet
http://www.cooperco.com/role/FinancialDerivativesandHedgingScheduleofChangesinAccumulatedOtherComprehensiveIncomeDetails Financial Derivatives and Hedging -
Schedule of Changes in Accumulated Other Comprehensive Income (Details) Details 53 false false All Reports Book All Reports coo-20240731.htm coo-20240731.xsd coo-
20240731_cal.xml coo-20240731_def.xml coo-20240731_lab.xml coo-20240731_pre.xml coo-20240731_g1.jpg coo-20240731_g10.jpg coo-20240731_g2.jpg coo-
20240731_g3.jpg coo-20240731_g4.jpg coo-20240731_g5.jpg coo-20240731_g6.jpg coo-20240731_g7.jpg coo-20240731_g8.jpg coo-20240731_g9.jpg
http://fasb.org/srt/2024 http://fasb.org/us-gaap/2024 http://xbrl.sec.gov/dei/2024 http://xbrl.sec.gov/ecd/2024 true JSON 81 MetaLinks.json IDEA: XBRL DOCUMENT f
"version": "2.2", "instance": f "coo-20240731.htm": f "nsprefix": "coo", "nsuri": "http://www.cooperco.com/20240731", "dts": f "inline": f "local": f "coo-20240731.htm" f
"schema": f "local": f "coo-20240731.xsd" f "remote": f "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" f "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-
31.xsd" f "http://www.xbrl.org/2003/xbrl-2003-12-31.xsd" f "http://www.xbrl.org/2003/xlink-2003-12-31.xsd" f "http://www.xbrl.org/2005/xbrldt-2005.xsd"
"http://www.xbrl.org/2006/rel-2006-02-27.xsd" f "http://www.xbrl.org/ir/role/negated-2009-12-16.xsd" f "http://www.xbrl.org/ir/role/net-2009-12-16.xsd"
"http://www.xbrl.org/ir/role/reference-2009-12-16.xsd" f "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd" f "https://www.xbrl.org/dtr/type/2020-01-
21/types.xsd" f "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" f "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd" f "https://xbrl.fasb.org/srt/2024/elts/srt-roles-
2024.xsd" f "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd" f "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd" f "https://xbrl.fasb.org/us-gaap/2024/elts/us-
roles-2024.xsd" f "https://xbrl.fasb.org/us-gaap/2024/us-types-2024.xsd" f "https://xbrl.sec.gov/country/2024/country-2024.xsd" f "https://xbrl.sec.gov/dei/2024/dei-
2024.xsd" f "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd" f "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd" f "calculationLink": f "local": f "coo-20240731_cal.xml" f f
"definitionLink": f "local": f "coo-20240731_def.xml" f f "labelLink": f "local": f "coo-20240731_lab.xml" f f "presentationLink": f "local": f "coo-20240731_pre.xml" f f f
"keyStandard": 213, "keyCustom": 8, "axisStandard": 20, "axisCustom": 1, "memberStandard": 32, "memberCustom": 26, "hidden": f "total": 7, "http://fasb.org/us-
gaap/2024": 2, "http://xbrl.sec.gov/dei/2024": 5, "contextCustom": 260, "entityCustom": 1, "segmentCount": 58, "elementCount": 483, "unitCount": 6, "baseTaxonomies": f
"http://fasb.org/us-gaap/2024": 734, "http://xbrl.sec.gov/dei/2024": 30, "http://xbrl.sec.gov/ecd/2024": 4, "http://fasb.org/srt/2024": 1, "report": f "R1": f "role":
"http://www.cooperco.com/role/Cover", "longName": "0000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document",
"subGroupType": "", "menuCat": "Cover", "order": 1, "firstAnchor": f "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US",
"decimals": null, "ancestors": f "span": "div", "body": "html" f "reportCount": 1, "baseRef": "coo-20240731.htm", "first": true, "unique": true f "uniqueAnchor": f
"contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": f "span": "div", "body": "html" f
"reportCount": 1, "baseRef": "coo-20240731.htm", "first": true, "unique": true f "R2": f "role":
"http://www.cooperco.com/role/ConsolidatedCondensedStatementsOfIncomeandComprehensiveIncome", "longName": "9952151 - Statement - Consolidated Condensed
Statements of Income and Comprehensive Income", "shortName": "Consolidated Condensed Statements of Income and Comprehensive Income", "isDefault": "false",
"groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": 2, "firstAnchor": f "contextRef": "c-3", "name": "us-
gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": 5, "ancestors": f "span": "td", "tr":
"table" f "div": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock" f "us-gaap:SegmentReportingDisclosureTextBlock" f "body": "html" f
"reportCount": 1, "baseRef": "coo-20240731.htm", "first": true f "uniqueAnchor": f "contextRef": "c-3", "name": "us-gaap:CostOfGoodsAndServicesSold", "unitRef": "usd",
"xsiNil": "false", "lang": "en-US", "decimals": 5, "ancestors": f "span": "td", "tr": "table" f "div": "body": "html" f "reportCount": 1, "baseRef": "coo-20240731.htm",
"unique": true f "R3": f "role": "http://www.cooperco.com/role/ConsolidatedCondensedStatementsOfIncomeandComprehensiveIncomeParenthetical", "longName":
"9952152 - Statement - Consolidated Condensed Statements of Income and Comprehensive Income (Parenthetical)", "shortName": "Consolidated Condensed Statements
of Income and Comprehensive Income (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements",
"order": 3, "firstAnchor": f "contextRef": "c-6", "name": "us-gaap:StockholdersEquityNoteStockSplitConversionRatio1", "unitRef": "number", "xsiNil": "false", "lang":
"en-US", "decimals": "INF", "ancestors": f "span": "link:footnote" f "div": "body": "html" f "reportCount": 1, "baseRef": "coo-20240731.htm", "first": true f "uniqueAnchor":
null f "R4": f "role": "http://www.cooperco.com/role/ConsolidatedCondensedBalanceSheets", "longName": "9952153 - Statement - Consolidated Condensed Balance
Sheets", "shortName": "Consolidated Condensed Balance Sheets", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order":
4, "firstAnchor": f "contextRef": "c-7", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": 5,
"ancestors": f "span": "td", "tr": "table" f "div": "body": "html" f "reportCount": 1, "baseRef": "coo-20240731.htm", "first": true f "uniqueAnchor": f "contextRef": "c-7",
"name": "us-gaap:AccountsReceivableNetCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": 5, "ancestors": f "span": "td", "tr": "table", "div",
"body": "html" f "reportCount": 1, "baseRef": "coo-20240731.htm", "unique": true f "R5": f "role":
"http://www.cooperco.com/role/ConsolidatedCondensedBalanceSheetsParenthetical", "longName": "9952154 - Statement - Consolidated Condensed Balance Sheets
(Parenthetical)", "shortName": "Consolidated Condensed Balance Sheets (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType":
"parenthetical", "menuCat": "Statements", "order": 5, "firstAnchor": f "contextRef": "c-7", "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent",
"unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": 5, "ancestors": f "span": "div", "td", "tr": "table" f "div": "body": "html" f "reportCount": 1, "baseRef": "coo-
20240731.htm", "first": true, "unique": true f "uniqueAnchor": f "contextRef": "c-7", "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent", "unitRef":
"usd", "xsiNil": "false", "lang": "en-US", "decimals": 5, "ancestors": f "span": "div", "td", "tr": "table" f "div": "body": "html" f "reportCount": 1, "baseRef": "coo-
20240731.htm", "first": true, "unique": true f "R6": f "role": "http://www.cooperco.com/role/ConsolidatedCondensedStatementsOfStockholdersEquity", "longName":
"9952155 - Statement - Consolidated Condensed Statements of Stockholders' Equity", "shortName": "Consolidated Condensed Statements of Stockholders' Equity",
"isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": 6, "firstAnchor": f "contextRef": "c-9", "name": "us-
gaap:CommonStockSharesOutstanding", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": 5, "ancestors": f "span": "td", "tr": "table", "div", "body":
"html" f "reportCount": 1, "baseRef": "coo-20240731.htm", "first": true f "uniqueAnchor": f "contextRef": "c-17", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd",
"xsiNil": "false", "lang": "en-US", "decimals": 5, "ancestors": f "span": "td", "tr": "table", "div": "body": "html" f "reportCount": 1, "baseRef": "coo-20240731.htm",
"unique": true f "R7": f "role": "http://www.cooperco.com/role/ConsolidatedCondensedStatementsOfStockholdersEquityParenthetical", "longName": "9952156 -
Statement - Consolidated Condensed Statements of Stockholders' Equity (Parenthetical)", "shortName": "Consolidated Condensed Statements of Stockholders' Equity
(Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": 7, "firstAnchor": f "contextRef": "c-
4", "name": "us-gaap:CommonStockDividendsPerShareCashPaid", "unitRef": "usdPerShare", "xsiNil": "false", "lang": "en-US", "decimals": 2, "ancestors": f "span": "div",
"td", "tr": "table" f "div": "body": "html" f "reportCount": 1, "baseRef": "coo-20240731.htm", "first": true, "unique": true f "uniqueAnchor": f "contextRef": "c-4", "name":
"us-gaap:CommonStockDividendsPerShareCashPaid", "unitRef": "usdPerShare", "xsiNil": "false", "lang": "en-US", "decimals": 2, "ancestors": f "span": "div", "td", "tr":
"table" f "div": "body": "html" f "reportCount": 1, "baseRef": "coo-20240731.htm", "first": true, "unique": true f "R8": f "role":
"http://www.cooperco.com/role/ConsolidatedCondensedStatementsOfCashFlows", "longName": "9952157 - Statement - Consolidated Condensed Statements of Cash
Flows", "shortName": "Consolidated Condensed Statements of Cash Flows", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements",
"order": 8, "firstAnchor": f "contextRef": "c-1", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": 5, "ancestors": f
"span": "td", "tr": "table" f "div": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" f "us-gaap:EarningsPerShareTableTextBlock" f "body": "html" f
"reportCount": 1, "baseRef": "coo-20240731.htm", "first": true f "uniqueAnchor": f "contextRef": "c-1", "name": "us-gaap:DepreciationDepletionAndAmortization",
"unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": 5, "ancestors": f "span": "td", "tr": "table", "div", "body": "html" f "reportCount": 1, "baseRef": "coo-
20240731.htm", "unique": true f "R9": f "role": "http://www.cooperco.com/role/General", "longName": "9952158 - Disclosure - General", "shortName": "General",
"isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": 9, "firstAnchor": f "contextRef": "c-1", "name": "us-
gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals":
null, "ancestors": f "body": "html" f "reportCount": 1, "baseRef": "coo-20240731.htm", "first": true, "unique": true f "uniqueAnchor": f "contextRef": "c-1", "name": "us-
gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals":
null, "ancestors": f "body": "html" f "reportCount": 1, "baseRef": "coo-20240731.htm", "first": true, "unique": true f "R10": f "role":
"http://www.cooperco.com/role/AcquisitionsandJointVenture", "longName": "9952159 - Disclosure - Acquisitions and Joint Venture", "shortName": "Acquisitions and Joint
Venture", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": 10, "firstAnchor": f "contextRef": "c-1", "name":
"coo:BusinessCombinationAndAssetAcquisitionTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": f "body": "html" f
"reportCount": 1, "baseRef": "coo-20240731.htm", "first": true, "unique": true f "uniqueAnchor": f "contextRef": "c-1", "name":
"coo:BusinessCombinationAndAssetAcquisitionTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": f "body": "html" f
"reportCount": 1, "baseRef": "coo-20240731.htm", "first": true, "unique": true f "R11": f "role": "http://www.cooperco.com/role/Inventories", "longName": "9952160 -
Disclosure - Inventories", "shortName": "Inventories", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": 11,
"firstAnchor": f "contextRef": "c-1", "name": "us-gaap:InventoryDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": f
"span": "div", "body": "html" f "reportCount": 1, "baseRef": "coo-20240731.htm", "first": true, "unique": true f "uniqueAnchor": f "contextRef": "c-1", "name": "us-
gaap:InventoryDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": f "span": "div", "body": "html" f "reportCount": 1,
"baseRef": "coo-20240731.htm", "first": true, "unique": true f "R12": f "role": "http://www.cooperco.com/role/IntangibleAssets", "longName": "9952161 - Disclosure -
Intangible Assets", "shortName": "Intangible Assets", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": 12, "firstAnchor":
f "contextRef": "c-1", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors":
f "body": "html" f "reportCount": 1, "baseRef": "coo-20240731.htm", "first": true, "unique": true f "uniqueAnchor": f "contextRef": "c-1", "name": "us-
gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": f "body": "html" f "reportCount":
1, "baseRef": "coo-20240731.htm", "first": true, "unique": true f "R13": f "role": "http://www.cooperco.com/role/FinancingArrangements", "longName": "9952162 -
Disclosure - Financing Arrangements", "shortName": "Financing Arrangements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes",
"order": 13, "firstAnchor": f "contextRef": "c-1", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null,
"ancestors": f "body": "html" f "reportCount": 1, "baseRef": "coo-20240731.htm", "first": true, "unique": true f "uniqueAnchor": f "contextRef": "c-1", "name": "us-
gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": f "body": "html" f "reportCount": 1, "baseRef": "coo-
20240731.htm", "first": true, "unique": true f "R14": f "role": "http://www.cooperco.com/role/IncomeTaxes", "longName": "9952163 - Disclosure - Income Taxes",
"shortName": "Income Taxes", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": 14, "firstAnchor": f "contextRef": "c-1",
"name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": f "body": "html" f "reportCount": 1,
"baseRef": "coo-20240731.htm", "first": true, "unique": true f "uniqueAnchor": f "contextRef": "c-1", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null,
"xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": f "body": "html" f "reportCount": 1, "baseRef": "coo-20240731.htm", "first": true, "unique": true f "R15":
f "role": "http://www.cooperco.com/role/EarningsPerShare", "longName": "9952164 - Disclosure - Earnings Per Share", "shortName": "Earnings Per Share", "isDefault":
"false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": 15, "firstAnchor": f "contextRef": "c-1", "name": "us-
gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": f "body": "html" f "reportCount": 1, "baseRef": "coo-
20240731.htm", "first": true, "unique": true f "uniqueAnchor": f "contextRef": "c-1", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false",
"lang": "en-US", "decimals": null, "ancestors": f "body": "html" f "reportCount": 1, "baseRef": "coo-20240731.htm", "first": true, "unique": true f "R16": f "role":
"http://www.cooperco.com/role/ShareBasedCompensation", "longName": "9952165 - Disclosure - Share-Based Compensation", "shortName": "Share-Based
Compensation", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": 16, "firstAnchor": f "contextRef": "c-1", "name": "us-
gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": f "body":
"html" f "reportCount": 1, "baseRef": "coo-20240731.htm", "first": true, "unique": true f "uniqueAnchor": f "contextRef": "c-1", "name": "us-
gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": f "body":
"html" f "reportCount": 1, "baseRef": "coo-20240731.htm", "first": true, "unique": true f "R17": f "role": "http://www.cooperco.com/role/StockholdersEquity",
"longName": "9952166 - Disclosure - Stockholders' Equity", "shortName": "Stockholders' Equity", "isDefault": "false", "groupType": "disclosure", "subGroupType": "",
"menuCat": "Notes", "order": 17, "firstAnchor": f "contextRef": "c-1", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false",

Expenses for Intangible Assets with Definite Lives (Details), "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "36", "firstAnchor": { "contextRef": "c-7", "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOffFiscalYear", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "5", "ancestors": { "span": "td", "tr": "table", "div": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock", "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "body": "html" }, "reportCount": 1, "baseRef": "coo-20240731.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-7", "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOffFiscalYear", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "5", "ancestors": { "span": "td", "tr": "table", "div": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock", "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "body": "html" }, "reportCount": 1, "baseRef": "coo-20240731.htm", "first": true, "unique": true } }, "R37": { "role": "http://www.cooperco.com/role/IntangibleAssetsNarrativeDetails", "longName": "9954485 - Disclosure - Intangible Assets - Narrative (Details)", "shortName": "Intangible Assets - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "37", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:GoodwillAndIntangibleAssetImpairment", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": { "span": "div", "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "body": "html" }, "reportCount": 1, "baseRef": "coo-20240731.htm", "first": true, "unique": true } }, "R38": { "role": "http://www.cooperco.com/role/FinancingArrangementsTotalDebtDetails", "longName": "9954486 - Disclosure - Financing Arrangements - Total Debt (Details)", "shortName": "Financing Arrangements - Total Debt (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "38", "firstAnchor": { "contextRef": "c-7", "name": "us-gaap:ShortTermBorrowings", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "5", "ancestors": { "span": "td", "tr": "table", "div": "us-gaap:DebtDisclosureTextBlock", "body": "html" }, "reportCount": 1, "baseRef": "coo-20240731.htm", "first": true, "unique": true } }, "R39": { "role": "http://www.cooperco.com/role/FinancingArrangementsNarrativeDetails", "longName": "9954487 - Disclosure - Financing Arrangements - Narrative (Details)", "shortName": "Financing Arrangements - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "39", "firstAnchor": { "contextRef": "c-137", "name": "coo:LineOfCreditFacilityAccordionFeatureIncreaseLimit", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "6", "ancestors": { "span": "div", "us-gaap:DebtDisclosureTextBlock", "body": "html" }, "reportCount": 1, "baseRef": "coo-20240731.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-137", "name": "coo:LineOfCreditFacilityAccordionFeatureIncreaseLimit", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "6", "ancestors": { "span": "div", "us-gaap:DebtDisclosureTextBlock", "body": "html" }, "reportCount": 1, "baseRef": "coo-20240731.htm", "first": true, "unique": true } }, "R40": { "role": "http://www.cooperco.com/role/IncomeTaxDetails", "longName": "9954488 - Disclosure - Income Taxes (Details)", "shortName": "Income Taxes (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "40", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": { "span": "div", "us-gaap:IncomeTaxDisclosureTextBlock", "body": "html" }, "reportCount": 1, "baseRef": "coo-20240731.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": { "span": "div", "us-gaap:IncomeTaxDisclosureTextBlock", "body": "html" }, "reportCount": 1, "baseRef": "coo-20240731.htm", "first": true, "unique": true } }, "R41": { "role": "http://www.cooperco.com/role/EarningsPerShareScheduleOfEarningsPerShareDetails", "longName": "9954489 - Disclosure - Earnings Per Share - Schedule of Earnings Per Share (Details)", "shortName": "Earnings Per Share - Schedule of Earnings Per Share (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "41", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "5", "ancestors": { "span": "td", "tr": "table", "div": "body", "html" }, "reportCount": 1, "baseRef": "coo-20240731.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "5", "ancestors": { "span": "td", "tr": "table", "div": "body", "html" }, "reportCount": 1, "baseRef": "coo-20240731.htm", "first": true, "unique": true } }, "R42": { "role": "http://www.cooperco.com/role/EarningsPerShareScheduleOfStockOptionsandRestrictedStockUnitsthatwerenotIncludedintheDilutedEarningsPerShareCalculationDetails", "longName": "9954490 - Disclosure - Earnings Per Share - Schedule of Stock Options and Restricted Stock Units that were not included in the Diluted Earnings Per Share Calculation (Details)", "shortName": "Earnings Per Share - Schedule of Stock Options and Restricted Stock Units that were not included in the Diluted Earnings Per Share Calculation (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "42", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit", "unitRef": "usdPerShare", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": { "span": "div", "td": "tr", "table": "div", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "us-gaap:EarningsPerShareTextBlock", "body": "html" }, "reportCount": 1, "baseRef": "coo-20240731.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit", "unitRef": "usdPerShare", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": { "span": "div", "td": "tr", "table": "div", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "us-gaap:EarningsPerShareTextBlock", "body": "html" }, "reportCount": 1, "baseRef": "coo-20240731.htm", "first": true, "unique": true } }, "R43": { "role": "http://www.cooperco.com/role/ShareBasedCompensationDetails", "longName": "9954491 - Disclosure - Share-Based Compensation (Details)", "shortName": "Share-Based Compensation (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "43", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "5", "ancestors": { "span": "td", "tr": "table", "div": "ix:continuation", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body": "html" }, "reportCount": 1, "baseRef": "coo-20240731.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "5", "ancestors": { "span": "td", "tr": "table", "div": "ix:continuation", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body": "html" }, "reportCount": 1, "baseRef": "coo-20240731.htm", "first": true, "unique": true } }, "R44": { "role": "http://www.cooperco.com/role/StockholdersEquityScheduleOfChangesinAccumulatedOtherComprehensiveIncomeLossIncomeDetails", "longName": "9954492 - Disclosure - Stockholders' Equity - Schedule of Changes in Accumulated Other Comprehensive Income (Loss) Income (Details)", "shortName": "Stockholders' Equity - Schedule of Changes in Accumulated Other Comprehensive Income (Loss) Income (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "44", "firstAnchor": { "contextRef": "c-8", "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "5", "ancestors": { "span": "td", "tr": "table", "div": "body", "html" }, "reportCount": 1, "baseRef": "coo-20240731.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:OtherComprehensiveIncomeLossBeforeTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "5", "ancestors": { "span": "td", "tr": "table", "div": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body": "html" }, "reportCount": 1, "baseRef": "coo-20240731.htm", "first": true, "unique": true } }, "R45": { "role": "http://www.cooperco.com/role/StockholdersEquityNarrativeDetails", "longName": "9954493 - Disclosure - Stockholders' Equity - Narrative (Details)", "shortName": "Stockholders' Equity - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "45", "firstAnchor": { "contextRef": "c-190", "name": "srt:StockRepurchaseProgramAuthorizedAmount1", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "8", "ancestors": { "span": "div", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body": "html" }, "reportCount": 1, "baseRef": "coo-20240731.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-190", "name": "srt:StockRepurchaseProgramAuthorizedAmount1", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "8", "ancestors": { "span": "div", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body": "html" }, "reportCount": 1, "baseRef": "coo-20240731.htm", "first": true, "unique": true } }, "R46": { "role": "http://www.cooperco.com/role/ContingenciesandCommitmentsDetails", "longName": "9954494 - Disclosure - Contingencies and Commitments (Details)", "shortName": "Contingencies and Commitments (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "46", "firstAnchor": { "contextRef": "c-191", "name": "us-gaap:UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "5", "ancestors": { "span": "div", "ix:continuation", "body": "html" }, "reportCount": 1, "baseRef": "coo-20240731.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-191", "name": "us-gaap:UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "5", "ancestors": { "span": "div", "ix:continuation", "body": "html" }, "reportCount": 1, "baseRef": "coo-20240731.htm", "first": true, "unique": true } }, "R47": { "role": "http://www.cooperco.com/role/BusinessSegmentInformationScheduleOfSegmentInformationDetails", "longName": "9954495 - Disclosure - Business Segment Information - Schedule of Segment Information (Details)", "shortName": "Business Segment Information - Schedule of Segment Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "47", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "5", "ancestors": { "span": "td", "tr": "table", "div": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "us-gaap:SegmentReportingDisclosureTextBlock", "body": "html" }, "reportCount": 1, "baseRef": "coo-20240731.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-202", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "5", "ancestors": { "span": "td", "tr": "table", "div": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "us-gaap:SegmentReportingDisclosureTextBlock", "body": "html" }, "reportCount": 1, "baseRef": "coo-20240731.htm", "first": true, "unique": true } }, "R48": { "role": "http://www.cooperco.com/role/BusinessSegmentInformationScheduleOfIdentifiableAssetsbySegmentDetails", "longName": "9954496 - Disclosure - Business Segment Information - Schedule of Identifiable Assets by Segment (Details)", "shortName": "Business Segment Information - Schedule of Identifiable Assets by Segment (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "48", "firstAnchor": { "contextRef": "c-7", "name": "us-gaap:Assets", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "5", "ancestors": { "span": "td", "tr": "table", "div": "body", "html" }, "reportCount": 1, "baseRef": "coo-20240731.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-222", "name": "us-gaap:Assets", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "5", "ancestors": { "span": "td", "tr": "table", "div": "us-gaap:ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock", "us-gaap:SegmentReportingDisclosureTextBlock", "body": "html" }, "reportCount": 1, "baseRef": "coo-20240731.htm", "first": true, "unique": true } }, "R49": { "role": "http://www.cooperco.com/role/BusinessSegmentInformationScheduleOfNetSalesToUnaffiliatedCustomersbyCountryofDomicileDetails", "longName": "9954497 - Disclosure - Business Segment Information - Schedule of Net Sales to Unaffiliated Customers by Country of Domicile (Details)", "shortName": "Business Segment Information - Schedule of Net Sales to Unaffiliated Customers by Country of Domicile (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "49", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "5", "ancestors": { "span": "td", "tr": "table", "div": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "us-gaap:SegmentReportingDisclosureTextBlock", "body": "html" }, "reportCount": 1, "baseRef": "coo-20240731.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-228", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "5", "ancestors": { "span": "td", "tr": "table", "div": "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock", "us-gaap:SegmentReportingDisclosureTextBlock", "body": "html" }, "reportCount": 1, "baseRef": "coo-20240731.htm", "first": true, "unique": true } }, "R50": { "role": "http://www.cooperco.com/role/BusinessSegmentInformationScheduleOfNetPropertyPlantandEquipmentByCountryofDomicileDetails", "longName": "9954498 - Disclosure - Business Segment Information - Schedule of Net Property, Plant and Equipment by Country of Domicile (Details)", "shortName": "Business Segment Information - Schedule of Net Property, Plant and Equipment by Country of Domicile (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "50", "firstAnchor": { "contextRef": "c-7", "name": "us-gaap:NoncurrentAssets", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "5", "ancestors": { "span": "td", "tr": "table", "div": "ix:continuation", "us-gaap:LongLivedAssetsByGeographicAreasTableTextBlock", "div": "body", "html" }, "reportCount": 1, "baseRef": "coo-20240731.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-7", "name": "us-gaap:NoncurrentAssets", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "5", "ancestors": { "span": "td", "tr": "table", "div": "ix:continuation", "us-gaap:LongLivedAssetsByGeographicAreasTableTextBlock", "div": "body", "html" }, "reportCount": 1, "baseRef": "coo-20240731.htm", "first": true, "unique": true } }, "R51": { "role": "http://www.cooperco.com/role/FinancialDerivativesandHedgingNarrativeDetails", "longName": "9954499 - Disclosure - Financial Derivatives and Hedging - Narrative (Details)", "shortName": "Financial Derivatives and Hedging - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "51", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax",

```


"unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "5", "ancestors": { "span": "div", "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "body", "html", "reportCount": 1, "baseRef": "coo-20240731.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-249", "name": "us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "5", "ancestors": { "span": "div", "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "body", "html", "reportCount": 1, "baseRef": "coo-20240731.htm", "first": true, "unique": true }, "R52": { "role": "http://www.cooperco.com/role/FinancialDerivativesandHedgingScheduleofDerivativeInstrumentsRecognizedinCondensedConsolidatedStatementsofIncomeDetails", "longName": "9954500 - Disclosure - Financial Derivatives and Hedging - Schedule of Derivative Instruments Recognized in Condensed Consolidated Statements of Income (Details)", "shortName": "Financial Derivatives and Hedging - Schedule of Derivative Instruments Recognized in Condensed Consolidated Statements of Income (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "52", "firstAnchor": { "contextRef": "c-249", "name": "us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "5", "ancestors": { "span": "td", "tr", "table", "div", "us-gaap:ScheduleOfCashFlowHedgingInstrumentsStatementsOffinancialPerformanceAndFinancialPositionLocationTableTextBlock", "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "body", "html", "reportCount": 1, "baseRef": "coo-20240731.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-249", "name": "us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "5", "ancestors": { "span": "td", "tr", "table", "div", "us-gaap:ScheduleOfCashFlowHedgingInstrumentsStatementsOffinancialPerformanceAndFinancialPositionLocationTableTextBlock", "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "body", "html", "reportCount": 1, "baseRef": "coo-20240731.htm", "first": true, "unique": true }, "R53": { "role": "http://www.cooperco.com/role/FinancialDerivativesandHedgingScheduleofChangesinAccumulatedOtherComprehensiveIncomeDetails", "longName": "9954501 - Disclosure - Financial Derivatives and Hedging - Schedule of Changes in Accumulated Other Comprehensive Income (Details)", "shortName": "Financial Derivatives and Hedging - Schedule of Changes in Accumulated Other Comprehensive Income (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "53", "firstAnchor": { "contextRef": "c-92", "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "5", "ancestors": { "span": "td", "tr", "table", "div", "body", "html", "reportCount": 1, "baseRef": "coo-20240731.htm", "first": true, "uniqueAnchor": { "contextRef": "c-253", "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "5", "ancestors": { "span": "td", "tr", "table", "div", "ix:continuation", "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "body", "html", "reportCount": 1, "baseRef": "coo-20240731.htm", "unique": true } } }, "tag": { "coo_AOCIAttributableToParentBeforeReclassificationAndTaxRollForward": { "xbrltype": "stringItemType", "nsuri": "http://www.cooperco.com/20240731", "localname": "AOCIAttributableToParentBeforeReclassificationAndTaxRollForward", "presentation": { "http://www.cooperco.com/role/FinancialDerivativesandHedgingScheduleofChangesinAccumulatedOtherComprehensiveIncomeDetails", "lang": { "en-us": { "role": { "terseLabel": "AOCI Attributable To Parent, Before Reclassification And Tax [Roll Forward]", "label": "AOCI Attributable To Parent, Before Reclassification And Tax [Roll Forward]", "documentation": "AOCI Attributable To Parent, Before Reclassification And Tax [Roll Forward]", "auth ref": { "us-gaap_AOCIAttributableToParentNetOfTaxRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AOCIAttributableToParentNetOfTaxRollForward", "presentation": { "http://www.cooperco.com/role/StockholdersEquityScheduleofChangesinAccumulatedOtherComprehensiveIncomeLossIncomeDetails", "lang": { "en-us": { "role": { "terseLabel": "AOCI Attributable to Parent, Net of Tax [Roll Forward]", "label": "AOCI Attributable to Parent, Net of Tax [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth ref": { "us-gaap_AccountsPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsPayableCurrent", "crdr": "credit", "calculation": { "http://www.cooperco.com/role/ConsolidatedCondensedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 5.0 } }, "presentation": { "http://www.cooperco.com/role/ConsolidatedCondensedBalanceSheets": { "lang": { "en-us": { "role": { "terseLabel": "Accounts payable", "label": "Accounts Payable", "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth ref": { "r65": "r753" } } }, "us-gaap_AccountsReceivableNetCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsReceivableNetCurrent", "crdr": "debit", "calculation": { "http://www.cooperco.com/role/ConsolidatedCondensedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": { "http://www.cooperco.com/role/ConsolidatedCondensedBalanceSheets": { "lang": { "en-us": { "role": { "terseLabel": "Trade accounts receivable, net of allowance for credit losses of $42.8 at Julyu00a031, 2024, and $31.3 at Octoberu00a031, 2023", "label": "Accounts Receivable, after Allowance for Credit Loss - Current", "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current." } } }, "auth ref": { "r892" } } }, "coo_AccruedAcquisitionTerminationFee": { "xbrltype": "monetaryItemType", "nsuri": "http://www.cooperco.com/20240731", "localname": "AccruedAcquisitionTerminationFee", "crdr": "debit", "calculation": { "http://www.cooperco.com/role/ConsolidatedCondensedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 6.0 } }, "presentation": { "http://www.cooperco.com/role/ConsolidatedCondensedStatementsofCashFlows": { "lang": { "en-us": { "role": { "terseLabel": "Accrual for acquisition termination fee", "label": "Accrued Acquisition Termination Fee", "documentation": "Accrued Acquisition Termination Fee" } } }, "auth ref": { "us-gaap_AccruedIncomeTaxesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccruedIncomeTaxesNoncurrent", "crdr": "credit", "calculation": { "http://www.cooperco.com/role/ConsolidatedCondensedBalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 4.0 } }, "presentation": { "http://www.cooperco.com/role/ConsolidatedCondensedBalanceSheets": { "lang": { "en-us": { "role": { "terseLabel": "Long-term tax payable", "label": "Accrued Income Taxes, Noncurrent", "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all domestic and foreign income tax obligations due beyond one year or the operating cycle, whichever is longer. Alternate captions include income taxes payable, noncurrent." } } }, "auth ref": { "r72": "r123" } } }, "us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedDefinedBenefitPlansAdjustmentMember", "presentation": { "http://www.cooperco.com/role/StockholdersEquityScheduleofChangesinAccumulatedOtherComprehensiveIncomeLossIncomeDetails", "lang": { "en-us": { "role": { "terseLabel": "Minimum Pension Liability", "label": "Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member]", "documentation": "Accumulated other comprehensive (income) loss related to defined benefit plans attributable to the parent." } } }, "auth ref": { "r5": "r6", "r13": "r22", "r87": "r874", "r875", "r876" } } }, "coo_AccumulatedGainLossNetCashFlowHedgeBeforeTaxParentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.cooperco.com/20240731", "localname": "AccumulatedGainLossNetCashFlowHedgeBeforeTaxParentMember", "presentation": { "http://www.cooperco.com/role/FinancialDerivativesandHedgingScheduleofChangesinAccumulatedOtherComprehensiveIncomeDetails", "lang": { "en-us": { "role": { "terseLabel": "Accumulated Gain (Loss), Net, Cash Flow Hedge, Before Tax, Parent", "label": "Accumulated Gain (Loss), Net, Cash Flow Hedge, Before Tax, Parent [Member]", "documentation": "Accumulated Gain (Loss), Net, Cash Flow Hedge, Before Tax, Parent [Member]" } } }, "auth ref": { "us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedGainLossNetCashFlowHedgeParentMember", "presentation": { "http://www.cooperco.com/role/FinancialDerivativesandHedgingScheduleofChangesinAccumulatedOtherComprehensiveIncomeDetails", "lang": { "en-us": { "role": { "terseLabel": "Derivative Instruments", "verboseLabel": "Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent", "label": "Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent [Member]", "documentation": "Accumulated other comprehensive income (loss) from gain (loss) of derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness, attributable to parent." } } }, "auth ref": { "r198": "r206", "r207", "r479", "r716", "r874" } } }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems", "presentation": { "http://www.cooperco.com/role/FinancialDerivativesandHedgingScheduleofChangesinAccumulatedOtherComprehensiveIncomeDetails", "lang": { "en-us": { "role": { "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Line Items]", "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth ref": { "r205": "r206", "r503", "r505", "r506", "r507", "r508", "r509" } } }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "crdr": "credit", "calculation": { "http://www.cooperco.com/role/ConsolidatedCondensedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 4.0 } }, "presentation": { "http://www.cooperco.com/role/ConsolidatedCondensedBalanceSheets": { "lang": { "en-us": { "role": { "verboseLabel": "Accumulated other comprehensive loss", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source." } } }, "auth ref": { "r21": "r22", "r88": "r192", "r570", "r607", "r608" } } }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedOtherComprehensiveIncomeLossTable", "presentation": { "http://www.cooperco.com/role/FinancialDerivativesandHedgingScheduleofChangesinAccumulatedOtherComprehensiveIncomeDetails", "lang": { "en-us": { "role": { "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Table]", "label": "Accumulated Other Comprehensive Income (Loss) [Table]", "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss)." } } }, "auth ref": { "r205": "r206", "r503", "r505", "r506", "r507", "r508", "r509" } } }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedOtherComprehensiveIncome


```

entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders." } } } , "auth_ref": { "r616", "r881", "r882", "r883", "r884", "r934", "r993" } } , "ecd_AdjToCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToCompAmt", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure" } , "lang": { "en-us" } , "role": { "terseLabel": "Adjustment to Compensation Amount", "label": "Adjustment to Compensation Amount" } } } , "auth_ref": { "r826" } } , "ecd_AdjToCompAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToCompAxis", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure" } , "lang": { "en-us" } , "role": { "terseLabel": "Adjustment to Compensation:", "label": "Adjustment to Compensation [Axis]" } } } , "auth_ref": { "r826" } } , "ecd_AdjToNonPeeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToNonPeeoCompFnTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure" } , "lang": { "en-us" } , "role": { "terseLabel": "Adjustment to Non-PEO-NEO Compensation Footnote", "label": "Adjustment to Non-PEO-NEO Compensation Footnote [Text Block]" } } } , "auth_ref": { "r826" } } , "ecd_AdjToPeeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToPeeoCompFnTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure" } , "lang": { "en-us" } , "role": { "terseLabel": "Adjustment to PEO Compensation, Footnote", "label": "Adjustment to PEO Compensation, Footnote [Text Block]" } } } , "auth_ref": { "r826" } } , "us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRequisiteServicePeriodRecognitionValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRequisiteServicePeriodRecognitionValue", "crdr": "credit", "presentation": { "http://www.cooperco.com/role/ConsolidatedCondensedStatementsOfStockholdersEquity" } , "lang": { "en-us" } , "role": { "terseLabel": "Share-based compensation expense", "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition", "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement." } } } , "auth_ref": { "r45", "r46", "r409" } } , "ecd_AggtChngPnsnValInSummryCompstnTbFlForApblYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtChngPnsnValInSummryCompstnTbFlForApblYrMember", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure" } , "lang": { "en-us" } , "role": { "terseLabel": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]", "label": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]" } } } , "auth_ref": { "r859" } } , "ecd_AggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtErrCompAmt", "presentation": { "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" } , "lang": { "en-us" } , "role": { "terseLabel": "Aggregate Erroneous Compensation Amount", "label": "Aggregate Erroneous Compensation Amount" } } } , "auth_ref": { "r785", "r795", "r805", "r837" } } , "ecd_AggtErrCompNotYetDeterminedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtErrCompNotYetDeterminedTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" } , "lang": { "en-us" } , "role": { "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined", "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]" } } } , "auth_ref": { "r788", "r798", "r808", "r840" } } , "ecd_AggtPnsnAdjsSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtPnsnAdjsSvcCstMember", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure" } , "lang": { "en-us" } , "role": { "terseLabel": "Aggregate Pension Adjustments Service Cost [Member]", "label": "Aggregate Pension Adjustments Service Cost [Member]" } } } , "auth_ref": { "r860" } } , "ecd_AllAdjToCompMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllAdjToCompMember", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure" } , "lang": { "en-us" } , "role": { "terseLabel": "All Adjustments to Compensation", "label": "All Adjustments to Compensation [Member]" } } } , "auth_ref": { "r826" } } , "ecd_AllExecutiveCategoriesMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllExecutiveCategoriesMember", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure" } , "lang": { "en-us" } , "role": { "terseLabel": "All Executive Categories", "label": "All Executive Categories [Member]" } } } , "auth_ref": { "r833" } } , "ecd_AllIndividualsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllIndividualsMember", "presentation": { "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" } , "lang": { "en-us" } , "role": { "terseLabel": "All Individuals [Member]", "label": "All Individuals [Member]" } } } , "auth_ref": { "r789", "r799", "r809", "r833", "r841", "r845", "r853" } } , "ecd_AllTradingArrangementsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllTradingArrangementsMember", "presentation": { "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" } , "lang": { "en-us" } , "role": { "terseLabel": "All Trading Arrangements", "label": "All Trading Arrangements [Member]" } } } , "auth_ref": { "r851" } } , "us-gaap_AllocatedShareBasedCompensationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AllocatedShareBasedCompensationExpense", "crdr": "debit", "presentation": { "http://www.cooperco.com/role/ShareBasedCompensationDetails" } , "lang": { "en-us" } , "role": { "verboseLabel": "Total share-based compensation expense", "label": "Share-Based Payment Arrangement, Expense", "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized." } } } , "auth_ref": { "r439", "r443" } } , "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AllowanceForDoubtfulAccountsReceivableCurrent", "crdr": "credit", "presentation": { "http://www.cooperco.com/role/ConsolidatedCondensedBalanceSheetsParentetical" } , "lang": { "en-us" } , "role": { "terseLabel": "Trade accounts receivable, allowance for doubtful accounts", "label": "Accounts Receivable, Allowance for Credit Loss, Current", "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current." } } } , "auth_ref": { "r193", "r284", "r291" } } , "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentFlag", "presentation": { "http://www.cooperco.com/role/Cover" } , "lang": { "en-us" } , "role": { "terseLabel": "Amendment Flag", "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously filed or accepted submission." } } } , "auth_ref": { " " } } , "us-gaap_AmortizationOfIntangibleAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AmortizationOfIntangibleAssets", "crdr": "debit", "calculation": { "http://www.cooperco.com/role/ConsolidatedCondensedStatementsOfIncomeandComprehensiveIncome" } , "parentTag": "us-gaap_OperatingIncomeLoss", "weight": "1.0", "order": "4.0" } , "presentation": { "http://www.cooperco.com/role/ConsolidatedCondensedStatementsOfIncomeandComprehensiveIncome" } , "lang": { "en-us" } , "role": { "terseLabel": "Amortization of intangibles", "label": "Amortization of Intangible Assets", "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method." } } } , "auth_ref": { "r10", "r305", "r312", "r731" } } , "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "xbrltype": "sharesItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "presentation": { "http://www.cooperco.com/role/EarningsPerShareScheduleofStockOptionsandRestrictedStockUnitsthatwerenotIncludedintheDilutedEarningsPerShareCalculationDetails" } , "lang": { "en-us" } , "role": { "terseLabel": "Number of awards excluded (in shares)", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented." } } } , "auth_ref": { "r243" } } , "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "presentation": { "http://www.cooperco.com/role/EarningsPerShareScheduleofStockOptionsandRestrictedStockUnitsthatwerenotIncludedintheDilutedEarningsPerShareCalculationDetails" } , "lang": { "en-us" } , "role": { "terseLabel": "Antidilutive Securities [Axis]", "label": "Antidilutive Securities [Axis]", "documentation": "Information by type of antidilutive security." } } } , "auth_ref": { "r27" } } , "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "presentation": { "http://www.cooperco.com/role/EarningsPerShareScheduleofStockOptionsandRestrictedStockUnitsthatwerenotIncludedintheDilutedEarningsPerShareCalculationDetails" } , "lang": { "en-us" } , "role": { "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } } , "auth_ref": { " " } } , "us-gaap_AntidilutiveSecuritiesNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesNameDomain", "presentation": { "http://www.cooperco.com/role/EarningsPerShareScheduleofStockOptionsandRestrictedStockUnitsthatwerenotIncludedintheDilutedEarningsPerShareCalculationDetails" } , "lang": { "en-us" } , "role": { "terseLabel": "Antidilutive Securities, Name [Domain]", "label": "Antidilutive Securities, Name [Domain]", "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented." } } } , "auth_ref": { "r27" } } , "us-gaap_AssetAcquisitionAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetAcquisitionAxis", "presentation": { "http://www.cooperco.com/role/AcquisitionsandJointVentureDetails" } , "lang": { "en-us" } , "role": { "terseLabel": "Asset Acquisition [Axis]", "label": "Asset Acquisition [Axis]", "documentation": "Information by asset acquisition." } } } , "auth_ref": { "r306", "r307", "r308", "r309", "r310", "r927" } } , "us-gaap_AssetAcquisitionConsiderationTransferred": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetAcquisitionConsiderationTransferred", "crdr": "credit", "presentation": { "http://www.cooperco.com/role/AcquisitionsandJointVentureDetails" } , "lang": { "en-us" } , "role": { "terseLabel": "Purchase price of acquisition", "label": "Asset Acquisition, Consideration Transferred", "documentation": "Amount of consideration transferred in asset acquisition. Includes, but is not limited to, cash, liability incurred by acquirer, and equity interest issued by acquirer." } } } , "auth_ref": { "r745", "r928", "r929", "r930" } } , "us-gaap_AssetAcquisitionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetAcquisitionDomain", "presentation": { "http://www.cooperco.com/role/AcquisitionsandJointVentureDetails" } , "lang": { "en-us" } , "role": { "terseLabel": "Asset Acquisition [Domain]", "label": "Asset Acquisition [Domain]", "documentation": "Amount of asset recognized for present right to economic benefit, classified as current." } } } , "auth_ref": { "r183", "r195", "r215", "r288", "r346", "r347", "r349", "r350", "r351", "r352", "r353", "r355", "r356", "r477", "r480", "r501", "r564", "r644", "r724", "r725", "r753", "r776", "r917", "r918", "r951" } } , "us-gaap_AssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsAbstract", "presentation": { "http://www.cooperco.com/role/ConsolidatedCondensedBalanceSheets" } , "lang": { "en-us" } , "role": { "terseLabel": "ASSETS", "label": "Assets [Abstract]" } } } , "auth_ref": { " " } } , "us-gaap_AssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrent", "crdr": "debit", "calculation": { "http://www.cooperco.com/role/ConsolidatedCondensedBalanceSheets" } , "parentTag": "us-gaap_Assets", "weight": "1.0", "order": "6.0" } , "presentation": { "http://www.cooperco.com/role/ConsolidatedCondensedBalanceSheets" } , "lang": { "en-us" } , "role": { "totalLabel": "Total current assets", "label": "Assets, Current", "documentation": "Amount of asset recognized for present right to economic benefit." } } } , "auth_ref": { "r183", "r195", "r215", "r288", "r346", "r347", "r349", "r350", "r351", "r352", "r353", "r355", "r356", "r477", "r480", "r501", "r564", "r644", "r724", "r725", "r753", "r776", "r917", "r918", "r951" } } , "us-gaap_AssetsCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrentAbstract", "presentation": { "http://www.cooperco.com/role/ConsolidatedCondensedBalanceSheets" } , "lang": { "en-us" } , "role": { "terseLabel": "Current assets", "label": "Assets, Current [Abstract]" } } } , "auth_ref": { " " } } , "ecd_AwardExcrPrice": { "xbrltype": "perShareItem", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardExcrPrice", "presentation": { "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" } , "lang": { "en-us" } , "role": { "terseLabel": "Exercise Price", "label": "Award Exercise Price" } } } , "auth_ref": { "r848" } } , "ecd_AwardGrantDateFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardGrantDateFairValue", "presentation": { "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" } , "lang": { "en-us" } , "role": { "terseLabel": "Fair Value as of Grant Date", "label": "Award Grant Date Fair Value" } } } , "auth_ref": { "r849" } } , "ecd_AwardTmgDiscLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgDiscLineItems", "lang": { "en-us" } , "role": { "label": "Award Timing Disclosures [Line Items]" } } } , "auth_ref": { "r844" } } , "ecd_AwardTmgHowMnpiCnsdrdTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgHowMnpiCnsdrdTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" } , "lang": { "en-us" } , "role": { "terseLabel": "Award Timing, How MNPI Considered", "label": "Award Timing, How MNPI Considered [Text Block]" } } } , "auth_ref": { "r844" } } , "ecd_AwardTmgMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMethodTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" } , "lang": { "en-us" } , "role": { "terseLabel": "Award Timing Method", "label": "Award Timing Method [Text Block]" } } } , "auth_ref": { " " } } }

}},"auth_ref":{"r844"}},{"ecdAwardTmgMnpiCnsrdFlag":{"xbrltype":"booleanItemType","nsuri":"http://xbrl.sec.gov/ecd/2024","localname":"AwardTmgMnpiCnsrdFlag","presentation":{"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"},"lang":{"en-us":{"role":{"terseLabel":"Award Timing MNPI Considered"},"label":"Award Timing MNPI Considered {Flag}"},"auth_ref":{"r844"}},{"ecdAwardTmgMnpiDiscTextBlock":{"xbrltype":"textBlockItemType","nsuri":"http://xbrl.sec.gov/ecd/2024","localname":"AwardTmgMnpiDiscTextBlock","presentation":{"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"},"lang":{"en-us":{"role":{"terseLabel":"Award Timing MNPI Disclosure"},"label":"Award Timing MNPI Disclosure {Text Block}"},"auth_ref":{"r844"}},{"ecdAwardTmgPredtrmndFlag":{"xbrltype":"booleanItemType","nsuri":"http://xbrl.sec.gov/ecd/2024","localname":"AwardTmgPredtrmndFlag","presentation":{"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"},"lang":{"en-us":{"role":{"terseLabel":"Award Timing Predetermined"},"label":"Award Timing Predetermined {Flag}"},"auth_ref":{"r844"}},{"usGaapAwardTypeAxis":{"xbrltype":"stringItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"AwardTypeAxis","presentation":{"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"},"lang":{"en-us":{"role":{"terseLabel":"Award Type"},"label":"Award Type {Axis}"},"documentation":"Information by type of award under share-based payment arrangement."}}},"auth_ref":{"r413","r414","r415","r416","r417","r418","r419","r420","r421","r422","r423","r424","r425","r426","r427","r428","r429","r430","r431","r432","r433","r434","r435","r436","r437","r438"}},{"ecdAwardUndrlygSecuritiesAmt":{"xbrltype":"decimalItemType","nsuri":"http://xbrl.sec.gov/ecd/2024","localname":"AwardUndrlygSecuritiesAmt","presentation":{"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"},"lang":{"en-us":{"role":{"terseLabel":"Underlying Securities"},"label":"Award Underlying Securities Amount"},"auth_ref":{"r847"}},{"ecdAwardsCloseToMnpiDiscIndName":{"xbrltype":"stringItemType","nsuri":"http://xbrl.sec.gov/ecd/2024","localname":"AwardsCloseToMnpiDiscIndName","presentation":{"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"},"lang":{"en-us":{"role":{"terseLabel":"Name"},"label":"Awards Close In Time to MNPI Disclosures, Individual Name"},"auth_ref":{"r846"}},{"ecdAwardsCloseToMnpiDiscTable":{"xbrltype":"stringItemType","nsuri":"http://xbrl.sec.gov/ecd/2024","localname":"AwardsCloseToMnpiDiscTable","presentation":{"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"},"lang":{"en-us":{"role":{"terseLabel":"Awards Close In Time to MNPI Disclosures"},"label":"Awards Close In Time to MNPI Disclosures {Table}"},"auth_ref":{"r845"}},{"ecdAwardsCloseToMnpiDiscTableTextBlock":{"xbrltype":"textBlockItemType","nsuri":"http://xbrl.sec.gov/ecd/2024","localname":"AwardsCloseToMnpiDiscTableTextBlock","presentation":{"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"},"lang":{"en-us":{"role":{"terseLabel":"Awards Close In Time to MNPI Disclosures, Table"},"label":"Awards Close In Time to MNPI Disclosures {Table Text Block}"},"auth_ref":{"r845"}},{"usGaapBaseRateMember":{"xbrltype":"domainItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"BaseRateMember","presentation":{"http://www.cooperccos.com/role/FinancingArrangementsNarrativeDetails"},"lang":{"en-us":{"role":{"terseLabel":"Base rate"},"label":"Base Rate {Member}"},"documentation":"Minimum rate investor will accept."}}},"auth_ref":{"r306","r307","r308","r309","r310","r471","r740","r741"}}, {"usGaapBusinessAcquisitionAcquireeDomain":{"xbrltype":"domainItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"BusinessAcquisitionAcquireeDomain","presentation":{"http://www.cooperccos.com/role/AcquisitionsandJointVentureDetails"},"lang":{"en-us":{"role":{"terseLabel":"Business Acquisition, Acquiree {Domain}"},"label":"Business Acquisition, Acquiree {Domain}"},"documentation":"Identification of the acquiree in a material business combination (or series of individually immaterial business combinations) which may include the name or other type of identification of the acquiree."}}},"auth_ref":{"r306","r307","r308","r309","r310","r471","r740","r741"}}, {"usGaapBusinessAcquisitionAxis":{"xbrltype":"stringItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"BusinessAcquisitionAxis","presentation":{"http://www.cooperccos.com/role/AcquisitionsandJointVentureDetails"},"lang":{"en-us":{"role":{"terseLabel":"Business Acquisition {Axis}"},"label":"Business Acquisition {Axis}"},"documentation":"Information by business combination or series of individually immaterial business combinations."}}},"auth_ref":{"r47","r48","r306","r307","r308","r309","r310","r471","r740","r741"}}, {"usGaapBusinessAcquisitionLineItems":{"xbrltype":"stringItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"BusinessAcquisitionLineItems","presentation":{"http://www.cooperccos.com/role/AcquisitionsandJointVentureDetails"},"lang":{"en-us":{"role":{"terseLabel":"Business Acquisition {Line Items}"},"label":"Business Acquisition {Line Items}"},"documentation":"Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."}}},"auth_ref":{"r471"}}, {"usGaapBusinessCombinationAndAssetAcquisitionAbstract":{"xbrltype":"stringItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"BusinessCombinationAndAssetAcquisitionAbstract","presentation":{"http://www.cooperccos.com/role/AcquisitionsandJointVentureDetails"},"lang":{"en-us":{"role":{"terseLabel":"Business Combination And Asset Acquisition {Abstract}"},"label":"Business Combination, Asset Acquisition, and Joint Venture Formation {Abstract}"},"auth_ref":{"r300","r301","r302","r303","r304","r305","r306","r307","r308","r309","r310","r471","r740","r741"}}, {"cooBusinessCombinationAndAssetAcquisitionTextBlock":{"xbrltype":"textBlockItemType","nsuri":"http://www.cooperccos.com/20240731","localname":"BusinessCombinationAndAssetAcquisitionTextBlock","presentation":{"http://www.cooperccos.com/role/AcquisitionsandJointVentureDetails"},"lang":{"en-us":{"role":{"terseLabel":"Acquisitions and Joint Venture"},"label":"Business Combination And Asset Acquisition {Text Block}"},"documentation":"Business Combination And Asset Acquisition"},"auth_ref":{"r300","r301","r302","r303","r304","r305","r306","r307","r308","r309","r310","r471","r740","r741"}}, {"usGaapBusinessCombinationConsiderationTransferred1":{"xbrltype":"monetaryItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"BusinessCombinationConsiderationTransferred1","presentation":{"http://www.cooperccos.com/role/AcquisitionsandJointVentureDetails"},"lang":{"en-us":{"role":{"terseLabel":"Aggregate consideration"},"label":"Business Combination, Consideration Transferred"},"documentation":"Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer."}}},"auth_ref":{"r0","r1","r12"}}, {"usGaapBusinessCombinationConsiderationTransferredLiabilitiesIncurred":{"xbrltype":"monetaryItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"BusinessCombinationConsiderationTransferredLiabilitiesIncurred","presentation":{"http://www.cooperccos.com/role/AcquisitionsandJointVentureDetails"},"lang":{"en-us":{"role":{"terseLabel":"Payables incurred in acquisition"},"label":"Business Combination, Consideration Transferred, Liabilities Incurred"},"documentation":"Amount of liabilities incurred by the acquirer as part of consideration transferred in a business combination."}}},"auth_ref":{"r0","r1","r53","r473"}}, {"cooBusinessCombinationConsiderationTransferredLiabilitiesIncurredByTypeAxis":{"xbrltype":"stringItemType","nsuri":"http://www.cooperccos.com/20240731","localname":"BusinessCombinationConsiderationTransferredLiabilitiesIncurredByTypeAxis","presentation":{"http://www.cooperccos.com/role/AcquisitionsandJointVentureDetails"},"lang":{"en-us":{"role":{"terseLabel":"Business Combination Consideration Transferred Liabilities Incurred By Type {Axis}"},"label":"Business Combination Consideration Transferred Liabilities Incurred By Type {Axis}"},"documentation":"Business Combination Consideration Transferred Liabilities Incurred By Type"},"auth_ref":{"r300","r301","r302","r303","r304","r305","r306","r307","r308","r309","r310","r471","r740","r741"}}, {"cooBusinessCombinationConsiderationTransferredLiabilitiesIncurredByTypeDomain":{"xbrltype":"domainItemType","nsuri":"http://www.cooperccos.com/20240731","localname":"BusinessCombinationConsiderationTransferredLiabilitiesIncurredByTypeDomain","presentation":{"http://www.cooperccos.com/role/AcquisitionsandJointVentureDetails"},"lang":{"en-us":{"role":{"terseLabel":"Business Combination Consideration Transferred Liabilities Incurred By Type {Domain}"},"label":"Business Combination Consideration Transferred Liabilities Incurred By Type {Domain}"},"documentation":"Business Combination Consideration Transferred Liabilities Incurred By Type {Domain}"},"auth_ref":{"r300","r301","r302","r303","r304","r305","r306","r307","r308","r309","r310","r471","r740","r741"}}, {"cooBusinessCombinationConsiderationTransferredLiabilitiesIncurredNumberOfInstallments":{"xbrltype":"integerItemType","nsuri":"http://www.cooperccos.com/20240731","localname":"BusinessCombinationConsiderationTransferredLiabilitiesIncurredNumberOfInstallments","presentation":{"http://www.cooperccos.com/role/AcquisitionsandJointVentureDetails"},"lang":{"en-us":{"role":{"terseLabel":"Number of installments"},"label":"Business Combination, Consideration Transferred, Liabilities Incurred, Number of Installments"},"documentation":"Business Combination, Consideration Transferred, Liabilities Incurred, Number of Installments"},"auth_ref":{"r300","r301","r302","r303","r304","r305","r306","r307","r308","r309","r310","r471","r740","r741"}}, {"usGaapBusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1":{"xbrltype":"monetaryItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1","presentation":{"http://www.cooperccos.com/role/ConsolidatedCondensedStatementsOfCashFlows"},"parentTag":"us-gaap-NetCashProvidedByUsedInOperatingActivities","weight":1.0,"order":5.0},"documentation":"http://www.cooperccos.com/role/ConsolidatedCondensedStatementsOfCashFlows"},"lang":{"en-us":{"role":{"terseLabel":"Change in fair value of contingent consideration"},"label":"Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability"},"documentation":"Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement."}}},"auth_ref":{"r474","r878"}}, {"usGaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles":{"xbrltype":"monetaryItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles","presentation":{"http://www.cooperccos.com/role/AcquisitionsandJointVentureDetails"},"lang":{"en-us":{"role":{"terseLabel":"Finite-lived intangibles"},"label":"Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles"},"documentation":"The amount of identifiable intangible assets recognized as of the acquisition date."}}},"auth_ref":{"r49","r50"}}, {"usGaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet":{"xbrltype":"monetaryItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet","presentation":{"http://www.cooperccos.com/role/AcquisitionsandJointVentureDetails"},"lang":{"en-us":{"role":{"terseLabel":"Present value of acquisition purchase price"},"label":"Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net"},"documentation":"Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed."}}},"auth_ref":{"r49","r50"}}, {"usGaapCashAndCashEquivalentsAtCarryingValue":{"xbrltype":"monetaryItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"CashAndCashEquivalentsAtCarryingValue","presentation":{"http://www.cooperccos.com/role/ConsolidatedCondensedStatementsOfCashFlows"},"parentTag":"us-gaap-CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents","weight":1.0,"order":1.0},"documentation":"http://www.cooperccos.com/role/ConsolidatedCondensedBalanceSheets"},"parentTag":"us-gaap-AssetsCurrent","weight":1.0,"order":3.0},"presentation":{"http://www.cooperccos.com/role/ConsolidatedCondensedBalanceSheets"},"lang":{"en-us":{"role":{"terseLabel":"Cash and cash equivalents","verboselabel":"Cash and cash equivalents"},"label":"Cash and Cash Equivalents at Carrying Value"},"documentation":"Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."}}},"auth_ref":{"r26","r185","r710"}}, {"usGaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents":{"xbrltype":"monetaryItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents","presentation":{"http://www.cooperccos.com/role/ConsolidatedCondensedStatementsOfCashFlows"},"parentTag":"us-gaap-CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents","weight":1.0,"order":1.0},"documentation":"http://www.cooperccos.com/role/ConsolidatedCondensedBalanceSheets"},"parentTag":"us-gaap-AssetsCurrent","weight":1.0,"order":3.0},"presentation":{"http://www.cooperccos.com/role/ConsolidatedCondensedBalanceSheets"},"lang":{"en-us":{"role":{"terseLabel":"Cash, cash equivalents, and restricted cash at beginning of period"},"label":"Cash, cash equivalents, and restricted cash at beginning of period"},"documentation":"Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."}}},"auth_ref":{"r26","r100","r212"}}, {"usGaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract":{"xbrltype":"stringItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract","presentation":{"http://www.cooperccos.com/role/ConsolidatedCondensedStatementsOfCashFlows"},"lang":{"en-us":{"role":{"terseLabel":"Reconciliation of cash flow information"},"label":"Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents {Abstract}"},"auth_ref":{"r300","r301","r302","r303","r304","r305","r306","r307","r308","r309","r310","r471","r740","r741"}}, {"usGaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect":{"xbrltype":"monetaryItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect","presentation":{"http://www.cooperccos.com/role/ConsolidatedCondensedStatementsOfCashFlows"},"parentTag":"us-gaap-CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents","weight":1.0,"order":1.0},"documentation":"http://www.cooperccos.com/role/ConsolidatedCondensedStatementsOfCashFlows"},"lang":{"en-us":{"role":{"terseLabel":"Net decrease in cash, cash equivalents, and restricted cash"},"label":"Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease) Including Exchange Rate Effect"},"documentation":"Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage, including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."}}},"auth_ref":{"r26","r100"}]}

}-us-gaap_CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths", "crdr": "credit", "presentation": -1}, {"http://www.cooperccos.com/role/FinancialDerivativesandHedgingNarrativeDetails": {"lang": "en-us", "role": "terseLabel", "Derivative loss expected to be realized in earnings over the next twelve months", "label": "Cash Flow Hedge Gain (Loss) to be Reclassified within 12 Months", "documentation": "The estimated net amount of existing gains or losses on cash flow hedges at the reporting date expected to be reclassified to earnings within the next 12 months."}}, {"auth_ref": "r63"}, {"eccd_ChangedPeerGroupFnTextBlock": {"xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChangedPeerGroupFnTextBlock", "presentation": -1}, {"http://xbrl.sec.gov/ecd/role/PvpDisclosure": {"lang": "en-us", "role": "terseLabel", "Changed Peer Group. Footnote", "label": "Changed Peer Group. Footnote [Text Block]"}, {"auth_ref": "r824"}, {"eccd_ChngInFrValAsOfVstngDtOfPrYrEqtyAwrdsVstDnCrYrMember": {"xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChngInFrValAsOfVstngDtOfPrYrEqtyAwrdsVstDnCrYrMember", "presentation": -1}, {"http://xbrl.sec.gov/ecd/role/PvpDisclosure": {"lang": "en-us", "role": "terseLabel", "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year", "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]"}, {"auth_ref": "r821"}, {"eccd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrYrsMember": {"xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrYrsMember", "presentation": -1}, {"http://xbrl.sec.gov/ecd/role/PvpDisclosure": {"lang": "en-us", "role": "terseLabel", "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested", "label": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]"}, {"auth_ref": "r819"}, {"dei_CityAreaCode": {"xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CityAreaCode", "presentation": -1}, {"http://www.cooperccos.com/role/Cover": {"lang": "en-us", "role": "terseLabel", "City Area Code", "documentation": "Area code of city"}, {"auth_ref": "I"}, {"eccd_CoSelectedMeasureAmt": {"xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CoSelectedMeasureAmt", "presentation": -1}, {"http://xbrl.sec.gov/ecd/role/PvpDisclosure": {"lang": "en-us", "role": "terseLabel", "Company Selected Measure Amount", "label": "Company Selected Measure Amount"}, {"auth_ref": "r825"}, {"eccd_CoSelectedMeasureName": {"xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CoSelectedMeasureName", "presentation": -1}, {"http://xbrl.sec.gov/ecd/role/PvpDisclosure": {"lang": "en-us", "role": "terseLabel", "Company Selected Measure Name", "label": "Company Selected Measure Name"}, {"auth_ref": "r825"}, {"us-gaap_CommitmentsAndContingencies": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingencies", "crdr": "credit", "calculation": -1}, {"http://www.cooperccos.com/role/ConsolidatedCondensedBalanceSheets": {"parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 3.0}}, {"presentation": -1}, {"http://www.cooperccos.com/role/ConsolidatedCondensedBalanceSheets": {"lang": "en-us", "role": "verboseLabel", "Contingencies (Note 10)", "label": "Commitments and Contingencies", "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."}}, {"auth_ref": "r73", "r125", "r567", "r631"}, {"us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingenciesDisclosureAbstract", "lang": "en-us", "role": "terseLabel", "Commitments and Contingencies Disclosure [Abstract]", "label": "Commitments and Contingencies Disclosure [Abstract]"}, {"auth_ref": "I"}, {"us-gaap_CommitmentsAndContingenciesPolicyTextBlock": {"xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingenciesPolicyTextBlock", "presentation": -1}, {"http://www.cooperccos.com/role/GeneralPolicies": {"lang": "en-us", "role": "terseLabel", "Contingencies and Commitments", "label": "Commitments and Contingencies. Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for commitments and contingencies, which may include policies for recognizing and measuring loss and gain contingencies."}}, {"auth_ref": "r37", "r694"}, {"us-gaap_CommonStockDividendsPerShareCashPaid": {"xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockDividendsPerShareCashPaid", "presentation": -1}, {"http://www.cooperccos.com/role/ConsolidatedCondensedStatementsOfStockholdersEquityParentetical": {"lang": "en-us", "role": "terseLabel", "Dividends on common stock (in dollars per share)", "label": "Common Stock. Dividends. Per Share. Cash Paid", "documentation": "Aggregate dividends paid during the period for each share of common stock outstanding."}}, {"auth_ref": "r114"}, {"coo_CommonStockExcludingTreasuryStockParNetValueMember": {"xbrltype": "domainItemType", "nsuri": "http://www.cooperccos.com/20240731", "localname": "CommonStockExcludingTreasuryStockParNetValueMember", "presentation": -1}, {"http://www.cooperccos.com/role/ConsolidatedCondensedStatementsOfStockholdersEquity": {"lang": "en-us", "role": "terseLabel", "Common Shares", "label": "Common Stock. Excluding Treasury Stock Par Net Value [Member]", "documentation": "Common Stock, Excluding Treasury Stock Par Net Value [Member]"}, {"auth_ref": "I"}, {"us-gaap_CommonStockParOrStatedValuePerShare": {"xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockParOrStatedValuePerShare", "presentation": -1}, {"http://www.cooperccos.com/role/ConsolidatedCondensedBalanceSheetsParentetical": {"lang": "en-us", "role": "terseLabel", "Common stock, par value (in dollars per share)", "label": "Common Stock. Par or Stated Value Per Share", "documentation": "Face amount or stated value per share of common stock."}}, {"auth_ref": "r76"}, {"us-gaap_CommonStockSharesAuthorized": {"xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesAuthorized", "presentation": -1}, {"http://www.cooperccos.com/role/ConsolidatedCondensedBalanceSheetsParentetical": {"lang": "en-us", "role": "terseLabel", "Common stock, authorized (in shares)", "label": "Common Stock. Shares Authorized", "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."}}, {"auth_ref": "r76", "r632"}, {"us-gaap_CommonStockSharesIssued": {"xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesIssued", "presentation": -1}, {"http://www.cooperccos.com/role/ConsolidatedCondensedBalanceSheetsParentetical": {"lang": "en-us", "role": "terseLabel", "Common stock, issued (in shares)", "label": "Common Stock. Shares. Issued", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."}}, {"auth_ref": "r76"}, {"us-gaap_CommonStockSharesOutstanding": {"xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesOutstanding", "presentation": -1}, {"http://www.cooperccos.com/role/ConsolidatedCondensedBalanceSheetsParentetical": {"lang": "en-us", "role": "terseLabel", "Common stock, outstanding (in shares)", "label": "Common Stock. Shares. Outstanding", "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."}}, {"auth_ref": "r14", "r76", "r632", "r650", "r993", "r994"}, {"us-gaap_CommonStockValue": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockValue", "crdr": "credit", "calculation": -1}, {"http://www.cooperccos.com/role/ConsolidatedCondensedBalanceSheets": {"parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 2.0}}, {"presentation": -1}, {"http://www.cooperccos.com/role/ConsolidatedCondensedBalanceSheets": {"lang": "en-us", "role": "verboseLabel", "Common stock, \$0.10 par value, 480.0 shares authorized, 216.7 issued and 199.1 outstanding at Julyu00a0031, 2024, and 215.8 issued and 198.1 outstanding at Octoberu00a0031, 2023", "label": "Common Stock, Value, Issued", "documentation": "Aggregate par or stated value of issued nonredeemable common stock for common stock redeemable solely at the option of the issuer. This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."}}, {"auth_ref": "r76", "r369", "r753"}, {"eccd_CompActuallyPaidVsCoSelectedMeasureTextBlock": {"xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock", "presentation": -1}, {"http://xbrl.sec.gov/ecd/role/PvpDisclosure": {"lang": "en-us", "role": "terseLabel", "Compensation Actually Paid vs. Company Selected Measure", "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]"}, {"auth_ref": "r830"}, {"eccd_CompActuallyPaidVsNetIncomeTextBlock": {"xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsNetIncomeTextBlock", "presentation": -1}, {"http://xbrl.sec.gov/ecd/role/PvpDisclosure": {"lang": "en-us", "role": "terseLabel", "Compensation Actually Paid vs. Net Income", "label": "Compensation Actually Paid vs. Net Income [Text Block]"}, {"auth_ref": "r829"}, {"eccd_CompActuallyPaidVsOtherMeasureTextBlock": {"xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsOtherMeasureTextBlock", "presentation": -1}, {"http://xbrl.sec.gov/ecd/role/PvpDisclosure": {"lang": "en-us", "role": "terseLabel", "Compensation Actually Paid vs. Other Measure", "label": "Compensation Actually Paid vs. Other Measure [Text Block]"}, {"auth_ref": "r831"}, {"eccd_CompActuallyPaidVsTotalShareholderRtnTextBlock": {"xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock", "presentation": -1}, {"http://xbrl.sec.gov/ecd/role/PvpDisclosure": {"lang": "en-us", "role": "terseLabel", "Compensation Actually Paid vs. Total Shareholder Return", "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]"}, {"auth_ref": "r828"}, {"coo_CompositeMember": {"xbrltype": "domainItemType", "nsuri": "http://www.cooperccos.com/20240731", "localname": "CompositeMember", "presentation": -1}, {"http://www.cooperccos.com/role/AcquisitionsandJointVentureDetails": {"http://www.cooperccos.com/role/intangibleAssetsSummaryOfIntangibleAssetsDetails": {"lang": "en-us", "role": "terseLabel", "Composite intangible assets", "verboseLabel": "Composite intangible assets", "label": "Composite [Member]", "documentation": "Composite [Member]"}, {"auth_ref": "I"}, {"us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "crdr": "credit", "calculation": -1}, {"http://www.cooperccos.com/role/ConsolidatedCondensedStatementsOfIncomeandComprehensiveIncome": {"parentTag": null, "weight": null, "order": null, "root": true}}, {"presentation": -1}, {"http://www.cooperccos.com/role/ConsolidatedCondensedStatementsOfIncomeandComprehensiveIncome": {"lang": "en-us", "role": "totalLabel", "Comprehensive income (Loss). Net of Tax. Including Portion Attributable to Noncontrolling Interest", "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners."}}, {"auth_ref": "r57", "r117", "r202", "r204", "r209", "r560", "r578"}, {"srt_ConsolidationItemsAxis": {"xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ConsolidationItemsAxis", "presentation": -1}, {"http://www.cooperccos.com/role/BusinessSegmentInformationScheduleofIdentifiableAssetsbySegmentDetails": {"http://www.cooperccos.com/role/BusinessSegmentInformationScheduleofSegmentInformationDetails": {"lang": "en-us", "role": "terseLabel", "Consolidation Items [Axis]", "label": "Consolidation Items [Axis]", "documentation": "Information by components, eliminations, non-segment corporate-level activity and reconciling items used in consolidating a parent entity and its subsidiaries or its operating segments."}}, {"auth_ref": "r131", "r167", "r168", "r169", "r170", "r171", "r172", "r173", "r174", "r175", "r217", "r247", "r255", "r269", "r270", "r271", "r272", "r273", "r275", "r276", "r277", "r346", "r347", "r348", "r349", "r351", "r352", "r353", "r354", "r355", "r724", "r725", "r870", "r871", "r917", "r918"}, {"srt_ConsolidationItemsDomain": {"xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ConsolidationItemsDomain", "presentation": -1}, {"http://www.cooperccos.com/role/BusinessSegmentInformationScheduleofIdentifiableAssetsbySegmentDetails": {"http://www.cooperccos.com/role/BusinessSegmentInformationScheduleofSegmentInformationDetails": {"lang": "en-us", "role": "terseLabel", "Consolidation Items [Domain]", "label": "Consolidation Items [Domain]", "documentation": "Components, elimination, non-segment corporate-level activity and reconciling items used in consolidating a parent entity and its subsidiaries or its operating segments."}}, {"auth_ref": "r131", "r141", "r167", "r168", "r169", "r170", "r171", "r172", "r173", "r174", "r175", "r217", "r247", "r255", "r269", "r270", "r271", "r272", "r273", "r275", "r276", "r277", "r346", "r347", "r348", "r349", "r351", "r352", "r353", "r354", "r355", "r724", "r725", "r870", "r871", "r917", "r918"}, {"us-gaap_ContractWithCustomerLiabilityCurrent": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ContractWithCustomerLiabilityCurrent", "crdr": "credit", "calculation": -1}, {"http://www.cooperccos.com/role/ConsolidatedCondensedBalanceSheets": {"parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 4.0}}, {"presentation": -1}, {"http://www.cooperccos.com/role/ConsolidatedCondensedBalanceSheets": {"lang": "en-us", "role": "terseLabel", "Deferred revenue", "label": "Contract with Customer. Liability. Current", "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current."}}, {"auth_ref": "r399", "r400", "r403"}, {"us-gaap_ContractWithCustomerLiabilityNoncurrent": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ContractWithCustomerLiabilityNoncurrent", "crdr": "credit", "calculation": -1}, {"http://www.cooperccos.com/role/ConsolidatedCondensedBalanceSheets": {"parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 6.0}}, {"presentation": -1}, {"http://www.cooperccos.com/role/ConsolidatedCondensedBalanceSheets": {"lang": "en-us", "role": "terseLabel", "Deferred revenue", "label": "Contract with Customer. Liability. Noncurrent", "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent."}}, {"auth_ref": "r399", "r400", "r403"}, {"us-gaap_ContractWithCustomerLiabilityRevenueRecognized": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ContractWithCustomerLiabilityRevenueRecognized", "crdr": "credit", "presentation": -1}


```

http://www.coopercos.com/role/AcquisitionsAndJointVentureDetails", "lang": "en-us", "role": "terseLabel", "Deferred tax liability", "label": "Deferred tax Liabilities, Intangible Assets", "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from intangible assets other than goodwill.", "auth_ref": "r922", "us-gaap_DerivativeContractTypeDomain": "xbrltype", "domainItemType": "nsuri", "http://fasb.org/us-gaap/2024", "localname": "DerivativeContractTypeDomain", "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 3.0, "presentation": "http://www.coopercos.com/role/ConsolidatedCondensedStatementsOfCashFlows", "lang": "en-us", "role": "terseLabel", "Depreciation and amortization", "label": "Depreciation, Depletion and Amortization", "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.", "auth_ref": "r10", "r247", "r258", "r275", "r724", "r725", "us-gaap_DerivativeContractTypeDomain": "xbrltype", "domainItemType": "nsuri", "http://fasb.org/us-gaap/2024", "localname": "DerivativeContractTypeDomain", "presentation": "http://www.coopercos.com/role/FinancialDerivativesandHedgingNarrativeDetails", "http://www.coopercos.com/role/FinancialDerivativesandHedgingScheduleofDerivativeInstrumentsRecognizedinCondensedConsolidatedStatementsOfIncomeDetails", "lang": "en-us", "role": "terseLabel", "Derivative Contract [Domain]", "label": "Derivative Contract [Domain]", "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.", "auth_ref": "r621", "r623", "r637", "r638", "r639", "r640", "r641", "r642", "r643", "r645", "r646", "r647", "r648", "r658", "r659", "r660", "r661", "r664", "r665", "r666", "r667", "r682", "r683", "r686", "r687", "r699", "r700", "r701", "r702", "r703", "r704", "r705", "r706", "r707", "r708", "r709", "r710", "r711", "r712", "r713", "r714", "r715", "r716", "r717", "r718", "r719", "r720", "r721", "r722", "r723", "r724", "r725", "r726", "r727", "r728", "r729", "r730", "r731", "r732", "r733", "r734", "r735", "r736", "r737", "r738", "r739", "r740", "r741", "r742", "r743", "r744", "r745", "r746", "r747", "r748", "r749", "r750", "r751", "r752", "r753", "r754", "r755", "r756", "r757", "r758", "r759", "r760", "r761", "r762", "r763", "r764", "r765", "r766", "r767", "r768", "r769", "r770", "r771", "r772", "r773", "r774", "r775", "r776", "r777", "r778", "r779", "r780", "r781", "r782", "r783", "r784", "r785", "r786", "r787", "r788", "r789", "r790", "r791", "r792", "r793", "r794", "r795", "r796", "r797", "r798", "r799", "r800", "r801", "r802", "r803", "r804", "r805", "r806", "r807", "r808", "r809", "r810", "r811", "r812", "r813", "r814", "r815", "r816", "r817", "r818", "r819", "r820", "r821", "r822", "r823", "r824", "r825", "r826", "r827", "r828", "r829", "r830", "r831", "r832", "r833", "r834", "r835", "r836", "r837", "r838", "r839", "r840", "r841", "r842", "r843", "r844", "r845", "r846", "r847", "r848", "r849", "r850", "r851", "r852", "r853", "r854", "r855", "r856", "r857", "r858", "r859", "r860", "r861", "r862", "r863", "r864", "r865", "r866", "r867", "r868", "r869", "r870", "r871", "r872", "r873", "r874", "r875", "r876", "r877", "r878", "r879", "r880", "r881", "r882", "r883", "r884", "r885", "r886", "r887", "r888", "r889", "r890", "r891", "r892", "r893", "r894", "r895", "r896", "r897", "r898", "r899", "r900", "r901", "r902", "r903", "r904", "r905", "r906", "r907", "r908", "r909", "r910", "r911", "r912", "r913", "r914", "r915", "r916", "r917", "r918", "r919", "r920", "r921", "r922", "r923", "r924", "r925", "r926", "r927", "r928", "r929", "r930", "r931", "r932", "r933", "r934", "r935", "r936", "r937", "r938", "r939", "r940", "r941", "r942", "r943", "r944", "r945", "r946", "r947", "r948", "r949", "r950", "r951", "r952", "r953", "r954", "r955", "r956", "r957", "r958", "r959", "r960", "r961", "r962", "r963", "r964", "r965", "r966", "r967", "r968", "r969", "r970", "r971", "r972", "r973", "r974", "r975", "r976", "r977", "r978", "r979", "r980", "r981", "r982", "r983", "r984", "r985", "r986", "r987", "r988", "r989", "r990", "r991", "r992", "r993", "r994", "r995", "r996", "r997", "r998", "r999", "us-gaap_DerivativeInstrumentRiskAxis": "xbrltype", "stringItemType": "nsuri", "http://fasb.org/us-gaap/2024", "localname": "DerivativeInstrumentRiskAxis", "presentation": "http://www.coopercos.com/role/FinancialDerivativesandHedgingNarrativeDetails", "http://www.coopercos.com/role/FinancialDerivativesandHedgingScheduleofDerivativeInstrumentsRecognizedinCondensedConsolidatedStatementsOfIncomeDetails", "lang": "en-us", "role": "terseLabel", "Derivative Instrument [Axis]", "label": "Derivative Instrument [Axis]", "documentation": "Information by type of derivative contract.", "auth_ref": "r60", "r61", "r62", "r63", "r64", "r65", "r66", "r67", "r68", "r69", "r70", "r71", "r72", "r73", "r74", "r75", "r76", "r77", "r78", "r79", "r80", "r81", "r82", "r83", "r84", "r85", "r86", "r87", "r88", "r89", "r90", "r91", "r92", "r93", "r94", "r95", "r96", "r97", "r98", "r99", "us-gaap_DerivativeInstrumentRiskAxis": "xbrltype", "stringItemType": "nsuri", "http://fasb.org/us-gaap/2024", "localname": "DerivativeInstrumentRiskAxis", "presentation": "http://www.coopercos.com/role/FinancialDerivativesandHedgingNarrativeDetails", "http://www.coopercos.com/role/FinancialDerivativesandHedgingScheduleofDerivativeInstrumentsRecognizedinCondensedConsolidatedStatementsOfIncomeDetails", "lang": "en-us", "role": "terseLabel", "Derivative Instruments and Hedging Activities [Table]", "label": "Derivative Instruments and Hedging Activities [Table]", "documentation": "The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.", "auth_ref": "r118", "r484", "r492", "us-gaap_DerivativeInstrumentRiskAxis": "xbrltype", "stringItemType": "nsuri", "http://fasb.org/us-gaap/2024", "localname": "DerivativeInstrumentRiskAxis", "presentation": "http://www.coopercos.com/role/FinancialDerivativesandHedgingNarrativeDetails", "http://www.coopercos.com/role/FinancialDerivativesandHedgingScheduleofDerivativeInstrumentsRecognizedinCondensedConsolidatedStatementsOfIncomeDetails", "lang": "en-us", "role": "terseLabel", "Derivative Instruments and Hedging Activities [Table]", "label": "Derivative Instruments and Hedging Activities [Table]", "documentation": "The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.", "auth_ref": "r118", "r484", "r492", "us-gaap_DerivativeInstrumentRiskAxis": "xbrltype", "stringItemType": "nsuri", "http://fasb.org/us-gaap/2024", "localname": "DerivativeInstrumentRiskAxis", "presentation": "http://www.coopercos.com/role/FinancialDerivativesandHedgingNarrativeDetails", "http://www.coopercos.com/role/FinancialDerivativesandHedgingScheduleofDerivativeInstrumentsRecognizedinCondensedConsolidatedStatementsOfIncomeDetails", "lang": "en-us", "role": "terseLabel", "Derivative Instruments and Hedging Activities [Table]", "label": "Derivative Instruments and Hedging Activities [Table]", "documentation": "The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.", "auth_ref": "r118", "r484", "r492", "us-gaap_DerivativeInstrumentRiskAxis": "xbrltype", "stringItemType": "nsuri", "http://fasb.org/us-gaap/2024", "localname": "DerivativeInstrumentRiskAxis", "presentation": "http://www.coopercos.com/role/FinancialDerivativesandHedgingNarrativeDetails", "http://www.coopercos.com/role/FinancialDerivativesandHedgingScheduleofDerivativeInstrumentsRecognizedinCondensedConsolidatedStatementsOfIncomeDetails", "lang": "en-us", "role": "terseLabel", "Derivative Instruments and Hedging Activities [Table]", "label": "Derivative Instruments and Hedging Activities [Table]", "documentation": "The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.", "auth_ref": "r118", "r484", "r492", "us-gaap_DerivativeInstrumentRiskAxis": "xbrltype", "stringItemType": "nsuri", "http://fasb.org/us-gaap/2024", "localname": "DerivativeInstrumentRiskAxis", "presentation": "http://www.coopercos.com/role/FinancialDerivativesandHedgingNarrativeDetails", "http://www.coopercos.com/role/FinancialDerivativesandHedgingScheduleofDerivativeInstrumentsRecognizedinCondensedConsolidatedStatementsOfIncomeDetails", "lang": "en-us", "role": "terseLabel", "Derivative Instruments and Hedging Activities [Table]", "label": "Derivative Instruments and Hedging Activities [Table]", "documentation": "The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.", "auth_ref": "r118", "r484", "r492", "us-gaap_DerivativeInstrumentRiskAxis": "xbrltype", "stringItemType": "nsuri", "http://fasb.org/us-gaap/2024", "localname": "DerivativeInstrumentRiskAxis", "presentation": "http://www.coopercos.com/role/FinancialDerivativesandHedgingNarrativeDetails", "http://www.coopercos.com/role/FinancialDerivativesandHedgingScheduleofDerivativeInstrumentsRecogn
```

gaap-EffectiveIncomeTaxRateContinuingOperations": { "xbrltype": "percentItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EffectiveIncomeTaxRateContinuingOperations", "presentation": { "http://www.cooperco.com/role/IncomeTaxDetails": { "lang": { "en-us": { "role": { "terseLabel": "Effective income tax rate", "label": "Effective Income Tax Rate Reconciliation, Percent", "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": { "r450", "r744" } }, "us-gaap-EmployeeRelatedLiabilitiesCurrent": { "xbrltype": "monetaryItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeRelatedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.cooperco.com/role/ConsolidatedCondensedBalanceSheets": { "parent": { "tag": "us-gaap-LiabilitiesCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": { "http://www.cooperco.com/role/ConsolidatedCondensedBalanceSheets": { "lang": { "en-us": { "role": { "terseLabel": "Employee compensation and benefits", "label": "Employee-related Liabilities, Current", "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": { "r68" } }, "us-gaap-EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense": { "xbrltype": "monetaryItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense", "crdr": "credit", "presentation": { "http://www.cooperco.com/role/ShareBasedCompensationDetails": { "lang": { "en-us": { "role": { "terseLabel": "Related income tax benefit", "label": "Share-Based Payment Arrangement, Expense, Tax Benefit", "documentation": "Amount of tax benefit for recognition of expense of award under share-based payment arrangement." } } }, "auth_ref": { "r439" } }, "us-gaap-EmployeeStockOptionMember": { "xbrltype": "domainItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeStockOptionMember", "presentation": { "http://www.cooperco.com/role/EarningsPerShareScheduleofStockOptionsandRestrictedStockUnitsthatwerenotIncludedintheDilutedEarningsPerShareCalculationDetails": { "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "Stock options", "label": "Share-Based Payment Arrangement, Option [Member]", "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time." } } }, "auth_ref": { "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItem", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine1", "presentation": { "http://www.cooperco.com/role/Cover": { "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line One", "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": { "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItem", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine2", "presentation": { "http://www.cooperco.com/role/Cover": { "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line Two", "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": { "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItem", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCityOrTown", "presentation": { "http://www.cooperco.com/role/Cover": { "lang": { "en-us": { "role": { "terseLabel": "Entity Address, City or Town", "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": { "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItem", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressPostalZipCode", "presentation": { "http://www.cooperco.com/role/Cover": { "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Postal Zip Code", "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": { "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItem", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressStateOrProvince", "presentation": { "http://www.cooperco.com/role/Cover": { "lang": { "en-us": { "role": { "terseLabel": "Entity Address, State or Province", "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": { "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItem", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCentralIndexKey", "presentation": { "http://www.cooperco.com/role/Cover": { "lang": { "en-us": { "role": { "terseLabel": "Entity Central Index Key", "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": { "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItem", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCommonStockSharesOutstanding", "presentation": { "http://www.cooperco.com/role/Cover": { "lang": { "en-us": { "role": { "terseLabel": "Entity Common Stock, Shares Outstanding", "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": { "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItem", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCurrentReportingStatus", "presentation": { "http://www.cooperco.com/role/Cover": { "lang": { "en-us": { "role": { "terseLabel": "Entity Current Reporting Status", "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": { "dei_EntityDomain": { "xbrltype": "domainItem", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityDomain", "presentation": { "http://www.cooperco.com/role/AcquisitionsandJointVentureDetails": { "lang": { "en-us": { "role": { "terseLabel": "Entity [Domain]", "label": "Entity [Domain]", "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains." } } }, "auth_ref": { "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItem", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityEmergingGrowthCompany", "presentation": { "http://www.cooperco.com/role/Cover": { "lang": { "en-us": { "role": { "terseLabel": "Entity Emerging Growth Company", "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": { "dei_EntityFileNumber": { "xbrltype": "fileNumberItem", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFileNumber", "presentation": { "http://www.cooperco.com/role/Cover": { "lang": { "en-us": { "role": { "terseLabel": "Entity File Number", "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": { "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItem", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFilerCategory", "presentation": { "http://www.cooperco.com/role/Cover": { "lang": { "en-us": { "role": { "terseLabel": "Entity Filer Category", "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": { "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItem", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityIncorporationStateCountryCode", "presentation": { "http://www.cooperco.com/role/Cover": { "lang": { "en-us": { "role": { "terseLabel": "Entity Incorporation, State or Country Code", "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": { "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItem", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityInteractiveDataCurrent", "presentation": { "http://www.cooperco.com/role/Cover": { "lang": { "en-us": { "role": { "terseLabel": "Entity Interactive Data Current", "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-F during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": { "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItem", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityRegistrantName", "presentation": { "http://www.cooperco.com/role/Cover": { "lang": { "en-us": { "role": { "terseLabel": "Entity Registrant Name", "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": { "dei_EntityShellCompany": { "xbrltype": "booleanItem", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityShellCompany", "presentation": { "http://www.cooperco.com/role/Cover": { "lang": { "en-us": { "role": { "terseLabel": "Entity Shell Company", "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": { "dei_EntitySmallBusiness": { "xbrltype": "booleanItem", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntitySmallBusiness", "presentation": { "http://www.cooperco.com/role/Cover": { "lang": { "en-us": { "role": { "terseLabel": "Entity Small Business", "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": { "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItem", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityTaxIdentificationNumber", "presentation": { "http://www.cooperco.com/role/Cover": { "lang": { "en-us": { "role": { "terseLabel": "Entity Tax Identification Number", "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": { "ecd-EqtyAwrdsAdjFnTextBlock": { "xbrltype": "textBlockItem", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjFnTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "Equity Awards Adjustments, Footnote", "label": "Equity Awards Adjustments, Footnote [Text Block]", "documentation": "Footnote [Text Block]", "auth_ref": { "r917" } }, "ecd-EqtyAwrdsAdjExclValRptdInSummaryCompstnTblMember": { "xbrltype": "domainItem", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjExclValRptdInSummaryCompstnTblMember", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table", "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]", "auth_ref": { "r858" } }, "ecd-EqtyAwrdsAdjMember": { "xbrltype": "domainItem", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjMember", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "Equity Awards Adjustments", "label": "Equity Awards Adjustments [Member]", "auth_ref": { "r858" } }, "ecd-EqtyAwrdsInSummaryCompstnTblForApblYrMember": { "xbrltype": "domainItem", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsInSummaryCompstnTblForApblYrMember", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table", "label": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]", "auth_ref": { "r858" } }, "us-gaap-EquityComponentDomain": { "xbrltype": "domainItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityComponentDomain", "presentation": { "http://www.cooperco.com/role/ConsolidatedCondensedStatementsOfStockholdersEquity": { "http://www.cooperco.com/role/FinancialDerivativesandHedgingScheduleofChangesinAccumulatedOtherComprehensiveIncomeDetails": { "http://www.cooperco.com/role/StockholdersEquityScheduleofChangesinAccumulatedOtherComprehensiveIncomeLossIncomeDetails": { "lang": { "en-us": { "role": { "terseLabel": "Equity Component [Domain]", "label": "Equity Component [Domain]", "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "auth_ref": { "r14", "r179", "r205", "r206", "r207", "r210", "r219", "r220", "r222", "r227", "r229", "r231", "r248", "r289", "r290", "r318", "r398", "r456", "r457", "r466", "r467", "r468", "r470", "r473", "r475", "r476", "r486", "r487", "r488", "r489", "r490", "r491", "r494", "r503", "r505", "r507", "r508", "r509", "r512", "r514", "r520", "r567", "r603", "r604", "r605", "r616", "r670" } } }, "srt-EquityMethodInvesteeNameDomain": { "xbrltype": "domainItem", "nsuri": "http://fasb.org/srt/2024", "localname": "EquityMethodInvesteeNameDomain", "presentation": { "http://www.cooperco.com/role/AcquisitionsandJointVentureDetails": { "lang": { "en-us": { "role": { "terseLabel": "Investment, Name [Domain]", "label": "Investment, Name [Domain]", "documentation": "Name of investment including named security. Excludes entity that is consolidated." } } }, "auth_ref": { "r285", "r286", "r287", "r465", "r463", "r464", "r465", "r466", "r467", "r468", "r469", "r470", "r471", "r472", "r473", "r474", "r475", "r476", "r477", "r478", "r479", "r480", "r481", "r482", "r483", "r484", "r485", "r486", "r487", "r488", "r489", "r490", "r491", "r492", "r493", "r494", "r495", "r496", "r497", "r498", "r499", "r500", "r501", "r502", "r503", "r504", "r505", "r506", "r507", "r508", "r509", "r510", "r511", "r512", "r513", "r514", "r515", "r516", "r517", "r518", "r519", "r520", "r521", "r522", "r523", "r524", "r525", "r526", "r527", "r528", "r529", "r530", "r531", "r532", "r533", "r534", "r535", "r536", "r537", "r538", "r539", "r540", "r541", "r542", "r543", "r544", "r545", "r546", "r547", "r548", "r549", "r550", "r551", "r552", "r553", "r554", "r555", "r556", "r557", "r558", "r559", "r560", "r561", "r562", "r563", "r564", "r565", "r566", "r567", "r568", "r569", "r570", "r571", "r572", "r573", "r574", "r575", "r576", "r577", "r578", "r579", "r580", "r581", "r582", "r583", "r584", "r585", "r586", "r587", "r588", "r589", "r590", "r591", "r592", "r593", "r594", "r595", "r596", "r597", "r598", "r599", "r600", "r601", "r602", "r603", "r604", "r605", "r606", "r607", "r608", "r609", "r610", "r611", "r612", "r613", "r614", "r615", "r616", "r617", "r618", "r619", "r620", "r621", "r622", "r623", "r624", "r625", "r626", "r627", "r628", "r629", "r630", "r631", "r632", "r633", "r634", "r635", "r636", "r637", "r638", "r639", "r640", "r641", "r642", "r643", "r644", "r645", "r646", "r647", "r648", "r649", "r650", "r651", "r652", "r653", "r654", "r655", "r656", "r657", "r658", "r659", "r660", "r661", "r662", "r663", "r664", "r665", "r666", "r667", "r668", "r669", "r670", "r671", "r672", "r673", "r674", "r675", "r676", "r677", "r678", "r679", "r680", "r681", "r682", "r683", "r684", "r685", "r686", "r687", "r688", "r689", "r690", "r691", "r692", "r693", "r694", "r695", "r696", "r697", "r698", "r699", "r700", "r701", "r702", "r703", "r704", "r705", "r706", "r707", "r708", "r709", "r710", "r711", "r712", "r713", "r714", "r715", "r716", "r717", "r718", "r719", "r720", "r721", "r722", "r723", "r724", "r725", "r726", "r727", "r728", "r729", "r730", "r731", "r732", "r733", "r734", "r735", "r736", "r737", "r738", "r739", "r740", "r741", "r742", "r743", "r744", "r745", "r746", "r747", "r748", "r749", "r750", "r751", "r752", "r753", "r754", "r755", "r756", "r757", "r758", "r759", "r760", "r761", "r762", "r763", "r764", "r765", "r766", "r767", "r768", "r769", "r770", "r771", "r772", "r773", "r774", "r775", "r776", "r777", "r778", "r779", "r780", "r781", "r782", "r783", "r784", "r785", "r786", "r787", "r788", "r789", "r790", "r791", "r792", "r793", "r794", "r795", "r796", "r797", "r798", "r799", "r800", "r801", "r802", "r803", "r804", "r805", "r806", "r807", "r808", "r809", "r810", "r811", "r812", "r813", "r814", "r815", "r816", "r817", "r818", "r819", "r820", "r821", "r822", "r823", "r824", "r825", "r826", "r827", "r828", "r829", "r830", "r831", "r832", "r833", "r834", "r835", "r836", "r837", "r838", "r839", "r840", "r841", "r842", "r843", "r844", "r845", "r846", "r847", "r848", "r849", "r850", "r851", "r852", "r853", "r854", "r855", "r856", "r857", "r858", "r859", "r860", "r861", "r862", "r863", "r864", "r865", "r866", "r867", "r868", "r869", "r870", "r871", "r872", "r873", "r874", "r875", "r876", "r877", "r878", "r879", "r880", "r881", "r882", "r883", "r884", "r885", "r886", "r887", "r888", "r889", "r890", "r891", "r892", "r893", "r894", "r895", "r896", "r897", "r898", "r899", "r900", "r901", "r902", "r903", "r904", "r905", "r906", "r907", "r908", "r909", "r910", "r911", "r912", "r913", "r914", "r915", "r916", "r917", "r918", "r919", "r920", "r921", "r922", "r923", "r924", "r925", "r926", "r927", "r928", "r929", "r930", "r931", "r932", "r933", "r934", "r935", "r936", "r937", "r938", "r939", "r940", "r941", "r942", "r943", "r944", "r945", "r946", "r947", "r948", "r949", "r950", "r951", "r952", "r953", "r954", "r955", "r956", "r957", "r958", "r959", "r960", "r961", "r962", "r963", "r964", "r965", "r966", "r967", "r968", "r969", "r970", "r971", "r972", "r973", "r974", "r975", "r976", "r977", "r978", "r979", "r980", "r981", "r982", "r983", "r984", "r985", "r986", "r987", "r988", "r989", "r990", "r991", "r992", "r993", "r994", "r995", "r996", "r997", "r998", "r999", "r1000" } } } }

Awarded Compensation Recovery [Table] } } }, "auth_ref": { "r782", "r792", "r802", "r834" } }, "coo_EssilorInternationalSASMember": { "xbrltype": "domainItemType", "nsuri": "http://www.coopercos.com/20240731", "localname": "EssilorInternationalSASMember", "presentation": { "http://www.coopercos.com/role/AcquisitionsandJointVentureDetails": { "lang": { "en-us": { "role": { "terseLabel": "Essilor International SAS", "label": "Essilor International SAS [Member]", "documentation": "Essilor International SAS" } } }, "auth_ref": { "srt_EuropeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "EuropeMember", "presentation": { "http://www.coopercos.com/role/BusinessSegmentInformationScheduleofNetPropertyPlantandEquipmentByCountryofDomicileDetails": { "http://www.coopercos.com/role/BusinessSegmentInformationScheduleofNetSalesandUnaffiliatedCustomersbyCountryofDomicileDetails": { "lang": { "en-us": { "role": { "terseLabel": "Europe", "verboseLabel": "Europe", "label": "Europe [Member]", "documentation": "Continent of Europe" } } }, "auth_ref": { "r866", "r867", "r868", "r869", "r995", "r996", "r997", "r998" } }, "ecd_ExecutiveCategoryAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ExecutiveCategoryAxis", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "Executive Category", "label": "Executive Category [Axis] } } }, "auth_ref": { "r833" } }, "coo_FertilityCompanyMember": { "xbrltype": "domainItemType", "nsuri": "http://www.coopercos.com/20240731", "localname": "FertilityCompanyMember", "presentation": { "http://www.coopercos.com/role/AcquisitionsandJointVentureDetails": { "lang": { "en-us": { "role": { "terseLabel": "Fertility company", "label": "Fertility Company [Member]", "documentation": "Fertility Company" } } }, "auth_ref": { "coo_FertilityMember": { "xbrltype": "domainItemType", "nsuri": "http://www.coopercos.com/20240731", "localname": "FertilityMember", "presentation": { "http://www.coopercos.com/role/BusinessSegmentInformationScheduleofSegmentInformationDetails": { "lang": { "en-us": { "role": { "terseLabel": "Fertility", "label": "Fertility [Member]", "documentation": "Fertility [Member]" } } }, "auth_ref": { "us-gaap_FinanceLeaseLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseLiabilityCurrent", "crdr": "credit", "calculation": { "http://www.coopercos.com/role/FinancingArrangementsTotalDebtDetails": { "parentTag": "us-gaap_DebtCurrent", "weight": -1.0, "order": 2.0 } }, "presentation": { "http://www.coopercos.com/role/FinancingArrangementsTotalDebtDetails": { "lang": { "en-us": { "role": { "terseLabel": "Financing lease liabilities", "label": "Finance Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]", "documentation": "Indicates line item in statement of financial position that includes current finance lease liability." } } }, "auth_ref": { "r516" } }, "us-gaap_FinanceLeaseLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseLiabilityNoncurrent", "crdr": "credit", "calculation": { "http://www.coopercos.com/role/FinancingArrangementsTotalDebtDetails": { "parentTag": "us-gaap_LongTermDebtAndCapitalLeaseObligations", "weight": -1.0, "order": 1.0 } }, "presentation": { "http://www.coopercos.com/role/FinancingArrangementsTotalDebtDetails": { "lang": { "en-us": { "role": { "terseLabel": "Financing lease liabilities", "label": "Finance Lease, Liability, Noncurrent", "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent." } } }, "auth_ref": { "r515" } }, "us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList", "presentation": { "http://www.coopercos.com/role/FinancingArrangementsTotalDebtDetails": { "lang": { "en-us": { "role": { "terseLabel": "Finance lease liabilities, long-term, location", "label": "Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]", "documentation": "Indicates line item in statement of financial position that includes noncurrent finance lease liability." } } }, "auth_ref": { "r516" } }, "coo_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://www.coopercos.com/20240731", "localname": "FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour", "crdr": "debit", "calculation": { "http://www.coopercos.com/role/IntangibleAssetsRemainingAmortizationExpensesforIntangibleAssetswithDefinitLivesDetails": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": -1.0, "order": 6.0 } }, "presentation": { "http://www.coopercos.com/role/IntangibleAssetsRemainingAmortizationExpensesforIntangibleAssetswithDefinitLivesDetails": { "lang": { "en-us": { "role": { "terseLabel": "Thereafter", "label": "Finite-Lived Intangible Asset, Expected Amortization, After Year Four", "documentation": "Finite-Lived Intangible Asset, Expected Amortization, After Year Four" } } }, "auth_ref": { "us-gaap_FiniteLivedIntangibleAssetUsefulLife": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetUsefulLife", "presentation": { "http://www.coopercos.com/role/IntangibleAssetsSummaryOffIntangibleAssetsDetails": { "lang": { "en-us": { "role": { "verboseLabel": "Weighted-Average Amortization Period (in years)", "label": "Finite-Lived Intangible Asset, Useful Life", "documentation": "Useful life of finite-lived intangible assets, in PnYnMnDnHnMnS format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": { "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization", "crdr": "credit", "calculation": { "http://www.coopercos.com/role/IntangibleAssetsSummaryOffIntangibleAssetsDetails": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": -1.0, "order": 2.0 } }, "presentation": { "http://www.coopercos.com/role/IntangibleAssetsSummaryOffIntangibleAssetsDetails": { "lang": { "en-us": { "role": { "terseLabel": "Accumulated Amortization", "label": "Finite-Lived Intangible Assets, Accumulated Amortization", "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": { "r187", "r293", "r311", "r731" } }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "crdr": "debit", "calculation": { "http://www.coopercos.com/role/IntangibleAssetsRemainingAmortizationExpensesforIntangibleAssetswithDefinitLivesDetails": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": -1.0, "order": 2.0 } }, "presentation": { "http://www.coopercos.com/role/IntangibleAssetsRemainingAmortizationExpensesforIntangibleAssetswithDefinitLivesDetails": { "lang": { "en-us": { "role": { "terseLabel": "2025", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": { "r313", "r706", "r731" } }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOffiscalYear": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOffiscalYear", "crdr": "debit", "calculation": { "http://www.coopercos.com/role/IntangibleAssetsRemainingAmortizationExpensesforIntangibleAssetswithDefinitLivesDetails": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": -1.0, "order": 1.0 } }, "presentation": { "http://www.coopercos.com/role/IntangibleAssetsRemainingAmortizationExpensesforIntangibleAssetswithDefinitLivesDetails": { "lang": { "en-us": { "role": { "terseLabel": "Remainder of 2024", "label": "Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year." } } }, "auth_ref": { "r999" } }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock", "presentation": { "http://www.coopercos.com/role/IntangibleAssetsTables": { "lang": { "en-us": { "role": { "terseLabel": "Schedule of remaining amortization expenses for intangible assets with definite lives", "label": "Finite-Lived Intangible Assets Amortization Expense [Table Text Block]", "documentation": "Tabular disclosure of amortization expense of assets, excluding financial assets, that lack physical substance, having a limited useful life." } } }, "auth_ref": { "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour", "crdr": "debit", "calculation": { "http://www.coopercos.com/role/IntangibleAssetsRemainingAmortizationExpensesforIntangibleAssetswithDefinitLivesDetails": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": -1.0, "order": 5.0 } }, "presentation": { "http://www.coopercos.com/role/IntangibleAssetsRemainingAmortizationExpensesforIntangibleAssetswithDefinitLivesDetails": { "lang": { "en-us": { "role": { "terseLabel": "2028", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": { "r313", "r706", "r731" } }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree", "crdr": "debit", "calculation": { "http://www.coopercos.com/role/IntangibleAssetsRemainingAmortizationExpensesforIntangibleAssetswithDefinitLivesDetails": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": -1.0, "order": 4.0 } }, "presentation": { "http://www.coopercos.com/role/IntangibleAssetsRemainingAmortizationExpensesforIntangibleAssetswithDefinitLivesDetails": { "lang": { "en-us": { "role": { "terseLabel": "2027", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": { "r313", "r706", "r731" } }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo", "crdr": "debit", "calculation": { "http://www.coopercos.com/role/IntangibleAssetsRemainingAmortizationExpensesforIntangibleAssetswithDefinitLivesDetails": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": -1.0, "order": 3.0 } }, "presentation": { "http://www.coopercos.com/role/IntangibleAssetsRemainingAmortizationExpensesforIntangibleAssetswithDefinitLivesDetails": { "lang": { "en-us": { "role": { "terseLabel": "2026", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": { "r313", "r706", "r731" } }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "presentation": { "http://www.coopercos.com/role/AcquisitionsandJointVentureDetails": { "http://www.coopercos.com/role/IntangibleAssetsSummaryOffIntangibleAssetsDetails": { "lang": { "en-us": { "role": { "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]", "label": "Finite-Lived Intangible Assets by Major Class [Axis]", "documentation": "Information by major type or class of finite-lived intangible assets." } } }, "auth_ref": { "r304", "r306", "r307", "r308", "r310", "r311", "r315", "r316", "r526", "r527", "r706" } }, "us-gaap_FiniteLivedIntangibleAssetsGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsGross", "crdr": "debit", "calculation": { "http://www.coopercos.com/role/IntangibleAssetsSummaryOffIntangibleAssetsDetails": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": -1.0, "order": 1.0 } }, "presentation": { "http://www.coopercos.com/role/IntangibleAssetsSummaryOffIntangibleAssetsDetails": { "lang": { "en-us": { "role": { "terseLabel": "Gross", "label": "Finite-Lived Intangible Assets, Gross", "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": { "r293", "r311", "r527", "r731" } }, "us-gaap_FiniteLivedIntangibleAssetsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsLineItems", "presentation": { "http://www.coopercos.com/role/IntangibleAssetsSummaryOffIntangibleAssetsDetails": { "lang": { "en-us": { "role": { "terseLabel": "Finite-Lived Intangible Assets [Line Items]", "label": "Finite-Lived Intangible Assets [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": { "r304", "r311", "r315", "r316", "r317", "r526", "r706", "r731" } }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "presentation": { "http://www.coopercos.com/role/AcquisitionsandJointVentureDetails": { "http://www.coopercos.com/role/IntangibleAssetsSummaryOffIntangibleAssetsDetails": { "lang": { "en-us": { "role": { "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company." } } }, "auth_ref": { "r304", "r306", "r307", "r308", "r310", "r311", "r315", "r316", "r706" } }, "us-gaap_FiniteLivedIntangibleAssetsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsNet", "crdr":

```

"debit": "calculation": { "http://www.cooperccos.com/role/IntangibleAssetsSummaryOffIntangibleAssetsDetails": { "parentTag": "us-gaap-IntangibleAssetsNetExcludingGoodwill", "weight": 1.0, "order": 1.0 }, "http://www.cooperccos.com/role/IntangibleAssetsRemainingAmortizationExpensesforIntangibleAssetswithDefiniteLivesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": { "http://www.cooperccos.com/role/IntangibleAssetsRemainingAmortizationExpensesforIntangibleAssetswithDefiniteLivesDetails": "http://www.cooperccos.com/role/IntangibleAssetsSummaryOffIntangibleAssetsDetails" }, "lang": { "en-us": { "role": { "totalLabel": "Intangible assets with definite lives, net", "label": "Finite-Lived Intangible Assets, Net", "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } }, "auth_ref": { "r526": "r905" } }, "us-gaap-FiniteLivedIntangibleAssetsAcquired": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAcquired", "crdr": "debit", "presentation": { "http://www.cooperccos.com/role/AcquisitionsandJointVentureDetails": { "lang": { "en-us": { "role": { "terseLabel": "Intangible assets acquired", "label": "Finite-Lived Intangible Assets Acquired", "documentation": "Amount of increase in assets, excluding financial assets, lacking physical substance with a definite life, from an acquisition." } }, "auth_ref": { "r306": "r306" } }, "coo-ForeignCurrencyRateMember": { "xbrltype": "domainItemType", "nsuri": "http://www.cooperccos.com/20240731", "localname": "ForeignCurrencyRateMember", "presentation": { "http://www.cooperccos.com/role/FinancingArrangementsNarrativeDetails": { "lang": { "en-us": { "role": { "terseLabel": "Adjusted foreign currency rate", "label": "Foreign Currency Rate [Member]", "documentation": "Foreign Currency Rate" } }, "auth_ref": { "r1": "us-gaap-ForeignExchangeForwardMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ForeignExchangeForwardMember", "presentation": { "http://www.cooperccos.com/role/FinancialDerivativesandHedgingNarrativeDetails": { "lang": { "en-us": { "role": { "terseLabel": "Foreign Exchange Forward", "label": "Foreign Exchange Forward [Member]", "documentation": "Foreign exchange forward traded on an exchange (examples include but are not limited to the International Securities Exchange, Philadelphia Stock Exchange, or the Chicago Mercantile Exchange) for options or future contracts to buy or sell a certain currency, at a specified date, at a fixed exercise exchange rate." } }, "auth_ref": { "r638": "r642", "r647": "r660", "r666": "r684", "r685": "r686", "r770" } }, "ecd-ForgoneRecoveryDueToDisqualificationOffTaxBenefitsAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToDisqualificationOffTaxBenefitsAmt", "presentation": { "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount", "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount" } }, "auth_ref": { "r789": "r799", "r809", "r841" } }, "ecd-ForgoneRecoveryDueToExpenseOfEnforcementAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt", "presentation": { "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount", "label": "Forgone Recovery due to Expense of Enforcement, Amount" } }, "auth_ref": { "r789": "r799", "r809", "r841" } }, "ecd-ForgoneRecoveryDueToViolationOffHomeCountryLawAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToViolationOffHomeCountryLawAmt", "presentation": { "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount", "label": "Forgone Recovery due to Violation of Home Country Law, Amount" } }, "auth_ref": { "r789": "r799", "r809", "r841" } }, "ecd-ForgoneRecoveryExplanationOfImpracticabilityTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery, Explanation of Impracticability", "label": "Forgone Recovery, Explanation of Impracticability [Text Block]" } }, "auth_ref": { "r789": "r799", "r809", "r841" } }, "ecd-ForgoneRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryIndName", "presentation": { "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Forgone Recovery, Individual Name" } }, "auth_ref": { "r789": "r799", "r809", "r841" } }, "ecd-FrValAsOfPrYrEndOffEqtyAwrdsGrntdInPrYrsFldYstngCondsDrngCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "FrValAsOfPrYrEndOffEqtyAwrdsGrntdInPrYrsFldYstngCondsDrngCvrdYrMember", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year", "label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]" } }, "auth_ref": { "r822": "r822" } }, "us-gaap-Goodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Goodwill", "crdr": "debit", "calculation": { "http://www.cooperccos.com/role/ConsolidatedCondensedBalanceSheets": { "parentTag": "us-gaap-Assets", "weight": 1.0, "order": 2.0 } }, "presentation": { "http://www.cooperccos.com/role/AcquisitionsandJointVentureDetails": { "http://www.cooperccos.com/role/ConsolidatedCondensedBalanceSheets": { "lang": { "en-us": { "role": { "terseLabel": "Goodwill", "label": "Goodwill", "documentation": "Amount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized." } }, "auth_ref": { "r186": "r294", "r558": "r725", "r730", "r746", "r753", "r895", "r966" } }, "us-gaap-GoodwillAndIntangibleAssetsImpairment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GoodwillAndIntangibleAssetsImpairment", "crdr": "debit", "presentation": { "http://www.cooperccos.com/role/IntangibleAssetsNarrativeDetails": { "lang": { "en-us": { "role": { "terseLabel": "Impairment of goodwill and intangible assets", "label": "Goodwill and Intangible Asset Impairment", "documentation": "Total loss recognized during the period from the impairment of goodwill plus the loss recognized in the period resulting from the impairment of the carrying amount of intangible assets, other than goodwill." } }, "auth_ref": { "r1": "us-gaap-GoodwillAndIntangibleAssetsDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Goodwill and Intangible Assets Disclosure Abstract", "label": "Goodwill and Intangible Assets Disclosure Abstract" } }, "auth_ref": { "r1": "us-gaap-GoodwillAndIntangibleAssetsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock", "presentation": { "http://www.cooperccos.com/role/IntangibleAssets": { "lang": { "en-us": { "role": { "verboseLabel": "Intangible Assets", "label": "Goodwill and Intangible Assets Disclosure [Text Block]", "documentation": "The entire disclosure for goodwill and intangible assets." } }, "auth_ref": { "r894": "r897" } }, "us-gaap-GrossProfit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GrossProfit", "crdr": "credit", "calculation": { "http://www.cooperccos.com/role/ConsolidatedCondensedStatementsofIncomeandComprehensiveIncome": { "parentTag": "us-gaap-OperatingIncomeLoss", "weight": 1.0, "order": 1.0 } }, "presentation": { "http://www.cooperccos.com/role/ConsolidatedCondensedStatementsofIncomeandComprehensiveIncome": { "lang": { "en-us": { "role": { "totalLabel": "Gross profit", "label": "Gross Profit", "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity." } }, "auth_ref": { "r89": "r93", "r132", "r215", "r288", "r346", "r347", "r349", "r350", "r351", "r352", "r353", "r355", "r356", "r501", "r719", "r724", "r886", "r887", "r889", "r890", "r917" } }, "us-gaap-IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "crdr": "credit", "calculation": { "http://www.cooperccos.com/role/ConsolidatedCondensedStatementsofIncomeandComprehensiveIncome": { "parentTag": "us-gaap-NetIncomeLoss", "weight": 1.0, "order": 1.0 } }, "presentation": { "http://www.cooperccos.com/role/BusinessSegmentInformationScheduleofSegmentInformationDetails": "http://www.cooperccos.com/role/ConsolidatedCondensedStatementsofIncomeandComprehensiveIncome" }, "lang": { "en-us": { "role": { "totalLabel": "Income before income taxes", "label": "Income (loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest." } }, "auth_ref": { "r90": "r128", "r132", "r562", "r575", "r719", "r724", "r886", "r887", "r889", "r890", "r891" } }, "us-gaap-IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "terseLabel": "Income Statement Abstract", "label": "Income Statement Abstract" } }, "auth_ref": { "r1": "us-gaap-IncomeStatementLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementLocationAxis", "presentation": { "http://www.cooperccos.com/role/FinancialDerivativesandHedgingScheduleofDerivativeInstrumentsRecognizedinCondensedConsolidatedStatementsofIncomeDetails": "http://www.cooperccos.com/role/ShareBasedCompensationDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Income Statement Location Axis", "label": "Statement of Income Location, Balance Axis", "documentation": "Information by location in statement of income where disaggregated amount has been reported." } }, "auth_ref": { "r319": "r326", "r327", "r498", "r499", "r500", "r600", "r602", "r655", "r706", "r747", "r963" } }, "us-gaap-IncomeStatementLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementLocationDomain", "presentation": { "http://www.cooperccos.com/role/FinancialDerivativesandHedgingScheduleofDerivativeInstrumentsRecognizedinCondensedConsolidatedStatementsofIncomeDetails": "http://www.cooperccos.com/role/ShareBasedCompensationDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Income Statement Location Domain", "label": "Statement of Income Location, Balance Domain", "documentation": "Location in statement of income where disaggregated amount has been reported." } }, "auth_ref": { "r326": "r327", "r498", "r499", "r500", "r600", "r602", "r655", "r706", "r747", "r963" } }, "us-gaap-IncomeTaxDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Income Tax Disclosure Abstract", "label": "Income Tax Disclosure Abstract" } }, "auth_ref": { "r1": "us-gaap-IncomeTaxDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxDisclosureTextBlock", "presentation": { "http://www.cooperccos.com/role/IncomeTaxes": { "lang": { "en-us": { "role": { "terseLabel
```

"ecd_InsiderTradingArrLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTradingArrLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Arrangements [Line Items]" } } }, "auth_ref": { "r851" } }, "ecd_InsiderTradingPoliciesProcLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTradingPoliciesProcLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures [Line Items]" } } }, "auth_ref": { "r781", "r857" } }, "ecd_InsiderTrdPoliciesProcAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTrdPoliciesProcAdoptedFlag", "presentation": { "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc", "lang": { "en-us": { "role": { "terseLabel": "Insider Trading Policies and Procedures Adopted", "label": "Insider Trading Policies and Procedures Adopted [Flag]" } } }, "auth_ref": { "r781", "r857" } }, "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc", "lang": { "en-us": { "role": { "terseLabel": "Insider Trading Policies and Procedures Not Adopted", "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]" } } }, "auth_ref": { "r781", "r857" } }, "us-gaap_IntangibleAssetsNetExcludingGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IntangibleAssetsNetExcludingGoodwill", "crdr": "debit", "calculation": { "http://www.cooperccos.com/role/ConsolidatedCondensedBalanceSheets", "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 5.0 }, "http://www.cooperccos.com/role/IntangibleAssetsSummaryOfIntangibleAssetsDetails": { "parentTag": null, "weight": null, "order": null, "root": true }, "presentation": { "http://www.cooperccos.com/role/ConsolidatedCondensedBalanceSheets", "http://www.cooperccos.com/role/IntangibleAssetsSummaryOfIntangibleAssetsDetails", "lang": { "en-us": { "role": { "terseLabel": "Other intangibles, net (Note 4)", "totalLabel": "Total other intangibles, net", "label": "Intangible Assets, Net (Excluding Goodwill)", "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges." } } }, "auth_ref": { "r304", "r905", "r906" } }, "us-gaap_InterestExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestExpenseMember", "presentation": { "http://www.cooperccos.com/role/FinancialDerivativesandHedgingScheduleOfDerivativeInstrumentsRecognizedinCondensedConsolidatedStatementsOfIncomeDetails", "lang": { "en-us": { "role": { "terseLabel": "Interest expense (income)", "label": "Interest Expense [Member]", "documentation": "Primary financial statement caption encompassing interest expense." } } }, "auth_ref": { "r16" } }, "us-gaap_InterestExpenseNonoperating": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestExpenseNonoperating", "crdr": "debit", "calculation": { "http://www.cooperccos.com/role/ConsolidatedCondensedStatementsOfIncomeandComprehensiveIncome", "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": -1.0, "order": 2.0 }, "presentation": { "http://www.cooperccos.com/role/BusinessSegmentInformationScheduleOfSegmentInformationDetails", "http://www.cooperccos.com/role/ConsolidatedCondensedStatementsOfIncomeandComprehensiveIncome", "lang": { "en-us": { "role": { "terseLabel": "Interest expense", "verboseLabel": "Interest expense", "label": "Interest Expense, Nonoperating", "documentation": "Amount of interest expense classified as nonoperating." } } }, "auth_ref": { "r257", "r877" } }, "us-gaap_InterestRateSwapMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestRateSwapMember", "presentation": { "http://www.cooperccos.com/role/FinancialDerivativesandHedgingNarrativeDetails", "http://www.cooperccos.com/role/FinancialDerivativesandHedgingScheduleOfDerivativeInstrumentsRecognizedinCondensedConsolidatedStatementsOfIncomeDetails", "lang": { "en-us": { "role": { "terseLabel": "Interest Rate Swap", "label": "Interest Rate Swap [Member]", "documentation": "Forward based contracts in which two parties agree to swap periodic payments that are fixed at the outset of the swap contract with variable payments based on a market interest rate (index rate) over a specified period." } } }, "auth_ref": { "r702", "r772", "r773" } }, "us-gaap_InventoryDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Inventory Disclosure [Abstract]", "label": "Inventory Disclosure [Abstract]" } } }, "auth_ref": { "us-gaap_InventoryDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryDisclosureTextBlock", "presentation": { "http://www.cooperccos.com/role/Inventories", "lang": { "en-us": { "role": { "terseLabel": "Inventories", "label": "Inventory Disclosure [Text Block]", "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory." } } }, "auth_ref": { "r292" } }, "us-gaap_InventoryFinishedGoodsNetOfReserves": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryFinishedGoodsNetOfReserves", "crdr": "debit", "calculation": { "http://www.cooperccos.com/role/InventoriesDetails", "parentTag": "us-gaap_InventoryNet", "weight": 1.0, "order": 1.0 }, "presentation": { "http://www.cooperccos.com/role/InventoriesDetails", "lang": { "en-us": { "role": { "terseLabel": "Finished goods", "label": "Inventory, Finished Goods, Net of Reserves", "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale." } } }, "auth_ref": { "r109", "r712" } }, "us-gaap_InventoryNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryNet", "crdr": "debit", "calculation": { "http://www.cooperccos.com/role/ConsolidatedCondensedBalanceSheets", "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 1.0 }, "http://www.cooperccos.com/role/InventoriesDetails": { "parentTag": null, "weight": null, "order": null, "root": true }, "presentation": { "http://www.cooperccos.com/role/ConsolidatedCondensedBalanceSheets", "http://www.cooperccos.com/role/InventoriesDetails", "lang": { "en-us": { "role": { "verboseLabel": "Inventories (Note 3)", "totalLabel": "Total inventories", "label": "Inventory, Net", "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer." } } }, "auth_ref": { "r194", "r711", "r753" } }, "us-gaap_InventoryRawMaterialsNetOfReserves": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryRawMaterialsNetOfReserves", "crdr": "debit", "calculation": { "http://www.cooperccos.com/role/InventoriesDetails", "parentTag": "us-gaap_InventoryNet", "weight": 1.0, "order": 2.0 }, "presentation": { "http://www.cooperccos.com/role/InventoriesDetails", "lang": { "en-us": { "role": { "terseLabel": "Raw materials", "label": "Inventory, Raw Materials, Net of Reserves", "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process." } } }, "auth_ref": { "r109", "r714" } }, "us-gaap_InventoryWorkInProcessNetOfReserves": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryWorkInProcessNetOfReserves", "crdr": "debit", "calculation": { "http://www.cooperccos.com/role/InventoriesDetails", "parentTag": "us-gaap_InventoryNet", "weight": 1.0, "order": 3.0 }, "presentation": { "http://www.cooperccos.com/role/InventoriesDetails", "lang": { "en-us": { "role": { "terseLabel": "Work-in-process", "label": "Inventory, Work in Process, Net of Reserves", "documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing." } } }, "auth_ref": { "r109", "r713" } }, "dei_LegalEntityAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LegalEntityAxis", "presentation": { "http://www.cooperccos.com/role/AcquisitionsandJointVentureDetails", "lang": { "en-us": { "role": { "terseLabel": "Legal Entity [Axis]", "label": "Legal Entity [Axis]", "documentation": "The set of legal entities associated with a report." } } }, "auth_ref": { "us-gaap_LesseeLeaseDescriptionLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeLeaseDescriptionLineItems", "presentation": { "http://www.cooperccos.com/role/ContingenciesandCommitmentsDetails", "lang": { "en-us": { "role": { "terseLabel": "Lessee, Lease, Description [Line Items]", "label": "Lessee, Lease, Description [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": { "r517", "r519" } }, "us-gaap_LesseeLeaseDescriptionTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeLeaseDescriptionTable", "presentation": { "http://www.cooperccos.com/role/ContingenciesandCommitmentsDetails", "lang": { "en-us": { "role": { "terseLabel": "Lessee, Lease, Description [Table]", "label": "Lessee, Lease, Description [Table]", "documentation": "Disclosure of information about lessee's leases." } } }, "auth_ref": { "r517", "r519" } }, "us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract", "presentation": { "http://www.cooperccos.com/role/ContingenciesandCommitmentsDetails", "lang": { "en-us": { "role": { "terseLabel": "Lease term (in years)", "label": "Lessee, Operating Lease, Lease Not yet Commenced, Term of Contract", "documentation": "Term of lessee's operating lease not yet commenced, in PnYnMnDnInHnMnS format, for example, P1Y5M13D represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": { "r950" } }, "us-gaap_Liabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Liabilities", "crdr": "credit", "calculation": { "http://www.cooperccos.com/role/ConsolidatedCondensedBalanceSheets", "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 2.0 }, "presentation": { "http://www.cooperccos.com/role/ConsolidatedCondensedBalanceSheets", "lang": { "en-us": { "role": { "totalLabel": "Total liabilities", "label": "Liabilities", "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others." } } }, "auth_ref": { "r19", "r67", "r68", "r69", "r71", "r72", "r73", "r74", "r215", "r288", "r346", "r347", "r349", "r350", "r351", "r352", "r353", "r355", "r356", "r478", "r480", "r481", "r501", "r630", "r718", "r776", "r917", "r951", "r952" } }, "us-gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "calculation": { "http://www.cooperccos.com/role/ConsolidatedCondensedBalanceSheets", "parentTag": null, "weight": null, "order": null, "root": true }, "presentation": { "http://www.cooperccos.com/role/ConsolidatedCondensedBalanceSheets", "lang": { "en-us": { "role": { "totalLabel": "Total liabilities and equity", "label": "Liabilities and Equity", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } }, "auth_ref": { "r81", "r127", "r573", "r753", "r880", "r893", "r944" } }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquityAbstract", "presentation": { "http://www.cooperccos.com/role/ConsolidatedCondensedBalanceSheets", "lang": { "en-us": { "role": { "terseLabel": "LIABILITIES AND STOCKHOLDERS' EQUITY", "label": "Liabilities and Equity [Abstract]" } } }, "auth_ref": { "us-gaap_LiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.cooperccos.com/role/ConsolidatedCondensedBalanceSheets", "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 3.0 }, "presentation": { "http://www.cooperccos.com/role/ConsolidatedCondensedBalanceSheets", "lang": { "en-us": { "role": { "totalLabel": "Total current liabilities", "label": "Liabilities, Current", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer." } } }, "auth_ref": { "r69", "r184", "r215", "r288", "r346", "r347", "r349", "r350", "r351", "r352", "r353", "r355", "r356", "r478", "r480", "r481", "r501", "r501", "r753", "r917", "r951", "r952" } }, "us-gaap_LiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrentAbstract", "presentation": { "http://www.cooperccos.com/role/ConsolidatedCondensedBalanceSheets", "lang": { "en-us": { "role": { "terseLabel": "Current liabilities", "label": "Liabilities, Current [Abstract]" } } }, "auth_ref": { "coo_LineOfCreditFacilityAccordionFeatureIncreaseLimit": { "xbrltype": "monetaryItemType", "nsuri": "http://www.cooperccos.com/20240731", "localname": "LineOfCreditFacilityAccordionFeatureIncreaseLimit", "crdr": "credit", "presentation": { "http://www.cooperccos.com/role/FinancingArrangementsNarrativeDetails", "lang": { "en-us": { "role": { "terseLabel": "Potential additional borrowing capacity", "label": "Line Of Credit Facility, Accordion Feature, Increase Limit", "documentation": "Line Of Credit Facility, Accordion Feature, Increase Limit" } } }, "auth_ref": { "coo_LineOfCreditFacilityAccordionFeatureIncreaseLimitPercentageOfEBITDA": { "xbrltype": "percentItemType", "nsuri": "http://www.cooperccos.com/20240731", "localname": "LineOfCreditFacilityAccordionFeatureIncreaseLimitPercentageOfEBITDA", "presentation": { "http://www.cooperccos.com/role/FinancingArrangementsNarrativeDetails", "lang": { "en-us": { "role": { "terseLabel": "Potential additional borrowing capacity, percentage of EBITDA", "label": "Line Of Credit Facility, Accordion Feature, Increase Limit, Percentage of EBITDA", "documentation": "Line Of Credit Facility, Accordion

"http://fasb.org/us-gaap/2024", "localname": "NetIncomeLoss", "crdr": "credit", "calculation": {
"http://www.cooperpcos.com/role/ConsolidatedCondensedStatementsOfIncomeAndComprehensiveIncome": { "parentTag": "us-gaap-ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0, "order": 1.0 },
"http://www.cooperpcos.com/role/ConsolidatedCondensedStatementsOfCashFlows": { "parentTag": "us-gaap-NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": { "http://www.cooperpcos.com/role/ConsolidatedCondensedStatementsOfCashFlows":
"http://www.cooperpcos.com/role/ConsolidatedCondensedStatementsOfIncomeAndComprehensiveIncome",
"http://www.cooperpcos.com/role/ConsolidatedCondensedStatementsOfStockholdersEquity",
"http://www.cooperpcos.com/role/EarningsPerShareScheduleOfEarningsPerShareDetails": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": { "en-us": { "role": {
"totalLabel": "Net income", "verboseLabel": "Net income", "terseLabel": "Net income", "label": "Net Income (Loss) Attributable to Parent", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth_ref": { "r94", "r102", "r129", "r182", "r200", "r203", "r207", "r215", "r221", "r223", "r224", "r225", "r226", "r227", "r230", "r231", "r239", "r288", "r346", "r347", "r349", "r350", "r351", "r352", "r353", "r355", "r356", "r469", "r476", "r496", "r501", "r576", "r652", "r668", "r669", "r774", "r917" } }, "us-gaap-NewAccountingPronouncementsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "NewAccountingPronouncementsPolicyTextBlock", "presentation": { "http://www.cooperpcos.com/role/GeneralPolicies": {
"lang": { "en-us": { "role": { "terseLabel": "Accounting Pronouncements Issued But Not Yet Adopted", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact." } } }, "auth_ref": { } }, "ecd-NonGaapMeasureDescriptionTextBlock": { "xbrltype": "textBlockItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "NonGaapMeasureDescriptionTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "Non-GAAP Measure Description", "label": "Non-GAAP Measure Description [Text Block]", "auth_ref": { "r825" } } } },
"ecd-NonNeosMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonNeosMember", "presentation": {
"http://xbrl.sec.gov/ecd/role/ErrCompDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "Non-NEOs", "label": "Non-NEOs [Member]", "auth_ref": { "r789", "r799", "r809", "r833", "r841" } } }, "ecd-NonPeoNeoAvgCompActuallyPaidAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"NonPeoNeoAvgCompActuallyPaidAmt", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount", "label": "Non-PEO NEO Average Compensation Actually Paid Amount", "auth_ref": { "r816" } } } },
"ecd-NonPeoNeoAvgTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoAvgTotalCompAmt", "presentation": {
"http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "Non-PEO NEO Average Total Compensation Amount", "label": "Non-PEO NEO Average Total Compensation Amount", "auth_ref": { "r815" } } } }, "ecd-NonPeoNeoMember": { "xbrltype": "domainItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoMember", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "Non-PEO NEO", "label": "Non-PEO NEO [Member]", "auth_ref": { "r833" } } } }, "ecd-NonRule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrAdoptedFlag", "presentation": { "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements": {
"lang": { "en-us": { "role": { "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted", "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]", "auth_ref": { "r852" } } } }, "ecd-NonRule10b51ArrTrmndFlag": { "xbrltype": "booleanItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrTrmndFlag", "presentation": { "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements": { "lang": { "en-us": { "role": { "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated", "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]", "auth_ref": { "r852" } } } }, "us-gaap-NoncontrollingInterestMember": { "xbrltype": "domainItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "NoncontrollingInterestMember", "presentation": {
"http://www.cooperpcos.com/role/ConsolidatedCondensedStatementsOfStockholdersEquity": { "lang": { "en-us": { "role": { "terseLabel": "Noncontrolling Interests", "label": "Noncontrolling Interest [Member]", "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest." } } }, "auth_ref": { "r54", "r398", "r881", "r882", "r883", "r884", "r993" } } }, "us-gaap-NoncurrentAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NoncurrentAssets", "crdr": "debit", "presentation": {
"http://www.cooperpcos.com/role/BusinessSegmentInformationScheduleOfNetPropertyPlantandEquipmentByCountryOfDomicileDetails": { "lang": { "en-us": { "role": { "terseLabel": "Net property, plant and equipment", "label": "Long-Lived Assets", "documentation": "Long-lived assets other than financial instruments, long-term customer relationships of a financial institution, mortgage and other servicing rights, deferred policy acquisition costs, and deferred tax assets." } } }, "auth_ref": { "r281" } } }, "us-gaap-NumberOfInterestRateDerivativesHeld": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"NumberOfInterestRateDerivativesHeld", "presentation": { "http://www.cooperpcos.com/role/FinancialDerivativesandHedgingNarrativeDetails": { "lang": { "en-us": { "role": { "terseLabel": "Number of interest rate swap contracts held", "label": "Number of Interest Rate Derivatives Held", "documentation": "Number of interest rate derivative instruments held by the entity at the reporting date." } } }, "auth_ref": { "r58", "r59" } } }, "coo-OfficeAndSurgicalMember": { "xbrltype": "domainItemType", "nsuri":
"http://www.cooperpcos.com/20240731", "localname": "OfficeAndSurgicalMember", "presentation": {
"http://www.cooperpcos.com/role/BusinessSegmentInformationScheduleOfSegmentInformationDetails": { "lang": { "en-us": { "role": { "terseLabel": "Office and surgical", "label": "Office And Surgical [Member]", "documentation": "Office And Surgical" } } }, "auth_ref": { } }, "us-gaap-OperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingIncomeLoss", "crdr": "credit", "calculation": {
"http://www.cooperpcos.com/role/ConsolidatedCondensedStatementsOfIncomeAndComprehensiveIncome": { "parentTag": "us-gaap-IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 1.0 } }, "presentation": {
"http://www.cooperpcos.com/role/BusinessSegmentInformationScheduleOfSegmentInformationDetails":
"http://www.cooperpcos.com/role/ConsolidatedCondensedStatementsOfIncomeAndComprehensiveIncome": { "lang": { "en-us": { "role": { "totalLabel": "Operating income", "terseLabel": "Total operating income", "label": "Operating Income (Loss)", "documentation": "The net result for the period of deducting operating expenses from operating revenues." } } }, "auth_ref": { "r132", "r719", "r886", "r887", "r889", "r890", "r891" } } }, "us-gaap-OperatingLeaseLeaseNotYetCommencedMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLeaseNotYetCommencedMember", "presentation": {
"http://www.cooperpcos.com/role/ContingenciesandCommitmentsDetails": { "lang": { "en-us": { "role": { "terseLabel": "Operating leases not yet commenced", "label": "Operating Lease, Lease Not yet Commenced [Member]", "documentation": "Lease that has not yet commenced, classified as operating." } } }, "auth_ref": { "r331", "r950" } } }, "us-gaap-OperatingSegmentsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingSegmentsMember", "presentation": {
"http://www.cooperpcos.com/role/BusinessSegmentInformationScheduleOfIdentifiableAssetsbySegmentDetails":
"http://www.cooperpcos.com/role/BusinessSegmentInformationScheduleOfSegmentInformationDetails": { "lang": { "en-us": { "role": { "terseLabel": "Operating Segments", "label": "Operating Segments [Member]", "documentation": "Identifies components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity." } } }, "auth_ref": { "r269", "r270", "r271", "r272", "r273", "r276", "r724", "r725" } } }, "us-gaap-OrganizationConsolidationAndPresentationOffinancialStatementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OrganizationConsolidationAndPresentationOffinancialStatementsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]", "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]", "auth_ref": { } } }, "us-gaap-OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "presentation": {
"http://www.cooperpcos.com/role/General": { "lang": { "en-us": { "role": { "terseLabel": "General", "label": "Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block]", "documentation": "The entire disclosure for the general note to the financial statements for the reporting entity which may include, descriptions of the basis of presentation, business description, significant accounting policies, consolidations, reclassifications, new pronouncements not yet adopted and changes in accounting principles." } } }, "auth_ref": { "r103", "r104", "r105", "r116" } } }, "us-gaap-OtherAssetsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherAssetsNoncurrent", "crdr": "debit", "calculation": {
"http://www.cooperpcos.com/role/ConsolidatedCondensedBalanceSheets": { "parentTag": "us-gaap-Assets", "weight": 1.0, "order": 4.0 } }, "presentation": {
"http://www.cooperpcos.com/role/ConsolidatedCondensedBalanceSheets": { "lang": { "en-us": { "role": { "terseLabel": "Other assets", "label": "Other Assets, Noncurrent", "documentation": "Amount of noncurrent assets classified as other." } } }, "auth_ref": { "r188" } } }, "us-gaap-OtherComprehensiveIncomeLossBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossBeforeTax", "crdr": "credit", "calculation": {
"http://www.cooperpcos.com/role/StockholdersEquityScheduleOfChangesinAccumulatedOtherComprehensiveIncomeLossIncomeDetails": { "lang": { "en-us": { "role": { "terseLabel": "Gross change in value", "label": "Other Comprehensive Income (Loss), before Tax", "documentation": "Amount before tax, after reclassification adjustments of other comprehensive income (loss)." } } }, "auth_ref": { "r208", "r503", "r504", "r509", "r559", "r577", "r874", "r875" } } }, "us-gaap-OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax", "crdr": "credit", "calculation": {
"http://www.cooperpcos.com/role/ConsolidatedCondensedStatementsOfIncomeandComprehensiveIncome": { "parentTag": "us-gaap-ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0, "order": 2.0 } }, "presentation": {
"http://www.cooperpcos.com/role/ConsolidatedCondensedStatementsOfIncomeandComprehensiveIncome": { "lang": { "en-us": { "role": { "terseLabel": "Cash flow hedges", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax", "documentation": "Amount, after tax and reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness." } } }, "auth_ref": { "r196", "r197", "r577" } } }, "us-gaap-OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax", "crdr": "credit", "presentation": {
"http://www.cooperpcos.com/role/FinancialDerivativesandHedgingNarrativeDetails": { "lang": { "en-us": { "role": { "terseLabel": "Amount recognized in other comprehensive income on interest rate swaps contracts, net of tax", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, after Tax", "documentation": "Amount, after tax and before reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness." } } }, "auth_ref": { "r196", "r197" } } }, "us-gaap-OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax", "crdr": "debit", "presentation": {
"http://www.cooperpcos.com/role/FinancialDerivativesandHedgingScheduleOfChangesinAccumulatedOtherComprehensiveIncomeDetails": { "lang": { "en-us": { "role": { "verboseLabel": "Amount recognized in accumulated other comprehensive income on interest rate swap contracts, gross", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax", "documentation": "Amount, before tax and reclassification, of gain (loss) from derivative instrument designated and qualifying cash flow hedge included in assessment of hedge effectiveness." } } }, "auth_ref": { "r196", "r197", "r482", "r483", "r485" } } }, "us-gaap-OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax", "crdr": "debit", "presentation": {
"http://www.cooperpcos.com/role/FinancialDerivativesandHedgingNarrativeDetails": { "lang": { "en-us": { "role": { "terseLabel": "Amount reclassified from other comprehensive income into earnings, net of tax", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, after Tax", "documentation": "Amount, after tax, of reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness." } } }, "auth_ref": { "r197", "r199" } } }, "us-gaap-OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax", "crdr": "debit", "presentation": {
"http://www.cooperpcos.com/role/FinancialDerivativesandHedgingScheduleOfChangesinAccumulatedOtherComprehensiveIncomeDetails":
"http://www.cooperpcos.com/role/FinancialDerivativesandHedgingScheduleOfChangesinAccumulatedOtherComprehensiveIncomeDetails": { "lang": { "en-us": { "role": { "negatedTerseLabel": "(Gain) loss recognized on derivatives within interest expense", "negatedLabel": "Amount reclassified from accumulated other comprehensive income into earnings, gross", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax", "documentation": "Amount, before tax, of reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness." } } }, "auth_ref": { "r139", "r197", "r199" } } }, "us-gaap-OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-

gaap/2024", "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax", "crdr": "credit", "calculation": {
"http://www.cooperccos.com/role/ConsolidatedCondensedStatementsOfIncomeAndComprehensiveIncome": { "parentTag": "us-
gaap_OtherComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0, "order": 3.0 } }, "presentation": {
"http://www.cooperccos.com/role/ConsolidatedCondensedStatementsOfIncomeAndComprehensiveIncome": { "lang": { "en-us": { "role": { "terseLabel": "Foreign currency
translation adjustment", "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax", "documentation": "Amount
after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic
hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term investment nature." } } }, "auth_ref": { "r4": "r577" }
} }, "us-gaap_OtherComprehensiveIncomeLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"OtherComprehensiveIncomeLossNetOfTax", "crdr": "credit", "presentation": { "http://www.cooperccos.com/role/ConsolidatedCondensedStatementsOfStockholdersEquity": {
"lang": { "en-us": { "role": { "terseLabel": "Other comprehensive income (loss), net of tax", "label": "Other Comprehensive Income (Loss), Net of Tax", "documentation":
"Amount after tax and reclassification adjustments of other comprehensive income (loss)." } } }, "auth_ref": { "r14": "r18", "r201": "r204", "r208": "r227", "r503": "r504",
"r509": "r559", "r577": "r874", "r875" } }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": { "xbrltype": "stringItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract", "presentation": {
"http://www.cooperccos.com/role/ConsolidatedCondensedStatementsOfIncomeAndComprehensiveIncome": { "lang": { "en-us": { "role": { "verboseLabel": "Other
comprehensive income, net of tax", "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]" } } }, "auth_ref": { } }, "us-
gaap_OtherComprehensiveIncomeLossTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"OtherComprehensiveIncomeLossTax", "crdr": "debit", "presentation": {
"http://www.cooperccos.com/role/StockholdersEquityScheduleOfChangesInAccumulatedOtherComprehensiveIncomeLossIncomeDetails": { "lang": { "en-us": { "role": {
"negatedLabel": "Tax effect", "label": "Other Comprehensive Income (Loss), Tax", "documentation": "Amount of tax expense (benefit) allocated to other comprehensive
income (loss)." } } }, "auth_ref": { "r7": "r205", "r208": "r449", "r461", "r462", "r503", "r507", "r509", "r559", "r577" } }, "coo_OtherDebtMember": { "xbrltype":
"domainItemType", "nsuri": "http://www.cooperccos.com/20240731", "localname": "OtherDebtMember", "presentation": {
"http://www.cooperccos.com/role/FinancingArrangementsTotalDebtDetails": { "lang": { "en-us": { "role": { "terseLabel": "Other", "label": "Other Debt [Member]" }
}, "documentation": "Other Debt [Member]" } } }, "auth_ref": { } }, "us-gaap_OtherLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "OtherLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.cooperccos.com/role/ConsolidatedCondensedBalanceSheets": {
"parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": { "http://www.cooperccos.com/role/ConsolidatedCondensedBalanceSheets": {
"lang": { "en-us": { "role": { "terseLabel": "Other current liabilities", "label": "Other Liabilities, Current", "documentation": "Amount of liabilities classified as other, due
within one year or the normal operating cycle, if longer." } } }, "auth_ref": { "r68": "r753" } }, "us-gaap_OtherLiabilitiesNoncurrent": { "xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherLiabilitiesNoncurrent", "crdr": "credit", "calculation": {
"http://www.cooperccos.com/role/ConsolidatedCondensedBalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 2.0 } }, "presentation": {
"http://www.cooperccos.com/role/ConsolidatedCondensedBalanceSheets": { "lang": { "en-us": { "role": { "terseLabel": "Other liabilities", "label": "Other Liabilities,
Noncurrent", "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer." } } }, "auth_ref": { "r72" } }, "us-
gaap_OtherNoncashIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherNoncashIncomeExpense", "crdr":
"credit", "calculation": { "http://www.cooperccos.com/role/ConsolidatedCondensedStatementsOfCashFlows": { "parentTag": "us-
gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 2.0 } }, "presentation": {
"http://www.cooperccos.com/role/ConsolidatedCondensedStatementsOfCashFlows": { "lang": { "en-us": { "role": { "negatedTerseLabel": "Other non-cash items", "label":
"Other Noncash Income (Expense)", "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other." } }
} }, "auth_ref": { "r102" } }, "us-gaap_OtherNonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"OtherNonoperatingIncomeExpense", "crdr": "credit", "calculation": {
"http://www.cooperccos.com/role/ConsolidatedCondensedStatementsOfIncomeAndComprehensiveIncome": { "parentTag": "us-
gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 3.0 } }, "presentation": {
"http://www.cooperccos.com/role/BusinessSegmentInformationScheduleOfSegmentInformationDetails": {
"http://www.cooperccos.com/role/ConsolidatedCondensedStatementsOfIncomeAndComprehensiveIncome": { "lang": { "en-us": { "role": { "negatedTerseLabel": "Other
expense, net", "label": "Other expense, net", "documentation": "Amount of income (expense) related to
nonoperating activities, classified as other." } } }, "auth_ref": { "r96" } }, "ecd_OtherPerfMeasureAmt": { "xbrltype": "decimalItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "OtherPerfMeasureAmt", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": { "en-us": { "role": {
"terseLabel": "Other Performance Measure, Amount", "label": "Other Performance Measure, Amount" } } }, "auth_ref": { "r825" } }, "ecd_OutstandingAggtErrCompAmt": {
"xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingAggtErrCompAmt", "presentation": {
"http://xbrl.sec.gov/ecd/role/ErrCompDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount", "label":
"Outstanding Aggregate Erroneous Compensation Amount" } } }, "auth_ref": { "r787": "r797", "r807": "r839" } }, "ecd_OutstandingRecoveryCompAmt": { "xbrltype":
"monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingRecoveryCompAmt", "presentation": {
"http://xbrl.sec.gov/ecd/role/ErrCompDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "Compensation Amount", "label": "Outstanding Recovery Compensation
Amount" } } }, "auth_ref": { "r790": "r800", "r810": "r842" } }, "ecd_OutstandingRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "OutstandingRecoveryIndName", "presentation": { "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "Name",
"label": "Outstanding Recovery, Individual Name" } } }, "auth_ref": { "r790": "r800", "r810": "r842" } }, "ecd_PayVsPerformanceDisclosureLineItems": { "xbrltype":
"stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PayVsPerformanceDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Pay vs Performance
Disclosure [Line Items]" } } }, "auth_ref": { "r814" } }, "coo_PayablesFirstInstallmentMember": { "xbrltype": "domainItemType", "nsuri":
"http://www.cooperccos.com/20240731", "localname": "PayablesFirstInstallmentMember", "presentation": {
"http://www.cooperccos.com/role/AcquisitionsandJointVentureDetails": { "lang": { "en-us": { "role": { "terseLabel": "Payables First Installment", "label": "Payables First
Installment [Member]", "documentation": "Payables First Installment" } } }, "auth_ref": { } }, "coo_PayablesSecondInstallmentMember": { "xbrltype": "domainItemType",
"nsuri": "http://www.cooperccos.com/20240731", "localname": "PayablesSecondInstallmentMember", "presentation": {
"http://www.cooperccos.com/role/AcquisitionsandJointVentureDetails": { "lang": { "en-us": { "role": { "terseLabel": "Payables Second Installment", "label": "Payables Second
Installment [Member]", "documentation": "Payables Second Installment" } } }, "auth_ref": { } }, "us-gaap_PaymentsOfDividendsCommonStock": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsOfDividendsCommonStock", "crdr": "credit", "calculation": {
"http://www.cooperccos.com/role/ConsolidatedCondensedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0,
"order": 5.0 } }, "presentation": { "http://www.cooperccos.com/role/ConsolidatedCondensedStatementsOfCashFlows": {
"http://www.cooperccos.com/role/StockholdersEquityNarrativeDetails": { "lang": { "en-us": { "role": { "negatedTerseLabel": "Dividends on common stock", "terseLabel":
"Dividends on common stock", "label": "Payments of Ordinary Dividends, Common Stock", "documentation": "Amount of cash outflow in the form of ordinary dividends to
common shareholders of the parent entity." } } }, "auth_ref": { "r98" } }, "coo_PaymentsToAcquireBusinessesAndAssetsNetOfCashAcquiredAndOther": { "xbrltype":
"monetaryItemType", "nsuri": "http://www.cooperccos.com/20240731", "localname": "PaymentsToAcquireBusinessesAndAssetsNetOfCashAcquiredAndOther", "crdr":
"credit", "calculation": { "http://www.cooperccos.com/role/ConsolidatedCondensedStatementsOfCashFlows": { "parentTag": "us-
gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": {
"http://www.cooperccos.com/role/ConsolidatedCondensedStatementsOfCashFlows": { "lang": { "en-us": { "role": { "negatedTerseLabel": "Acquisitions of businesses and
assets, net of cash acquired, and other", "label": "Payments To Acquire Businesses And Assets, Net Of Cash Acquired, And Other", "documentation": "Payments To Acquire
Businesses And Assets, Net Of Cash Acquired, And Other" } } }, "auth_ref": { } }, "us-gaap_PaymentsToAcquireBusinessesGross": { "xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquireBusinessesGross", "crdr": "credit", "presentation": {
"http://www.cooperccos.com/role/AcquisitionsandJointVentureDetails": { "lang": { "en-us": { "role": { "terseLabel": "Payments to acquire business", "label": "Payments to
Acquire Businesses, Gross", "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition
price." } } }, "auth_ref": { "r24": "r472" } }, "us-gaap_PaymentsToAcquireEquityMethodInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "PaymentsToAcquireEquityMethodInvestments", "crdr": "credit", "presentation": {
"http://www.cooperccos.com/role/AcquisitionsandJointVentureDetails": { "lang": { "en-us": { "role": { "terseLabel": "Payments to form joint venture", "label": "Payments to
Acquire Equity Method Investments", "documentation": "The cash outflow associated with the purchase of or advances to an equity method investments, which are
investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence." } } },
"auth_ref": { "r24" } }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"PaymentsToAcquirePropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://www.cooperccos.com/role/ConsolidatedCondensedStatementsOfCashFlows": {
"parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 2.0 } }, "presentation": {
"http://www.cooperccos.com/role/ConsolidatedCondensedStatementsOfCashFlows": { "lang": { "en-us": { "role": { "negatedLabel": "Purchases of property, plant and
equipment", "label": "Payments to Acquire Property, Plant, and Equipment", "documentation": "The cash outflow associated with the acquisition of long-lived, physical
assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-
constructed assets." } } }, "auth_ref": { "r97" } }, "ecd_PeerGroupIssuersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "PeerGroupIssuersFnTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "Peer Group
Issuers, Footnote", "label": "Peer Group Issuers, Footnote [Text Block]" } } }, "auth_ref": { "r824" } }, "ecd_PeerGroupTotalShareholderRtnAmt": { "xbrltype":
"monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeerGroupTotalShareholderRtnAmt", "presentation": {
"http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "Peer Group Total Shareholder Return Amount", "label": "Peer Group Total
Shareholder Return Amount" } } }, "auth_ref": { "r824" } }, "ecd_PeoActuallyPaidCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "PeoActuallyPaidCompAmt", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "PEO Actually Paid
Compensation Amount", "label": "PEO Actually Paid Compensation Amount" } } }, "auth_ref": { "r816" } }, "ecd_PeoMember": { "xbrltype": "domainItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "PeoMember", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": { "en-us": { "role": { "terseLabel":
"PEO", "label": "PEO [Member]" } } }, "auth_ref": { "r833" } }, "ecd_PeoName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "PeoName", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "PEO Name", "label": "PEO Name" } }
} }, "auth_ref": { "r826" } }, "ecd_PeoTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoTotalCompAmt",
"presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "PEO Total Compensation Amount", "label": "PEO Total
Compensation Amount" } } }, "auth_ref": { "r815" } }, "ecd_PnsnAdjsPrsSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "PnsnAdjsPrsSvcCstMember", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "Pension Adjustments
Prior Service Cost", "label": "Pension Adjustments Prior Service Cost [Member]" } } }, "auth_ref": { "r817" } }, "ecd_PnsnAdjsSvcCstMember": { "xbrltype":
"domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnAdjsSvcCstMember", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang":
"en-us": { "role": { "terseLabel": "Pension Adjustments Service Cost", "label": "Pension Adjustments Service Cost [Member]" } } }, "auth_ref": { "r861" } },
"ecd_PnsnBnftsAdjFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnBnftsAdjFnTextBlock", "presentation": {
"http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "Pension Benefits Adjustments, Footnote", "label": "Pension Benefits Adjustments,
Footnote [Text Block]" } } }, "auth_ref": { "r816" } }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "PreferredStockParOrStatedValuePerShare", "presentation": {
"http://www.cooperccos.com/role/ConsolidatedCondensedBalanceSheetsParentetical": { "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, par value (in dollars
per share)", "label": "Preferred Stock, Par or Stated Value Per Share", "documentation": "Face amount or stated value per share of preferred stock nonredeemable or
redeemable solely at the option of the issuer." } } }, "auth_ref": { "r75": "r386" } }, "us-gaap_PreferredStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesAuthorized", "presentation": {

"http://www.cooperco.com/role/ConsolidatedCondensedBalanceSheetsParenthetical", "lang": "en-us", "role": "terseLabel", "Preferred stock, authorized (in shares)", "label": "Preferred Stock, Shares Authorized", "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "auth_ref": "r75", "r632", "us-gaap_PreferredStockSharesIssued", "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesIssued", "presentation": "http://www.cooperco.com/role/ConsolidatedCondensedBalanceSheetsParenthetical", "lang": "en-us", "role": "terseLabel", "Preferred stock, issued (in shares)", "label": "Preferred Stock, Shares Issued", "documentation": "Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt.", "auth_ref": "r75", "r386", "us-gaap_PreferredStockSharesOutstanding", "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesOutstanding", "presentation": "http://www.cooperco.com/role/ConsolidatedCondensedBalanceSheetsParenthetical", "lang": "en-us", "role": "terseLabel", "Preferred stock, outstanding (in shares)", "label": "Preferred Stock, Shares Outstanding", "documentation": "Aggregate share number for all nonredeemable preferred stock for preferred stock redeemable solely at the option of the issuer held by stockholders. Does not include preferred shares that have been repurchased.", "auth_ref": "r75", "r632", "r650", "r993", "r994", "us-gaap_PreferredStockValue", "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockValue", "crdr": "credit", "calculation": "http://www.cooperco.com/role/ConsolidatedCondensedBalanceSheets", "parentTag": "us-gaap_StockholdersEquity", "weight": "1.0", "order": "1.0", "presentation": "http://www.cooperco.com/role/ConsolidatedCondensedBalanceSheets", "lang": "en-us", "role": "verboseLabel", "Preferred stock, \$0.10 par value, 1.0 shares authorized, zero shares issued or outstanding", "label": "Preferred Stock, Value, Issued", "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "auth_ref": "r75", "r568", "r753", "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PrepaidExpenseAndOtherAssetsCurrent", "crdr": "debit", "calculation": "http://www.cooperco.com/role/ConsolidatedCondensedBalanceSheets", "parentTag": "us-gaap_AssetsCurrent", "weight": "1.0", "order": "2.0", "presentation": "http://www.cooperco.com/role/ConsolidatedCondensedBalanceSheets", "lang": "en-us", "role": "terseLabel", "Prepaid expense and other current assets", "label": "Prepaid Expense and Other Assets, Current", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.", "auth_ref": "r873", "us-gaap_ProceedsFromDivestitureOfInterestInConsolidatedSubsidiaries", "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromDivestitureOfInterestInConsolidatedSubsidiaries", "crdr": "debit", "presentation": "http://www.cooperco.com/role/AcquisitionsandJointVentureDetails", "lang": "en-us", "role": "terseLabel", "Proceeds from sale of interest in a subsidiary", "label": "Proceeds from Divestiture of Interest in Consolidated Subsidiaries", "documentation": "The cash inflow associated with the deconsolidation of a previously consolidated subsidiary or the sale of investment in consolidated subsidiaries (generally greater than 50 percent).", "auth_ref": "r23", "us-gaap_ProceedsFromIssuanceOfLongTermDebt", "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromIssuanceOfLongTermDebt", "crdr": "debit", "calculation": "http://www.cooperco.com/role/ConsolidatedCondensedStatementsOfCashFlows", "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": "1.0", "order": "4.0", "presentation": "http://www.cooperco.com/role/ConsolidatedCondensedStatementsOfCashFlows", "lang": "en-us", "role": "terseLabel", "Proceeds from long-term debt, net of issuance costs", "label": "Proceeds from Issuance of Long-Term Debt", "documentation": "The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.", "auth_ref": "r25", "r611", "coo_ProceedsFromPaymentsOfShareBasedArrangement", "xbrltype": "monetaryItemType", "nsuri": "http://www.cooperco.com/20240731", "localname": "ProceedsFromPaymentsOfShareBasedArrangement", "crdr": "debit", "calculation": "http://www.cooperco.com/role/ConsolidatedCondensedStatementsOfCashFlows", "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": "1.0", "order": "6.0", "presentation": "http://www.cooperco.com/role/ConsolidatedCondensedStatementsOfCashFlows", "lang": "en-us", "role": "verboseLabel", "Net proceeds related to share-based compensation awards", "label": "Proceeds From (Payments Of) Share-Based Arrangement", "documentation": "Proceeds from (Payments Of) Share-Based Arrangement", "auth_ref": "r1", "us-gaap_ProceedsFromRepaymentsOfShortTermDebt", "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromRepaymentsOfShortTermDebt", "crdr": "debit", "calculation": "http://www.cooperco.com/role/ConsolidatedCondensedStatementsOfCashFlows", "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": "1.0", "order": "2.0", "presentation": "http://www.cooperco.com/role/ConsolidatedCondensedStatementsOfCashFlows", "lang": "en-us", "role": "terseLabel", "Net repayments of short-term debt", "label": "Proceeds from (Repayments Of) Short-Term Debt", "documentation": "The net cash inflow or outflow for borrowing having initial term of repayment within one year or the normal operating cycle, if longer.", "auth_ref": "r1", "us-gaap_ProceedsFromStockPlans", "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromStockPlans", "crdr": "debit", "calculation": "http://www.cooperco.com/role/ConsolidatedCondensedStatementsOfCashFlows", "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": "1.0", "order": "3.0", "presentation": "http://www.cooperco.com/role/ConsolidatedCondensedStatementsOfCashFlows", "lang": "en-us", "role": "terseLabel", "Issuance of common stock for employee stock purchase plan", "label": "Proceeds from Stock Plans", "documentation": "The cash inflow associated with the amount received from the stock plan during the period.", "auth_ref": "r8", "srt_ProductOrServiceAxis", "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ProductOrServiceAxis", "presentation": "http://www.cooperco.com/role/BusinessSegmentInformationScheduleofSegmentInformationDetails", "lang": "en-us", "role": "terseLabel", "Product and Service [Axis]", "label": "Product and Service [Axis]", "documentation": "Information by product and service, or group of similar products and similar services.", "auth_ref": "r151", "r152", "r153", "r154", "r155", "r156", "r176", "r278", "r525", "r592", "r593", "r594", "r595", "r596", "r597", "r598", "r708", "r738", "r762", "r763", "r764", "r767", "r768", "r872", "r913", "r914", "r921", "r962", "r964", "r965", "r966", "r967", "r968", "r969", "r970", "r971", "r972", "r973", "r974", "r975", "r976", "r977", "r978", "r979", "r980", "r981", "r982", "r983", "r984", "r985", "r986", "r987", "r988", "r989", "r990", "r991", "srt_ProductsAndServicesDomain", "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ProductsAndServicesDomain", "presentation": "http://www.cooperco.com/role/BusinessSegmentInformationScheduleofSegmentInformationDetails", "lang": "en-us", "role": "terseLabel", "Product and Service [Domain]", "label": "Product and Service [Domain]", "documentation": "Product or service, or a group of similar products or similar services.", "auth_ref": "r151", "r152", "r153", "r154", "r155", "r156", "r176", "r278", "r525", "r592", "r593", "r594", "r595", "r596", "r597", "r598", "r708", "r738", "r762", "r763", "r764", "r767", "r768", "r872", "r913", "r914", "r921", "r962", "r964", "r965", "r966", "r967", "r968", "r969", "r970", "r971", "r972", "r973", "r974", "r975", "r976", "r977", "r978", "r979", "r980", "r981", "r982", "r983", "r984", "r985", "r986", "r987", "r988", "r989", "r990", "r991", "us-gaap_PropertyPlantAndEquipmentNet", "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentNet", "crdr": "debit", "calculation": "http://www.cooperco.com/role/ConsolidatedCondensedBalanceSheets", "parentTag": "us-gaap_Assets", "weight": "1.0", "order": "1.0", "presentation": "http://www.cooperco.com/role/ConsolidatedCondensedBalanceSheets", "lang": "en-us", "role": "terseLabel", "Property, plant and equipment, net", "label": "Property, Plant and Equipment, Net", "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "auth_ref": "r11", "r518", "r563", "r574", "r753", "ecd_PvpTable", "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PvpTable", "presentation": "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": "en-us", "role": "terseLabel", "Pay vs Performance Disclosure", "label": "Pay vs Performance Disclosure [Table]", "auth_ref": "r814", "ecd_PvpTableTextBlock", "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PvpTableTextBlock", "presentation": "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": "en-us", "role": "terseLabel", "Pay vs Performance Disclosure, Table", "label": "Pay vs Performance [Table Text Block]", "auth_ref": "r814", "srt_RangeAxis", "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RangeAxis", "presentation": "http://www.cooperco.com/role/ContingenciesandCommitmentsDetails", "lang": "en-us", "role": "terseLabel", "Statistical Measurement [Axis]", "label": "Statistical Measurement [Axis]", "documentation": "Information by statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median.", "auth_ref": "r142", "r144", "r146", "r147", "r149", "r177", "r178", "r337", "r339", "r340", "r341", "r405", "r406", "r435", "r436", "r437", "r444", "r497", "r522", "r523", "r524", "r599", "r601", "r609", "r622", "r623", "r675", "r677", "r679", "r680", "r688", "r704", "r705", "r729", "r737", "r742", "r748", "r749", "r750", "r751", "r763", "r770", "r912", "r919", "r935", "r954", "r955", "r956", "r957", "r958", "srt_RangeMember", "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RangeMember", "presentation": "http://www.cooperco.com/role/ContingenciesandCommitmentsDetails", "lang": "en-us", "role": "terseLabel", "Statistical Measurement [Domain]", "label": "Statistical Measurement [Domain]", "documentation": "Statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median.", "auth_ref": "r142", "r144", "r146", "r147", "r149", "r177", "r178", "r337", "r339", "r340", "r341", "r405", "r406", "r435", "r436", "r437", "r444", "r497", "r522", "r523", "r524", "r599", "r601", "r609", "r622", "r623", "r675", "r677", "r679", "r680", "r688", "r704", "r705", "r729", "r737", "r742", "r748", "r749", "r750", "r751", "r763", "r770", "r912", "r919", "r935", "r954", "r955", "r956", "r957", "r958", "us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock", "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock", "presentation": "http://www.cooperco.com/role/BusinessSegmentInformationTables", "lang": "en-us", "role": "verboseLabel", "Schedule of identifiable assets by segment", "label": "Reconciliation of Assets from Segment to Consolidated [Table Text Block]", "documentation": "Tabular disclosure of all significant reconciling items in the reconciliation of total assets from reportable segments to the entity's consolidated assets.", "auth_ref": "r34", "r35", "ecd_RecoveryOfErrCompDisclosureLineItems", "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RecoveryOfErrCompDisclosureLineItems", "lang": "en-us", "role": "label", "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]", "auth_ref": "r782", "r792", "r802", "r834", "us-gaap_RepaymentsOfLongTermDebt", "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RepaymentsOfLongTermDebt", "crdr": "credit", "calculation": "http://www.cooperco.com/role/ConsolidatedCondensedStatementsOfCashFlows", "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": "1.0", "order": "1.0", "presentation": "http://www.cooperco.com/role/ConsolidatedCondensedStatementsOfCashFlows", "lang": "en-us", "role": "negatedLabel", "Repayments of long-term debt", "label": "Repayments of Long-Term Debt", "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.", "auth_ref": "r99", "r612", "us-gaap_RepaymentsOfSecuredDebt", "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RepaymentsOfSecuredDebt", "crdr": "credit", "presentation": "http://www.cooperco.com/role/FinancingArrangementsNarrativeDetails", "lang": "en-us", "role": "terseLabel", "Repayment of borrowings", "label": "Repayments of Secured Debt", "documentation": "The cash outflow to repay long-term debt that is wholly or partially secured by collateral. Excludes repayments of tax exempt secured debt.", "auth_ref": "r99", "us-gaap_ResearchAndDevelopmentExpense", "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpense", "crdr": "debit", "calculation": "http://www.cooperco.com/role/ConsolidatedCondensedStatementsOfIncomeandComprehensiveIncome", "parentTag": "us-gaap_OperatingIncomeLoss", "weight": "1.0", "order": "3.0", "presentation": "http://www.cooperco.com/role/ConsolidatedCondensedStatementsOfIncomeandComprehensiveIncome", "lang": "en-us", "role": "terseLabel", "Research and development expense", "label": "Research and Development Expense", "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.", "auth_ref": "r445", "r706", "r724", "r959", "us-gaap_ResearchAndDevelopmentExpenseMember", "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpenseMember", "presentation": "http://www.cooperco.com/role/ShareBasedCompensationDetails", "lang": "en-us", "role": "terseLabel", "Research and development expense", "label": "Research and Development Expense [Member]", "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.", "auth_ref": "r1", "coo_RestOfWorldExcludingUnitedStatesAndEuropeMember", "xbrltype": "domainItemType", "nsuri": "http://www.cooperco.com/20240731", "localname": "RestOfWorldExcludingUnitedStatesAndEuropeMember", "presentation": "http://www.cooperco.com/role/BusinessSegmentInformationScheduleofNetPropertyPlantandEquipmentByCountryOfDomicileDetails", "lang": "en-us", "role": "terseLabel", "Rest of world", "label": "Rest of World, Excluding United States And Europe [Member]", "documentation": "Rest of World, Excluding United States And Europe [Member]", "auth_ref": "r1", "ecd_RestatementDateAxis", "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024",

"localname": "RestatementDateAxis", "presentation": { "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "Restatement Determination Date", "label": "Restatement Determination Date [Axis]" } } }, "auth_ref": { "r783", "r793", "r803", "r835" } }, "ecd_RestatementDeterminationDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDeterminationDate", "presentation": { "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "Restatement Determination Date", "label": "Restatement Determination Date" } } }, "auth_ref": { "r784", "r794", "r804", "r836" } }, "ecd_RestatementDoesNotRequireRecoveryTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDoesNotRequireRecoveryTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "Restatement does not require Recovery", "label": "Restatement Does Not Require Recovery [Text Block]" } } }, "auth_ref": { "r791", "r801", "r811", "r843" } }, "us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedCashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "calculation": { "http://www.cooperccos.com/role/ConsolidatedCondensedStatementsOfCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0, "order": 2.0 } }, "presentation": { "http://www.cooperccos.com/role/ConsolidatedCondensedStatementsOfCashFlows": { "lang": { "en-us": { "role": { "terseLabel": "Restricted cash included in other current assets", "label": "Restricted Cash and Cash Equivalents, Current", "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": { "r26", "r185", "r212" } }, "us-gaap_RestrictedStockUnitsRSUMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedStockUnitsRSUMember", "presentation": { "http://www.cooperccos.com/role/EarningsPerShareScheduleOfStockOptionsandRestrictedStockUnitsthatwerenotIncludedintheDilutedEarningsPerShareCalculationDetails": { "lang": { "en-us": { "role": { "terseLabel": "Restricted stock units", "label": "Restricted Stock Units (RSUs) [Member]", "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met." } } }, "auth_ref": { "us-gaap_RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsAccumulatedDeficit", "crdr": "credit", "calculation": { "http://www.cooperccos.com/role/ConsolidatedCondensedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 5.0 } }, "presentation": { "http://www.cooperccos.com/role/ConsolidatedCondensedBalanceSheets": { "lang": { "en-us": { "role": { "terseLabel": "Retained earnings", "label": "Retained Earnings (Accumulated Deficit)", "documentation": "Amount of accumulated undistributed earnings (deficit)." } } }, "auth_ref": { "r78", "r114", "r574", "r606", "r608", "r613", "r633", "r753" } }, "us-gaap_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsMember", "presentation": { "http://www.cooperccos.com/role/ConsolidatedCondensedStatementsOfStockholdersEquity": { "lang": { "en-us": { "role": { "terseLabel": "Retained Earnings", "label": "Retained Earnings [Member]", "documentation": "Accumulated undistributed earnings (deficit)." } } }, "auth_ref": { "r179", "r218", "r219", "r220", "r222", "r227", "r229", "r231", "r289", "r290", "r318", "r456", "r457", "r466", "r467", "r468", "r470", "r475", "r476", "r486", "r488", "r489", "r491", "r494", "r512", "r514", "r603", "r605", "r616", "r993" } }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "crdr": "credit", "calculation": { "http://www.cooperccos.com/role/ConsolidatedCondensedStatementsOfIncomeandComprehensiveIncome": { "parentTag": "us-gaap_GrossProfit", "weight": 1.0, "order": 2.0 } }, "presentation": { "http://www.cooperccos.com/role/BusinessSegmentInformationScheduleOfNetSalesToUnaffiliatedCustomersbyCountryofDomicileDetails": { "http://www.cooperccos.com/role/ConsolidatedCondensedStatementsOfIncomeandComprehensiveIncome": { "lang": { "en-us": { "role": { "terseLabel": "Net sales", "verboseLabel": "Total net sales", "label": "Revenue from Contract with Customer, Excluding Assessed Tax", "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise." } } }, "auth_ref": { "r130", "r131", "r247", "r254", "r255", "r269", "r275", "r278", "r280", "r282", "r401", "r402", "r525" } }, "us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueFromExternalCustomersByGeographicAreasTableTextBlock", "presentation": { "http://www.cooperccos.com/role/BusinessSegmentInformationTables": { "lang": { "en-us": { "role": { "verboseLabel": "Schedule of net sales to unaffiliated customers by country of domicile", "label": "Revenue from External Customers by Geographic Areas [Table Text Block]", "documentation": "Tabular disclosure of revenue from external customers by geographic areas attributed to the entity's country of domicile and to foreign countries from which the entity derives revenue." } } }, "auth_ref": { "r106" } }, "us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenuesFromExternalCustomersAndLongLivedAssetsLineItems", "presentation": { "http://www.cooperccos.com/role/BusinessSegmentInformationScheduleOfNetSalesToUnaffiliatedCustomersbyCountryofDomicileDetails": { "http://www.cooperccos.com/role/BusinessSegmentInformationScheduleOfNetSalesToUnaffiliatedCustomersbyCountryofDomicileDetails": { "lang": { "en-us": { "role": { "terseLabel": "Revenues from External Customers and Long-Lived Assets [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": { "coo_RevolvingCreditFacilityAndTermLoanFacility2020Member": { "xbrltype": "domainItemType", "nsuri": "http://www.cooperccos.com/20240731", "localname": "RevolvingCreditFacilityAndTermLoanFacility2020Member", "presentation": { "http://www.cooperccos.com/role/FinancingArrangementsNarrativeDetails": { "lang": { "en-us": { "role": { "terseLabel": "Revolving Credit Facility and Term Loan Facility 2020", "label": "Revolving Credit Facility and Term Loan Facility 2020 [Member]", "documentation": "Revolving Credit Facility and Term Loan Facility 2020 [Member]" } } }, "auth_ref": { "us-gaap_RevolvingCreditFacilityMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevolvingCreditFacilityMember", "presentation": { "http://www.cooperccos.com/role/FinancingArrangementsNarrativeDetails": { "http://www.cooperccos.com/role/FinancingArrangementsTotalDebtDetails": { "lang": { "en-us": { "role": { "terseLabel": "Revolving Credit Facility", "label": "Revolving Credit Facility [Member]", "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount." } } }, "auth_ref": { "ecd_Rule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Rule10b51ArrTrmtdFlag", "presentation": { "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements": { "lang": { "en-us": { "role": { "terseLabel": "Rule 10b5-1 Arrangement Adopted", "label": "Rule 10b5-1 Arrangement Adopted [Flag]" } } }, "auth_ref": { "ecd_Rule10b51ArrTrmtdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Rule10b51ArrTrmtdFlag", "presentation": { "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements": { "lang": { "en-us": { "role": { "terseLabel": "Rule 10b5-1 Arrangement Terminated", "label": "Rule 10b5-1 Arrangement Terminated [Flag]" } } }, "auth_ref": { "us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "presentation": { "http://www.cooperccos.com/role/FinancialDerivativesandHedgingTables": { "http://www.cooperccos.com/role/StockholdersEquityTables": { "lang": { "en-us": { "role": { "terseLabel": "Schedule of changes in accumulated other comprehensive income", "verboseLabel": "Schedule of changes in accumulated other comprehensive income", "label": "Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]", "documentation": "Tabular disclosure of the components of accumulated other comprehensive income (loss)." } } }, "auth_ref": { "r22", "r945", "r946" } }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "presentation": { "http://www.cooperccos.com/role/EarningsPerShareScheduleOfStockOptionsandRestrictedStockUnitsthatwerenotIncludedintheDilutedEarningsPerShareCalculationDetails": { "lang": { "en-us": { "role": { "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]", "label": "Antidilutive Security, Excluded EPS Calculation [Table]", "documentation": "Disclosure of information about security that could potentially dilute basic earnings per share (EPS) in future that was not included in calculation of diluted EPS." } } }, "auth_ref": { "r27" } }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "presentation": { "http://www.cooperccos.com/role/EarningsPerShareTables": { "lang": { "en-us": { "role": { "terseLabel": "Schedule of stock options and restricted stock units that were not included in the diluted earnings per share calculation", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]", "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities." } } }, "auth_ref": { "r27" } }, "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable", "presentation": { "http://www.cooperccos.com/role/AcquisitionsandJointVentureDetails": { "lang": { "en-us": { "role": { "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]", "label": "Schedule of Business Acquisitions, by Acquisition [Table]", "documentation": "Disclosure of information about business combination. Includes, but is not limited to, recognized asset and liability." } } }, "auth_ref": { "r47", "r48", "r471" } }, "us-gaap_ScheduleOfCashFlowHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfCashFlowHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock", "presentation": { "http://www.cooperccos.com/role/FinancialDerivativesandHedgingTables": { "lang": { "en-us": { "role": { "terseLabel": "Schedule of derivative instruments recognized in condensed consolidated statements of income", "label": "Schedule of Cash Flow Hedging Instruments, Statements of Financial Performance and Financial Position, Location [Table Text Block]", "documentation": "Tabular disclosure for cash flow hedging instruments of (a) the location and amount of gains and losses reported in the statement of financial performance and (b) the location and fair value amounts of the instruments reported in the statement of financial position." } } }, "auth_ref": { "r120" } }, "us-gaap_ScheduleOfDebtTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfDebtTableTextBlock", "presentation": { "http://www.cooperccos.com/role/FinancingArrangementsTables": { "lang": { "en-us": { "role": { "terseLabel": "Schedule of debt", "label": "Schedule of Debt [Table Text Block]", "documentation": "Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation." } } }, "auth_ref": { "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "presentation": { "http://www.cooperccos.com/role/EarningsPerShareTables": { "lang": { "en-us": { "role": { "terseLabel": "Schedule of earnings per share", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations." } } }, "auth_ref": { "r885" } }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable", "presentation": { "http://www.cooperccos.com/role/ShareBasedCompensationDetails": { "lang": { "en-us": { "role": { "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]", "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]", "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements." } } }, "auth_ref": { "r44" } }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "presentation": { "http://www.cooperccos.com/role/ShareBasedCompensationTables": { "lang": { "en-us": { "role": { "terseLabel": "Schedule of compensation expense and related income tax benefit for share-based awards", "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]", "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement." } } }, "auth_ref": { "r44" } } } }

"srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis", "presentation": { "http://www.cooperco.com/role/AcquisitionsandJointVentureDetails": { "lang": { "en-us": { "role": { "terseLabel": "Investment, Name [Axis]", "label": "Investment, Name [Axis]", "documentation": "Information by name of investment including named security. Excludes entity that is consolidated." } } }, "auth_ref": { "r285", "r286", "r287", "r465", "r863", "r864", "r865", "r923", "r924", "r925", "r926" } }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable", "presentation": { "http://www.cooperco.com/role/IntangibleAssetsSummaryOfIntangibleAssetsDetails": { "lang": { "en-us": { "role": { "terseLabel": "Schedule of Finite-Lived Intangible Assets [Table]", "label": "Intangible Asset, Finite-Lived [Table]", "documentation": "Disclosure of information about finite-lived intangible asset. Excludes indefinite-lived intangible asset." } } }, "auth_ref": { "r304", "r311", "r315", "r316", "r317", "r526", "r706", "r731" } }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "presentation": { "http://www.cooperco.com/role/IntangibleAssetsTables": { "lang": { "en-us": { "role": { "terseLabel": "Schedule of finite-lived intangible assets", "label": "Schedule of Indefinite-Lived Intangible Assets [Table Text Block]", "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment." } } }, "auth_ref": { "r731", "r904" } }, "us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock", "presentation": { "http://www.cooperco.com/role/IntangibleAssetsTables": { "lang": { "en-us": { "role": { "terseLabel": "Schedule of indefinite-lived intangible assets", "label": "Schedule of Indefinite-Lived Intangible Assets [Table Text Block]", "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance and exist in perpetuity, by either major class or business segment." } } }, "auth_ref": { "r731", "r906" } }, "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfInventoryCurrentTableTextBlock", "presentation": { "http://www.cooperco.com/role/InventoriesTables": { "lang": { "en-us": { "role": { "terseLabel": "Schedule of inventories", "label": "Schedule of Inventory, Current [Table Text Block]", "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process." } } }, "auth_ref": { "r20", "r82", "r83", "r84" } }, "coo_ScheduleOfLongTermAndShortTermDebtInstrumentsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.cooperco.com/20240731", "localname": "ScheduleOfLongTermAndShortTermDebtInstrumentsLineItems", "presentation": { "http://www.cooperco.com/role/FinancingArrangementsNarrativeDetails": { "lang": { "en-us": { "role": { "terseLabel": "Schedule of Long Term And Short Term Debt Instruments [Line Items]", "label": "Schedule of Long Term And Short Term Debt Instruments [Line Items]", "documentation": "Schedule of Long Term And Short Term Debt Instruments [Line Items]" } } }, "auth_ref": { "us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable", "presentation": { "http://www.cooperco.com/role/BusinessSegmentInformationScheduleofNetPropertyPlantandEquipmentByCountryofDomicileDetails": { "http://www.cooperco.com/role/BusinessSegmentInformationScheduleofNetSalesofUnaffiliatedCustomersbyCountryofDomicileDetails": { "lang": { "en-us": { "role": { "terseLabel": "Schedule of Revenues from External Customers and Long-Lived Assets [Table]", "label": "Schedule of Revenues from External Customers and Long-Lived Assets [Table]", "documentation": "Disclosure of information about revenue from external customer and long-lived asset by geographical area. Long-lived asset excludes financial instrument, customer relationship with financial institution, mortgage and other servicing right, deferred policy acquisition cost, and deferred tax asset." } } }, "auth_ref": { "r36", "r89" } }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfSegmentReportingInformationBySegmentTable", "presentation": { "http://www.cooperco.com/role/BusinessSegmentInformationScheduleofIdentifiableAssetsbySegmentDetails": { "http://www.cooperco.com/role/BusinessSegmentInformationScheduleofSegmentInformationDetails": { "lang": { "en-us": { "role": { "terseLabel": "Schedule of Segment Reporting Information, by Segment [Table]", "label": "Schedule of Segment Reporting Information, by Segment [Table]", "documentation": "Disclosure of information about profit (loss) and total assets by reportable segment." } } }, "auth_ref": { "r31", "r32", "r33" } }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock", "presentation": { "http://www.cooperco.com/role/BusinessSegmentInformationTables": { "lang": { "en-us": { "role": { "verboseLabel": "Schedule of segment information", "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]", "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss." } } }, "auth_ref": { "r31", "r32", "r33" } }, "coo_ScheduleOfLongTermAndShortTermDebtInstrumentsTable": { "xbrltype": "stringItemType", "nsuri": "http://www.cooperco.com/20240731", "localname": "ScheduleOfLongTermAndShortTermDebtInstrumentsTable", "presentation": { "http://www.cooperco.com/role/FinancingArrangementsNarrativeDetails": { "lang": { "en-us": { "role": { "terseLabel": "Schedule of Long Term And Short Term Debt Instruments [Table]", "label": "Schedule of Long Term And Short Term Debt Instruments [Table]", "documentation": "Schedule of Long Term And Short Term Debt Instruments [Table]" } } }, "auth_ref": { "us-gaap_ScheduleOfOvernightFinancingRateSofrMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SecuredOvernightFinancingRateSofrMember", "presentation": { "http://www.cooperco.com/role/FinancingArrangementsNarrativeDetails": { "lang": { "en-us": { "role": { "terseLabel": "Adjusted SOFR", "label": "Secured Overnight Financing Rate (SOFR) [Member]", "documentation": "Interest rate at which bank can borrow U.S. dollar overnight while posting U.S. Treasury bond as collateral." } } }, "auth_ref": { "r933" } }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12bTitle", "presentation": { "http://www.cooperco.com/role/Cover": { "lang": { "en-us": { "role": { "terseLabel": "Title of 12(b) Security", "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": { "r777" } }, "dei_SecurityExchangeName": { "xbrltype": "securityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityExchangeName", "presentation": { "http://www.cooperco.com/role/Cover": { "lang": { "en-us": { "role": { "terseLabel": "Security Exchange Name", "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": { "r779" } }, "us-gaap_SegmentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentDomain", "presentation": { "http://www.cooperco.com/role/BusinessSegmentInformationScheduleofIdentifiableAssetsbySegmentDetails": { "http://www.cooperco.com/role/BusinessSegmentInformationScheduleofSegmentInformationDetails": { "lang": { "en-us": { "role": { "terseLabel": "Segments [Domain]", "label": "Segments [Domain]", "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity." } } }, "auth_ref": { "r130", "r131", "r132", "r133", "r247", "r250", "r253", "r254", "r255", "r256", "r257", "r258", "r259", "r260", "r261", "r262", "r263", "r264", "r266", "r267", "r268", "r269", "r270", "r271", "r272", "r273", "r275", "r276", "r277", "r286", "r295", "r296", "r297", "r298", "r299", "r300", "r301", "r302", "r303", "r317", "r328", "r329", "r581", "r582", "r583", "r584", "r585", "r586", "r587", "r588", "r589", "r590", "r591", "r721", "r724", "r725", "r730", "r766", "r962", "r964", "r965", "r966", "r967", "r968", "r969", "r970", "r971", "r972", "r973", "r974", "r975", "r976", "r977", "r978", "r979", "r980", "r981", "r982", "r983", "r984", "r985", "r986", "r987", "r988", "r989", "r990", "r991" } }, "srt_SegmentGeographicalDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "SegmentGeographicalDomain", "presentation": { "http://www.cooperco.com/role/BusinessSegmentInformationScheduleofNetPropertyPlantandEquipmentByCountryofDomicileDetails": { "http://www.cooperco.com/role/BusinessSegmentInformationScheduleofNetSalesofUnaffiliatedCustomersbyCountryofDomicileDetails": { "lang": { "en-us": { "role": { "terseLabel": "Geographical [Domain]", "label": "Geographical [Domain]", "documentation": "Geographical area." } } }, "auth_ref": { "r143", "r145", "r148", "r150", "r157", "r158", "r159", "r160", "r161", "r162", "r163", "r164", "r165", "r166", "r280", "r281", "r528", "r529", "r530", "r531", "r532", "r533", "r534", "r535", "r536", "r537", "r538", "r539", "r540", "r541", "r542", "r543", "r544", "r545", "r546", "r547", "r548", "r549", "r550", "r551", "r552", "r553", "r554", "r555", "r556", "r557", "r618", "r619", "r620", "r676", "r681", "r689", "r693", "r695", "r696", "r697", "r698", "r699", "r700", "r701", "r702", "r703", "r709", "r739", "r754", "r755", "r756", "r757", "r758", "r759", "r760", "r761", "r765", "r770", "r921", "r962", "r964", "r965", "r967", "r968", "r969", "r970", "r971", "r972", "r973", "r974", "r975", "r976", "r977", "r978", "r979", "r980", "r981", "r982", "r983", "r984", "r985", "r986", "r987", "r988", "r989", "r990", "r991" } }, "us-gaap_SegmentReportingAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentReportingAbstract", "lang": { "en-us": { "role": { "terseLabel": "Segment Reporting [Abstract]", "label": "Segment Reporting [Abstract]" } } }, "auth_ref": { "us-gaap_SegmentReportingDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentReportingDisclosureTextBlock", "presentation": { "http://www.cooperco.com/role/BusinessSegmentInformation": { "lang": { "en-us": { "role": { "terseLabel": "Business Segment Information", "label": "Segment Reporting Disclosure [Text Block]", "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments." } } }, "auth_ref": { "r133", "r247", "r249", "r250", "r251", "r252", "r253", "r265", "r267", "r268", "r273", "r274", "r275", "r276", "r277", "r278", "r279", "r282", "r290", "r720", "r722", "r723", "r724", "r726", "r727", "r728" } }, "us-gaap_SegmentReportingInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentReportingInformationLineItems", "presentation": { "http://www.cooperco.com/role/BusinessSegmentInformationScheduleofIdentifiableAssetsbySegmentDetails": { "http://www.cooperco.com/role/BusinessSegmentInformationScheduleofSegmentInformationDetails": { "lang": { "en-us": { "role": { "terseLabel": "Segment Reporting Information [Line Items]", "label": "Segment Reporting Information [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": { "us-gaap_SellingGeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SellingGeneralAndAdministrativeExpense", "crdr": "debit", "calculation": { "http://www.cooperco.com/role/ConsolidatedCondensedStatementsOfIncomeandComprehensiveIncome": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 2.0 }, "presentation": { "http://www.cooperco.com/role/ConsolidatedCondensedStatementsOfIncomeandComprehensiveIncome": { "lang": { "en-us": { "role": { "terseLabel": "Selling, general and administrative expense", "label": "Selling, General and Administrative Expense", "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc." } } }, "auth_ref": { "r95" } }, "us-gaap_SellingGeneralAndAdministrativeExpensesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SellingGeneralAndAdministrativeExpensesMember", "presentation": { "http://www.cooperco.com/role/ShareBasedCompensationDetails": { "lang": { "en-us": { "role": { "terseLabel": "Selling, general and administrative expense", "label": "Selling, General and Administrative Expenses [Member]", "documentation": "Primary financial statement caption encompassing selling, general and administrative expense." } } }, "auth_ref": { "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "presentation": { "http://www.cooperco.com/role/ShareBasedCompensationDetails": { "lang": { "en-us": { "role": { "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": { "r408", "r410", "r413", "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r422", "r423", "r424", "r425", "r426", "r427", "r428", "r429", "r430", "r431", "r432", "r433", "r434", "r435", "r436", "r437", "r438" } }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardTypeAndPlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardTypeAndPlanNameDomain", "presentation": { "http://xbrl.sec.gov/role/AwardFirmingDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "All Award Types", "label": "Award Type [Domain]", "documentation": "Award under share-based payment arrangement." } } }, "auth_ref": { "r413", "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r422", "r423", "r424", "r425", "r426", "r427", "r428", "r429", "r430", "r431", "r432", "r433", "r434", "r435", "r436", "r437", "r438" } }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit", "presentation": {

[illegible]

[illegible]

!E(K1119:P2IN2R-?I=H%>7^B!\$D?Z=JCA!<LMC%V&SZ&E M\$Y9!9KC!MFR!K<CFW!1\$>SDJ6!0Q(VJ?3>4V\$MD8&8U15H8\$>0-JPRUN-1
M6W3,K24M!>3Y"Z5HSY2WC<A<+00Z?F6%W%<G135 HR6?>6R87AY@?H M)>=FN>GMR<R>B^!6+!<OH?OGH J?ZHO7KE5?EKL7.IQ2=V47AG!H?2.14 M7*0EDD4-G
U*#0LK7F5?>SAR!F6H5K!YKHHZ M=#5W)DU.FOL<K!>.BV5\$ARGZ\$D6F0\$>YTO.&1040!UXSYFK0!P\$>EHZJ?>W
M<N?2>.#F!<F9NX1!06C=87."P\$3!05!NBU5!<S01#8U.R!>F&F!>MDH!E=<E!W09!V7FW!U%>1?V2/XE(<33DB2=?)IK7.%<MDK0<*>H(V%<M-5/
MO?>Y.L5J24!/@?37G=F8KJ!>""F3<28ER!<+<K4U4">=>^0^V! M%4.\$MC\$<B\$!/#H" TU)O!4<36^2(2%5&%.00)"M(FAA&*>XD^#Q/IF5AUBT. M&&46G.U7\$&U3)&18\$Y-
7W(40!>P.MM)N!<U>BAS\$G-280K10!L7GB0Q!<DMV M!>PP!E9 H.<P.>PB003)HJ3!>L8B?X#A+6UX3!ND.R!>RU?>3GN@<X<.<=<M=C.
(SC^HJ?KJY#WZA!H8023UR@YC\$<G!G?<!02.WMHE?F7K!>P3?>9V0294!X-79U?Y?T?>F&6%<R8=<\$M.S28+<\$2X!V5DJ%J3!>+O1Y!>DFV5)9&?
9!U2A?>6C>W@E!>6!V1VUB? T.M4@<8V%>+V4-LZ5?H?<M!H8!>DO9V!OJ02GACD?>L<1^<S.PMV.P.>DE M>UNTR.U%<6&6!9+>P.C.>VK0\$<8%>M!>N!>HJOYF=

adjustments will be made to these provisions periodically to reflect new facts and circumstances that may indicate that historical experience may not be indicative of current and/or future results.

Stock Split

On February 16, 2024, the Company effected a four-for-one stock split of its outstanding shares of common stock. The par value of the common stock remains at \$0.10 per share. Accordingly, an amount equal to the par value of the increased shares resulting from the stock split was reclassified from "Additional paid-in capital" to "Common stock". All share and per share information has been retroactively adjusted to reflect the stock split for all periods presented.

Accounting Pronouncements Issued But Not Yet Adopted

In December 2023, the Financial Accounting Standards Board (FASB) issued ASU 2023-09, "Improvements to Income Tax Disclosures." This ASU requires public entities to disclose specific categories in the effective tax rate reconciliation and additional information for reconciling items that exceed a quantitative threshold. The guidance also requires all disaggregated information pertaining to taxes paid, net of refunds received, for federal, state and foreign income taxes. The new guidance is effective for fiscal years beginning after December 15, 2024, with the option to apply prospectively or retrospectively. Early adoption is permitted. We are currently evaluating the impact that the adoption of this guidance will have on our consolidated financial statements and disclosures.

In November 2023, the FASB issued ASU 2023-07, "Segment Reporting," which enhances the disclosures required for operating segments in our annual and interim consolidated financial statements. The ASU is effective for us beginning on November 1, 2024, and will be applied retrospectively. Early adoption is permitted. We are currently evaluating the impact of adopting this ASU on our consolidated financial statements and disclosures.

Estimates

The preparation of Consolidated Condensed Financial Statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported amounts of net sales and expenses during the reporting period. Actual results could differ from those estimates. The Company continually monitors and evaluates the estimates used as additional information becomes available. Adjustments will be made to these provisions periodically to reflect new facts and circumstances that may indicate that historical experience may not be indicative of current and/or future results.

Acquisitions and Joint Venture

All acquisitions were funded by cash generated from operations or facility borrowings.

On June 7, 2024, CooperSurgical acquired a fertility company that specializes in sperm separation devices. The purchase price of the acquisition was \$33.5 million. The Company accounted for this acquisition as an asset acquisition, whereby the Company allocated the total cost of the acquisition to the net assets acquired on the basis of their estimated relative fair values on the acquisition date. The primary asset acquired in this asset acquisition is a composite intangible asset of \$39.6 million. The value of the composite intangible asset reflects, in addition to the purchase price, a deferred tax liability of \$8.3 million arising from book/tax basis differences generated upon the acquisition. The composite intangible asset encompasses the portfolio of intellectual property associated with the sperm separation devices including the patents, trademarks, customer relationships, regulatory approvals, and commercialization rights, which have been valued as a single composite intangible asset as they are inextricably linked.

On November 1, 2023, CooperSurgical completed the acquisition of select Cook Medical assets focused primarily on the obstetrics, doppler monitoring, and gynecology surgery markets. The purchase price of the acquisition was \$300.0 million, with \$200.0 million paid at closing and two cash payments of \$50.0 million each to be paid on November 1, 2024, and November 1, 2025. The present value of the acquisition purchase price was \$291.6 million, which is included in the Company's balance sheet. Assets acquired primarily comprised of \$157.9 million of technologies, \$26.6 million of customer relationship related intangibles, and \$107.2 million of goodwill. The goodwill is deductible for tax purposes.

Joint Venture

CooperVision and Essilor International SAS (Essilor) executed a Contribution Agreement and a Stock Purchase Agreement (the Agreements) in March 2022 to form a joint venture in SightGlass Vision, Inc. (SGV), which is a medical device company developing spectacle lenses for myopia management. Essilor paid CooperVision \$52.1 million in exchange for a 50% interest in SGV and their proportionate share of the revenue payments. As part of the Agreements, each party contributed their interest in SGV and \$10 million in cash. Prior to March 2022, CooperVision owned 100% of SGV.

Further information regarding the joint venture is included in the notes to our consolidated financial statements in our Annual Report on Form 10-K for the fiscal year ended October 31, 2023.

Subsequent Event

On August 1, 2024, subsequent to fiscal quarter ended July 31, 2024, CooperSurgical completed the acquisition of obp Surgical, a U.S.-based medical device company with a suite of single-use cordless surgical retractors with integrated light source and evacuation channels. The purchase price of the acquisition was approximately \$100.0 million, paid on August 1, 2024. The Company is in the process of finalizing purchase accounting information.

Inventories
\$335,000,000
\$396,000,000
\$300,000,000
\$20,000,000
\$30,000,000
\$8,000,000
\$8,000,000
\$3,000,000
\$2,000,000
\$2,000,000
\$500,000,000
\$500,000,000
\$1,600,000,000
\$1,750,000,000
\$2,660,000,000
\$1,072,000,000
\$521,000,000

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

Three Months

Nine Months

Beginning balance gain

Amount recognized in accumulated other comprehensive income on interest rate swap contracts, gross

(21.6)

31.4

14.6

Amount reclassified from accumulated other comprehensive income into earnings, gross

(14.1)

(12.1)

(30.3)

Ending balance gain

Contingencies and Commitments

The Company is involved in various lawsuits, claims and other legal matters from time to time that arise in the ordinary course of conducting business, including matters involving our products, intellectual property, supplier relationships, distributors, competitor relationships, employees and other matters. The Company does not believe that the ultimate resolution of these proceedings or claims pending against it could have a material adverse effect on its financial condition or results of operations. At each reporting period, the Company evaluates whether or not a potential loss amount or a potential range of loss is probable and reasonably estimable under ASC 450.

Contingencies

Legal fees are expensed as incurred.

As of July 31, 2024, the Company entered into additional leases that have not yet commenced in order to expand capacity. The undiscounted lease payments are estimated at \$214.0 million for leases that will commence between the fourth quarter of fiscal 2024 through fiscal 2026, with initial terms ranging from 15 to 25 years.

The Company is involved in various lawsuits, claims and other legal matters from time to time that arise in the ordinary course of conducting business, including matters involving our products, intellectual property, supplier relationships, distributors, competitor relationships, employees and other matters. The Company does not believe that the ultimate resolution of these proceedings or claims pending against it could have a material adverse effect on its financial condition or results of operations. At each reporting period, the Company evaluates whether or not a potential loss amount or a potential range of loss is probable and reasonably estimable under ASC 450.

Contingencies

Legal fees are expensed as incurred.

Periods Ended July 31

The following tables present revenue and other financial information by reportable segment:

Segment Information	Revenue	Gross Profit	Operating Income	Other Comprehensive Income	Total Comprehensive Income
Consumer Electronics	\$1,000,000	\$500,000	\$250,000	\$100,000	\$850,000
Computing & Graphics	\$1,000,000	\$500,000	\$250,000	\$100,000	\$850,000
Mobile Computing	\$1,000,000	\$500,000	\$250,000	\$100,000	\$850,000
Services & Solutions	\$1,000,000	\$500,000	\$250,000	\$100,000	\$850,000
Other	\$1,000,000	\$500,000	\$250,000	\$100,000	\$850,000
Total	\$5,000,000	\$2,500,000	\$1,250,000	\$500,000	\$4,250,000

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

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i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f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

[illegible]